NCTId;BriefTitle;LeadSponsorName;CollaboratorName;OverallStatus;StudyType;HasResults;StudyFirstPostDate;StartDate;CompletionDate;pmid;type;title;authors;doi;year;publication_types
NCT02014727;Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel ® as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults;Institut National de la Santé Et de la Recherche Médicale, France;EVI Industries, Inc. | BPRC | Recherche Clinique Paris Descartes Necker Cochin Sainte Anne | Centre national de recherche et de formation sur le paludisme;COMPLETED;INTERVENTIONAL;False;2013-12-18;2014-01;2015-07;28947345;DERIVED;Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial.;"Sirima SB; Durier C; Kara L; Houard S; Gansane A; Loulergue P; Bahuaud M; Benhamouda N; Nebié I; Faber B; Remarque E; Launay O; AMA1-DiCo Study Group";10.1016/j.vaccine.2017.09.027;2017;"['Clinical Trial, Phase I', 'Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00117494;Rosuvastatin Versus Pravastatin in HIV Patients Treated With Boosted Protease Inhibitors (PI) (ANRS126);French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2005-07-07;2005-10;2007-06;22739396;DERIVED;Effects of rosuvastatin versus pravastatin on low-density lipoprotein diameter in HIV-1-infected patients receiving ritonavir-boosted protease inhibitor.;"Bittar R; Giral P; Aslangul E; Assoumou L; Valantin MA; Kalmykova O; Federspiel MC; Cherfils C; Costagliola D; Bonnefont-Rousselot D; French National Agency for AIDS and Viral Hepatitis Research (ANRS) 126 study group";10.1097/QAD.0b013e328357063c;2012;"['Comparative Study', 'Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00117494;Rosuvastatin Versus Pravastatin in HIV Patients Treated With Boosted Protease Inhibitors (PI) (ANRS126);French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2005-07-07;2005-10;2007-06;22318219;DERIVED;Determinants of low-density lipoprotein particle diameter during antiretroviral therapy including protease inhibitors in HIV-1-infected patients.;"Bittar R; Giral P; Aslangul E; Assoumou L; Valantin MA; Kalmykova O; Fesel-Fouquier V; Costagliola D; Bonnefont-Rousselot D; ANRS 126 study group";10.3851/IMP2065;2012;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT00536627;Efficacy and Tolerance of Naked DNA Vaccine in Patients With Chronic B Hepatitis;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2007-09-28;2008-01;2010-11;24394187;DERIVED;Immunological and antiviral responses after therapeutic DNA immunization in chronic hepatitis B patients efficiently treated by analogues.;"Godon O; Fontaine H; Kahi S; Meritet JF; Scott-Algara D; Pol S; Michel ML; Bourgine M; ANRS HB02 study group";10.1038/mt.2013.274;2014;"['Clinical Trial, Phase I', 'Clinical Trial, Phase II', 'Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00536627;Efficacy and Tolerance of Naked DNA Vaccine in Patients With Chronic B Hepatitis;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2007-09-28;2008-01;2010-11;15382173;BACKGROUND;Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers.;"Mancini-Bourgine M; Fontaine H; Scott-Algara D; Pol S; Bréchot C; Michel ML";10.1002/hep.20408;2004;"['Clinical Trial', 'Clinical Trial, Phase I', 'Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT00536627;Efficacy and Tolerance of Naked DNA Vaccine in Patients With Chronic B Hepatitis;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2007-09-28;2008-01;2010-11;24555998;DERIVED;Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial--ANRS HB02 VAC-ADN.;"Fontaine H; Kahi S; Chazallon C; Bourgine M; Varaut A; Buffet C; Godon O; Meritet JF; Saïdi Y; Michel ML; Scott-Algara D; Aboulker JP; Pol S; ANRS HB02 study group";10.1136/gutjnl-2013-305707;2015;"['Clinical Trial, Phase I', 'Clinical Trial, Phase II', 'Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00536627;Efficacy and Tolerance of Naked DNA Vaccine in Patients With Chronic B Hepatitis;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2007-09-28;2008-01;2010-11;16310901;BACKGROUND;Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers.;"Mancini-Bourgine M; Fontaine H; Bréchot C; Pol S; Michel ML";10.1016/j.vaccine.2005.08.013;2006;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01033760;Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM);ANRS, Emerging Infectious Diseases;Gilead Sciences | Merck Sharp & Dohme LLC | Pfizer | Janssen-Cilag Ltd.;COMPLETED;INTERVENTIONAL;False;2009-12-16;2010-04;2013-12;25701561;DERIVED;Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial.;"Chéret A; Nembot G; Mélard A; Lascoux C; Slama L; Miailhes P; Yeni P; Abel S; Avettand-Fenoel V; Venet A; Chaix ML; Molina JM; Katlama C; Goujard C; Tamalet C; Raffi F; Lafeuillade A; Reynes J; Ravaux I; Hoën B; Delfraissy JF; Meyer L; Rouzioux C; OPTIPRIM ANRS Study Group";10.1016/S1473-3099(15)70021-6;2015;"['Clinical Trial, Phase III', 'Comparative Study', 'Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT01033760;Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM);ANRS, Emerging Infectious Diseases;Gilead Sciences | Merck Sharp & Dohme LLC | Pfizer | Janssen-Cilag Ltd.;COMPLETED;INTERVENTIONAL;False;2009-12-16;2010-04;2013-12;28708873;DERIVED;Impact of early cART on HIV blood and semen compartments at the time of primary infection.;"Chéret A; Durier C; Mélard A; Ploquin M; Heitzmann J; Lécuroux C; Avettand-Fenoël V; David L; Pialoux G; Chennebault JM; Müller-Trutwin M; Goujard C; Rouzioux C; Meyer L; ANRS OPTIPRIM study group";10.1371/journal.pone.0180191;2017;['Clinical Trial, Phase III', 'Journal Article', 'Randomized Controlled Trial']
NCT05349162;Epicardial vs. Transvenous ICDs in Children;Paris Cardiovascular Research Center (Inserm U970);Hôpital Necker-Enfants Malades;COMPLETED;OBSERVATIONAL;False;2022-04-27;2003-01-01;2022-04-01;36735263;PUBMED;Epicardial vs. transvenous implantable cardioverter defibrillators in children.;"Le Bos PA; Pontailler M; Maltret A; Kraiche D; Gaudin R; Barbanti C; Marijon E; Raisky O; Bonnet D; Waldmann V";10.1093/europace/euad015;2023;['Clinical Trial', 'Journal Article']
NCT01164462;Feasibility and Limitations of Offering Community Based Rapid HIV Testing to Men Who Have Sex With Men (MSM);French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2010-07-16;2010-03;2011-04;;;;;;;
NCT02777229;Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings;ANRS, Emerging Infectious Diseases;Institut de Recherche pour le Developpement | UNITAID;COMPLETED;INTERVENTIONAL;False;2016-05-19;2016-07;2021-07;37851566;PUBMED;Improvements in Patient-Reported Outcomes Following Initiation of Dolutegravir-Based or Low-Dose Efavirenz-Based First-Line Antiretroviral Therapy: A Four-Year Longitudinal Analysis in Cameroon (NAMSAL ANRS 12313 Trial).;"Bousmah MA; Protopopescu C; Mpoudi-Etame M; Omgba Bassega P; Maradan G; Olinga J; Varloteaux M; Tovar-Sanchez T; Delaporte É; Kouanfack C; Boyer S; NAMSAL ANRS 12313 Study Group";10.1097/QAI.0000000000003273;2023;"['Randomized Controlled Trial', 'Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT02777229;Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings;ANRS, Emerging Infectious Diseases;Institut de Recherche pour le Developpement | UNITAID;COMPLETED;INTERVENTIONAL;False;2016-05-19;2016-07;2021-07;33010241;DERIVED;Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon.;"Calmy A; Tovar Sanchez T; Kouanfack C; Mpoudi-Etame M; Leroy S; Perrineau S; Lantche Wandji M; Tetsa Tata D; Omgba Bassega P; Abong Bwenda T; Varloteaux M; Tongo M; Mpoudi-Ngolé E; Montoyo A; Mercier N; LeMoing V; Peeters M; Reynes J; Delaporte E; New Antiretroviral and Monitoring Strategies in HIV-infected Adults in Low-Income Countries (NAMSAL) ANRS 12313 Study Group";10.1016/S2352-3018(20)30238-1;2020;"['Clinical Trial, Phase III', 'Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT02777229;Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings;ANRS, Emerging Infectious Diseases;Institut de Recherche pour le Developpement | UNITAID;COMPLETED;INTERVENTIONAL;False;2016-05-19;2016-07;2021-07;33355914;DERIVED;Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial).;"Bousmah MA; Nishimwe ML; Tovar-Sanchez T; Lantche Wandji M; Mpoudi-Etame M; Maradan G; Omgba Bassega P; Varloteaux M; Montoyo A; Kouanfack C; Delaporte E; Boyer S; New Antiretroviral and Monitoring Strategies in HIV-infected Adults in Low-Income Countries (NAMSAL) ANRS 12313 Study Group";10.1007/s40273-020-00987-3;2021;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT02777229;Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings;ANRS, Emerging Infectious Diseases;Institut de Recherche pour le Developpement | UNITAID;COMPLETED;INTERVENTIONAL;False;2016-05-19;2016-07;2021-07;38156046;PUBMED;Durability of the Efficacy and Safety of Dolutegravir-Based and Low-Dose Efavirenz-Based Regimens for the Initial Treatment of Human Immunodeficiency Virus Type 1 Infection in Cameroon: Week 192 Data of the NAMSAL-ANRS-12313 Study.;"Mpoudi-Etame M; Tovar Sanchez T; Bousmah MA; Omgba Bassega P; Olinga J; Mimbe E; Foalem M; Chiep C; Edimo S; Varloteaux M; Pelloquin R; Lamare N; Boyer S; Peeters M; Reynes J; Calmy A; Hill A; Delaporte E; Kouanfack C; New Antiretroviral and Monitoring Strategies in HIV-infected Adults in Low-income countries (NAMSAL-ANRS-12313) study group";10.1093/ofid/ofad582;2023;['Journal Article']
NCT02777229;Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings;ANRS, Emerging Infectious Diseases;Institut de Recherche pour le Developpement | UNITAID;COMPLETED;INTERVENTIONAL;False;2016-05-19;2016-07;2021-07;31339676;DERIVED;Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1.;"NAMSAL ANRS 12313 Study Group; Kouanfack C; Mpoudi-Etame M; Omgba Bassega P; Eymard-Duvernay S; Leroy S; Boyer S; Peeters M; Calmy A; Delaporte E";10.1056/NEJMoa1904340;2019;"['Clinical Trial, Phase III', 'Equivalence Trial', 'Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00480792;Trial Comparing Three Strategies of Vaccination Against the Virus of Hepatitis B in HIV Infected Patients;ANRS, Emerging Infectious Diseases;MCM Vaccines B.V.;COMPLETED;INTERVENTIONAL;False;2007-05-31;2007-06;2012-09;21486976;DERIVED;Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial.;"Launay O; van der Vliet D; Rosenberg AR; Michel ML; Piroth L; Rey D; Colin de Verdière N; Slama L; Martin K; Lortholary O; Carrat F; ANRS HB03 VIHVAC-B Trial";10.1001/jama.2011.351;2011;"['Clinical Trial, Phase III', 'Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00480792;Trial Comparing Three Strategies of Vaccination Against the Virus of Hepatitis B in HIV Infected Patients;ANRS, Emerging Infectious Diseases;MCM Vaccines B.V.;COMPLETED;INTERVENTIONAL;False;2007-05-31;2007-06;2012-09;27064975;DERIVED;Long-term Immune Response to Hepatitis B Virus Vaccination Regimens in Adults With Human Immunodeficiency Virus 1: Secondary Analysis of a Randomized Clinical Trial.;"Launay O; Rosenberg AR; Rey D; Pouget N; Michel ML; Reynes J; Neau D; Raffi F; Piroth L; Carrat F; ANRS HB03 VIHVAC-B (Trial Comparing 3 Strategies of Vaccination Against the Virus of Hepatitis B in HIV-Infected Patients) Group";10.1001/jamainternmed.2016.0741;2016;"['Clinical Trial', 'Clinical Trial, Phase III', 'Comparative Study', 'Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT01095744;Influence of Age on Amyloid Load in Alzheimer's Disease and in Atypical Focal Cortical Alzheimer's Disease;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2010-03-30;2009-03;2012-05;;;;;;;
NCT01489592;Effect of Curcumin on Iron Metabolism in Healthy Volunteer;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-12-09;2011-10;2012-03;15974953;BACKGROUND;Hepcidin in iron metabolism.;"Loréal O; Haziza-Pigeon C; Troadec MB; Detivaud L; Turlin B; Courselaud B; Ilyin G; Brissot P";10.2174/1389203054065392;2005;"['Journal Article', ""Research Support, Non-U.S. Gov't"", 'Review']"
NCT01489592;Effect of Curcumin on Iron Metabolism in Healthy Volunteer;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-12-09;2011-10;2012-03;18559556;BACKGROUND;Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects.;"Vareed SK; Kakarala M; Ruffin MT; Crowell JA; Normolle DP; Djuric Z; Brenner DE";10.1158/1055-9965.EPI-07-2693;2008;"['Journal Article', 'Randomized Controlled Trial', 'Research Support, N.I.H., Extramural', ""Research Support, Non-U.S. Gov't""]"
NCT01489592;Effect of Curcumin on Iron Metabolism in Healthy Volunteer;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-12-09;2011-10;2012-03;20169331;BACKGROUND;Natural and synthetic STAT3 inhibitors reduce hepcidin expression in differentiated mouse hepatocytes expressing the active phosphorylated STAT3 form.;"Fatih N; Camberlein E; Island ML; Corlu A; Abgueguen E; Détivaud L; Leroyer P; Brissot P; Loréal O";10.1007/s00109-009-0588-3;2010;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01489592;Effect of Curcumin on Iron Metabolism in Healthy Volunteer;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-12-09;2011-10;2012-03;15501961;BACKGROUND;Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance.;"Sharma RA; Euden SA; Platton SL; Cooke DN; Shafayat A; Hewitt HR; Marczylo TH; Morgan B; Hemingway D; Plummer SM; Pirmohamed M; Gescher AJ; Steward WP";10.1158/1078-0432.CCR-04-0744;2004;"['Clinical Trial', 'Clinical Trial, Phase I', 'Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01489592;Effect of Curcumin on Iron Metabolism in Healthy Volunteer;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-12-09;2011-10;2012-03;16946298;BACKGROUND;STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation.;"Verga Falzacappa MV; Vujic Spasic M; Kessler R; Stolte J; Hentze MW; Muckenthaler MU";10.1182/blood-2006-07-033969;2007;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01453192;Renal Transplantation and Raltegravir in HIV-Infected Patients;ANRS, Emerging Infectious Diseases;Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2011-10-17;2011-12;2015-11;30688008;PUBMED;Low incidence of acute rejection within 6 months of kidney transplantation in HIV-infected recipients treated with raltegravir: the Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS) 153 TREVE trial.;"Matignon M; Lelièvre JD; Lahiani A; Abbassi K; Desvaux D; Diallo A; Peraldi MN; Taburet AM; Saillard J; Delaugerre C; Costagliola D; Assoumou L; Grimbert P; ANRS 153 TREVE study group";10.1111/hiv.12700;2019;"['Journal Article', 'Multicenter Study', ""Research Support, Non-U.S. Gov't""]"
NCT00460382;Clinical Trial to Assess the Efficacy of Darunavir/Ritonavir (DRV/r), Etravirine (ETV) and Raltegravir (MK-0518) in HIV Patients With Resistant Viruses;French National Agency for Research on AIDS and Viral Hepatitis;Merck Sharp & Dohme LLC | Janssen-Cilag Tibotec;COMPLETED;INTERVENTIONAL;False;2007-04-13;2007-05;2009-09;;;;;;;
NCT02486731;Hormonal Sensitivity in Patients With Noonan and LEOPARD Syndromes;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2015-07-01;2015-12-16;2018-12;;;;;;;
NCT02116374;Physiopathology Study of the Microbiota Biodiversity of HIV Seropositive Patients;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2014-04-16;2014-12;2016-06;;;;;;;
NCT02497274;Obesity and Lipids: a Matter of Taste?;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2016-01-11;2019-01;;;;;;;
NCT01022476;Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients;ANRS, Emerging Infectious Diseases;Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2009-12-01;2010-05;2013-05;;;;;;;
NCT00528060;Measure of Pharmacokinetic Parameters and Adherence With MEMS in Naive HIV Infected Patients Treated With Reyataz Once Daily Combined With Norvir and Truvada;French National Agency for Research on AIDS and Viral Hepatitis;Bristol-Myers Squibb | Gilead Sciences;COMPLETED;INTERVENTIONAL;False;2007-09-11;2008-01;2008-11;23459496;DERIVED;Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial.;"Parienti JJ; Barrail-Tran A; Duval X; Nembot G; Descamps D; Vigan M; Vrijens B; Panhard X; Taburet AM; Mentré F; Goujard C";10.1128/AAC.02605-12;2013;"['Clinical Trial', 'Journal Article', 'Multicenter Study', ""Research Support, Non-U.S. Gov't""]"
NCT02078076;IRM Cardiaque en Respiration Libre Pour Des Patients Atteints de Dystrophinopathie sévère;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-03-05;2013-06;2015-11;;;;;;;
NCT04008927;A Community-based Intervention Among Active Drug Users in Montpellier;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2019-07-05;2020-09-18;2021-09-10;22310560;BACKGROUND;Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact.;"Curran GM; Bauer M; Mittman B; Pyne JM; Stetler C";10.1097/MLR.0b013e3182408812;2012;"['Journal Article', 'Research Support, N.I.H., Extramural', ""Research Support, U.S. Gov't, Non-P.H.S.""]"
NCT04008927;A Community-based Intervention Among Active Drug Users in Montpellier;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2019-07-05;2020-09-18;2021-09-10;28004616;BACKGROUND;Age- and time-dependent prevalence and incidence of hepatitis C virus infection in drug users in France, 2004-2011: model-based estimation from two national cross-sectional serosurveys.;"Leon L; Kasereka S; Barin F; Larsen C; Weill-Barillet L; Pascal X; Chevaliez S; Pillonel J; Jauffret-Roustide M; LE Strat Y";10.1017/S0950268816002934;2017;['Journal Article']
NCT04008927;A Community-based Intervention Among Active Drug Users in Montpellier;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2019-07-05;2020-09-18;2021-09-10;27537841;BACKGROUND;Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.;"Dore GJ; Altice F; Litwin AH; Dalgard O; Gane EJ; Shibolet O; Luetkemeyer A; Nahass R; Peng CY; Conway B; Grebely J; Howe AY; Gendrano IN; Chen E; Huang HC; Dutko FJ; Nickle DC; Nguyen BY; Wahl J; Barr E; Robertson MN; Platt HL; C-EDGE CO-STAR Study Group";10.7326/M16-0816;2016;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT04008927;A Community-based Intervention Among Active Drug Users in Montpellier;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2019-07-05;2020-09-18;2021-09-10;26806260;BACKGROUND;Prospective assessment of rapid diagnostic tests for the detection of antibodies to hepatitis C virus, a tool for improving access to care.;"Chevaliez S; Poiteau L; Rosa I; Soulier A; Roudot-Thoraval F; Laperche S; Hézode C; Pawlotsky JM";10.1016/j.cmi.2016.01.009;2016;['Comparative Study', 'Evaluation Study', 'Journal Article']
NCT04008927;A Community-based Intervention Among Active Drug Users in Montpellier;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2019-07-05;2020-09-18;2021-09-10;27178119;BACKGROUND;Integrated respondent-driven sampling and peer support for persons who inject drugs in Haiphong, Vietnam: a case study with implications for interventions.;"Des Jarlais D; Duong HT; Pham Minh K; Khuat OH; Nham TT; Arasteh K; Feelemyer J; Heckathorn DD; Peries M; Moles JP; Laureillard D; Nagot N; (The Drive Study Team)";10.1080/09540121.2016.1178698;2016;['Journal Article']
NCT04008927;A Community-based Intervention Among Active Drug Users in Montpellier;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2019-07-05;2020-09-18;2021-09-10;29432973;BACKGROUND;Using dual capture/recapture studies to estimate the population size of persons who inject drugs (PWID) in the city of Hai Phong, Vietnam.;"Des Jarlais D; Khue PM; Feelemyer J; Arasteh K; Thi Huong D; Thi Hai Oanh K; Thi Giang H; Thi Tuyet Thanh N; Vinh VH; Heckathorn DD; Moles JP; Vallo R; Quillet C; Rapoud D; Michel L; Laureillard D; Hammett T; Nagot N";10.1016/j.drugalcdep.2017.11.033;2018;['Journal Article']
NCT04008927;A Community-based Intervention Among Active Drug Users in Montpellier;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2019-07-05;2020-09-18;2021-09-10;35774932;DERIVED;Reaching Hard-to-Reach People Who Use Drugs: A Community-Based Strategy for the Elimination of Hepatitis C.;"Nagot N; D'Ottavi M; Quillet C; Debellefontaine A; Castellani J; Langendorfer N; Hanslik B; Guichard S; Baglioni R; Faucherre V; Tuaillon E; Pageaux GP; Laureillard D; Donnadieu-Rigole H";10.1093/ofid/ofac181;2022;['Journal Article']
NCT04008927;A Community-based Intervention Among Active Drug Users in Montpellier;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2019-07-05;2020-09-18;2021-09-10;27168667;BACKGROUND;Improving Screening Methods for Hepatitis C Among People Who Inject Drugs: Findings from the HepTLC Initiative, 2012-2014.;"Blackburn NA; Patel RC; Zibbell JE";10.1177/00333549161310S214;2016;['Journal Article']
NCT01331876;Modification of Cerebral Activity of Obsessive Compulsive Disorder (OCD) Patients During Cognitive and Behavioral Therapy;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-04-08;2009-10;2012-07;;;;;;;
NCT00820820;IDA (Immunothérapie de la Dermatite Atopique) Adult - Immunotherapy in Atopic Dermatitis;Institut National de la Santé Et de la Recherche Médicale, France;Ministry of Health, France;COMPLETED;INTERVENTIONAL;False;2009-01-12;2009-01-09;2012-03-26;;;;;;;
NCT02273765;Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis;ANRS, Emerging Infectious Diseases;Merck Sharp & Dohme LLC | Ministry of Health, Brazil;COMPLETED;INTERVENTIONAL;False;2014-10-24;2015-09-11;2018-11-28;33667406;DERIVED;Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial.;"De Castro N; Marcy O; Chazallon C; Messou E; Eholié S; N'takpe JB; Bhatt N; Khosa C; Timana Massango I; Laureillard D; Chau GD; Domergue A; Veloso V; Escada R; Wagner Cardoso S; Delaugerre C; Anglaret X; Molina JM; Grinsztejn B; ANRS 12300 Reflate TB2 study group";10.1016/S1473-3099(20)30869-0;2021;"['Clinical Trial, Phase III', 'Comparative Study', 'Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT02107365;Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO);ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb;COMPLETED;INTERVENTIONAL;False;2014-04-08;2013-11;2015-04;;;;;;;
NCT00113282;Efficacy of Adding Interleukin-2 to an Optimized Antiretroviral Regimen in HIV Patients in Therapeutic Failure (ANRS123);French National Agency for Research on AIDS and Viral Hepatitis;Chiron Corporation;COMPLETED;INTERVENTIONAL;False;2005-06-08;2004-06;2008-02;;;;;;;
NCT01055873;Immunology of the Infection Perinatal;French National Agency for Research on AIDS and Viral Hepatitis;Institut Pasteur | University of Paris 5 - Rene Descartes | Hôpital Necker-Enfants Malades;COMPLETED;OBSERVATIONAL;False;2010-01-26;2007-02;2009-02;22427678;DERIVED;Relationships between HIV disease history and blood HIV-1 DNA load in perinatally infected adolescents and young adults: the ANRS-EP38-IMMIP study.;"Avettand-Fenoel V; Blanche S; Le Chenadec J; Scott-Algara D; Dollfus C; Viard JP; Bouallag N; Benmebarek Y; Rivière Y; Warszawski J; Rouzioux C; Buseyne F";10.1093/infdis/jis233;2012;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT05199831;Situational Analysis of HIV-related Disability in the Context of Ivory Coast;Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire;Institute of Research for Development, France | Institut de Sante Publique, d'Epidemiologie et de Developpement | University of Toronto | Université de Lille;COMPLETED;OBSERVATIONAL;False;2022-01-20;2021-02-05;2022-08-10;;;;;;;
NCT01359774;31P-MRS and Huntington Disease;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-05-25;2011-04;2012-04;17653274;BACKGROUND;Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression.;"Mochel F; Charles P; Seguin F; Barritault J; Coussieu C; Perin L; Le Bouc Y; Gervais C; Carcelain G; Vassault A; Feingold J; Rabier D; Durr A";10.1371/journal.pone.0000647;2007;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01359774;31P-MRS and Huntington Disease;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-05-25;2011-04;2012-04;21320997;BACKGROUND;Validation of plasma branched chain amino acids as biomarkers in Huntington disease.;"Mochel F; Benaich S; Rabier D; Durr A";10.1001/archneurol.2010.358;2011;['Letter', 'Validation Study']
NCT01359774;31P-MRS and Huntington Disease;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-05-25;2011-04;2012-04;21285522;BACKGROUND;Energy deficit in Huntington disease: why it matters.;"Mochel F; Haller RG";10.1172/JCI45691;2011;['Journal Article', 'Review']
NCT02099474;Evaluation of Raltegravir During the Third Trimester of Pregnancy;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2014-03-31;2014-06-30;2017-04;32661003;DERIVED;Effect of Pregnancy on Unbound Raltegravir Concentrations in the ANRS 160 RalFe Trial.;"Zheng Y; Hirt D; Delmas S; Lui G; Benaboud S; Lechedanec J; Tréluyer JM; Chenevier-Gobeaux C; Arezes E; Gelley A; Amri I; Urien S; Bouazza N; Foissac F; Warszawski J; Ghosn J";10.1128/AAC.00759-20;2020;"['Journal Article', 'Multicenter Study', ""Research Support, Non-U.S. Gov't""]"
NCT03546127;Molecular Profiling to Improve Outcome of Patients in Cancer. A Pilot Study;Institut National de la Santé Et de la Recherche Médicale, France;Institut Bergonié | Plateforme labellisée Inca - Institut Bergonié, Bordeaux | Plateforme labellisée Inca - Hôpital Européen Georges Pompidou, Paris | CNRGH, Evry | EUCLID Clinical Trial Platform;COMPLETED;OBSERVATIONAL;False;2018-06-06;2017-05-23;2017-09-21;;;;;;;
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;34350582;DERIVED;Remdesivir for the treatment of COVID-19.;"Ansems K; Grundeis F; Dahms K; Mikolajewska A; Thieme V; Piechotta V; Metzendorf MI; Stegemann M; Benstoem C; Fichtner F";10.1002/14651858.CD014962;2021;['Journal Article', 'Systematic Review']
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;37269068;BACKGROUND;Management of pharmacovigilance during the COVID-19 pandemic crisis by the safety department of an academic sponsor: Lessons learnt and challenges from the EU DisCoVeRy clinical trial.;"Mercier N; Belhadi D; DeChanet A; Delmas C; Saillard J; Dumousseaux M; Le Mestre S; Fougerou-Leurent C; Ferrane A; Burdet C; Espérou H; Ader F; Hites M; Peiffer-Smadja N; Poissy J; Andrejak C; Paiva JA; Tacconelli E; Staub T; Greil R; Costagliola D; Mentre F; Yazdanpanah Y; Diallo A; DisCoVeRy Safety Working group";10.1002/prp2.1072;2023;"['Journal Article', 'Review', ""Research Support, Non-U.S. Gov't""]"
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;32473020;BACKGROUND;Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial.;"Lê MP; Peiffer-Smadja N; Guedj J; Néant N; Mentré F; Ader F; Yazdanpanah Y; Peytavin G";10.1093/jac/dkaa191;2020;"['Journal Article', ""Research Support, Non-U.S. Gov't"", 'Review']"
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;37302469;BACKGROUND;Ensuring quality control in a COVID-19 clinical trial during the pandemic: The experience of the Inserm C20-15 DisCoVeRy study.;"Fougerou-Leurent C; Delmas C; Saillard J; Dumousseaux M; Ferrane A; Mercier N; Terzic V; Le Mestre S; Dechanet A; Belhadi D; Metois A; Burdet C; Mentré F; Noret M; Diallo A; Petrov-Sanchez V; Couffin-Cadiergues S; Hites M; Ader F; Esperou H";10.1016/j.cct.2023.107267;2023;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;35512728;DERIVED;Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses.;WHO Solidarity Trial Consortium;10.1016/S0140-6736(22)00519-0;2022;['Journal Article', 'Meta-Analysis']
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;34048876;RESULT;An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19.;"Ader F; Peiffer-Smadja N; Poissy J; Bouscambert-Duchamp M; Belhadi D; Diallo A; Delmas C; Saillard J; Dechanet A; Mercier N; Dupont A; Alfaiate T; Lescure FX; Raffi F; Goehringer F; Kimmoun A; Jaureguiberry S; Reignier J; Nseir S; Danion F; Clere-Jehl R; Bouiller K; Navellou JC; Tolsma V; Cabié A; Dubost C; Courjon J; Leroy S; Mootien J; Gaci R; Mourvillier B; Faure E; Pourcher V; Gallien S; Launay O; Lacombe K; Lanoix JP; Makinson A; Martin-Blondel G; Bouadma L; Botelho-Nevers E; Gagneux-Brunon A; Epaulard O; Piroth L; Wallet F; Richard JC; Reuter J; Staub T; Lina B; Noret M; Andrejak C; Lê MP; Peytavin G; Hites M; Costagliola D; Yazdanpanah Y; Burdet C; Mentré F; DisCoVeRy study group";10.1016/j.cmi.2021.05.020;2021;['Clinical Trial, Phase III', 'Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;36680782;BACKGROUND;Implementation of a centralized pharmacovigilance system in academic pan-European clinical trials: Experience from EU-Response and conect4children consortia.;"Terzić V; Levoyer L; Figarella M; Bigagli E; Mercier N; De Gastines L; Gibowski S; Trøseid M; Demotes J; Olsen IC; Hites M; Ader F; Lopez JRA; Mentré F; Espérou H; Costagliola D; Røttingen JA; Poissy J; Rozé JC; Warris A; O'Leary J; Fernandes RM; Assoumou L; Hankard R; Turner MA; Yazdanpanah Y; Diallo A; EU-Response safety group; c4c safety group";10.1111/bcp.15669;2023;"['Journal Article', 'Review', ""Research Support, Non-U.S. Gov't""]"
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;34763056;BACKGROUND;Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from DisCoVeRy and the EU-SolidAct EU response group.;"EU-Response investigators group; Diallo A; Trøseid M; Simensen VC; Boston A; Demotes J; Olsen IC; Chung F; Paiva JA; Hites M; Ader F; Arribas JR; Baratt-Due A; Melien Ø; Tacconelli E; Staub T; Greil R; Tsiodras S; Briel M; Esperou H; Mentré F; Eustace J; Saillard J; Delmas C; LeMestre S; Dumousseaux M; Costagliola D; Røttingen JA; Yazdanpanah Y";10.1016/j.cmi.2021.10.011;2022;['Journal Article']
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;36695483;PUBMED;Remdesivir for the treatment of COVID-19.;"Grundeis F; Ansems K; Dahms K; Thieme V; Metzendorf MI; Skoetz N; Benstoem C; Mikolajewska A; Griesel M; Fichtner F; Stegemann M";10.1002/14651858.CD014962.pub2;2023;"['Journal Article', 'Review', ""Research Support, Non-U.S. Gov't"", 'Systematic Review']"
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;32958495;BACKGROUND;Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults.;"Ader F; Discovery French Trial Management Team";10.1136/bmjopen-2020-041437;2020;"['Clinical Trial Protocol', 'Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;33089306;BACKGROUND;Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial-authors' response.;"Lê MP; Peiffer-Smadja N; Guedj J; Neant N; Mentré F; Ader F; Yazdanpanah Y; Peytavin G; C-20-15 DisCoVeRy French Steering Committee";10.1093/jac/dkaa415;2021;['Journal Article', 'Comment']
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;37728045;RESULT;Association between SARS-CoV-2 viral kinetics and clinical score evolution in hospitalized patients.;"Néant N; Lingas G; Gaymard A; Belhadi D; Hites M; Staub T; Greil R; Paiva JA; Poissy J; Peiffer-Smadja N; Costagliola D; Yazdanpanah Y; Bouscambert-Duchamp M; Gagneux-Brunon A; Ader F; Mentré F; Wallet F; Burdet C; Guedj J; DisCoVeRy study group";10.1002/psp4.13051;2023;['Journal Article', 'Randomized Controlled Trial']
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;35233617;RESULT;Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial.;"Lingas G; Néant N; Gaymard A; Belhadi D; Peytavin G; Hites M; Staub T; Greil R; Paiva JA; Poissy J; Peiffer-Smadja N; Costagliola D; Yazdanpanah Y; Wallet F; Gagneux-Brunon A; Mentré F; Ader F; Burdet C; Guedj J; Bouscambert-Duchamp M";10.1093/jac/dkac048;2022;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;33264556;RESULT;Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.;"WHO Solidarity Trial Consortium; Pan H; Peto R; Henao-Restrepo AM; Preziosi MP; Sathiyamoorthy V; Abdool Karim Q; Alejandria MM; Hernández García C; Kieny MP; Malekzadeh R; Murthy S; Reddy KS; Roses Periago M; Abi Hanna P; Ader F; Al-Bader AM; Alhasawi A; Allum E; Alotaibi A; Alvarez-Moreno CA; Appadoo S; Asiri A; Aukrust P; Barratt-Due A; Bellani S; Branca M; Cappel-Porter HBC; Cerrato N; Chow TS; Como N; Eustace J; García PJ; Godbole S; Gotuzzo E; Griskevicius L; Hamra R; Hassan M; Hassany M; Hutton D; Irmansyah I; Jancoriene L; Kirwan J; Kumar S; Lennon P; Lopardo G; Lydon P; Magrini N; Maguire T; Manevska S; Manuel O; McGinty S; Medina MT; Mesa Rubio ML; Miranda-Montoya MC; Nel J; Nunes EP; Perola M; Portolés A; Rasmin MR; Raza A; Rees H; Reges PPS; Rogers CA; Salami K; Salvadori MI; Sinani N; Sterne JAC; Stevanovikj M; Tacconelli E; Tikkinen KAO; Trelle S; Zaid H; Røttingen JA; Swaminathan S";10.1056/NEJMoa2023184;2021;"['Comparative Study', 'Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;36828006;BACKGROUND;Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials.;"Amstutz A; Speich B; Mentré F; Rueegg CS; Belhadi D; Assoumou L; Burdet C; Murthy S; Dodd LE; Wang Y; Tikkinen KAO; Ader F; Hites M; Bouscambert M; Trabaud MA; Fralick M; Lee TC; Pinto R; Barratt-Due A; Lund-Johansen F; Müller F; Nevalainen OPO; Cao B; Bonnett T; Griessbach A; Taji Heravi A; Schönenberger C; Janiaud P; Werlen L; Aghlmandi S; Schandelmaier S; Yazdanpanah Y; Costagliola D; Olsen IC; Briel M";10.1016/S2213-2600(22)00528-8;2023;"['Systematic Review', 'Meta-Analysis', 'Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;35623577;BACKGROUND;Immunocompromised patients have been neglected in COVID-19 trials: a call for action.;"Trøseid M; Hentzien M; Ader F; Cardoso SW; Arribas JR; Molina JM; Mueller N; Hites M; Bonnet F; Manuel O; Costagliola D; Grinsztejn B; Olsen IC; Yazdapanah Y; Calmy A; EU RESPONSE; COMBINE";10.1016/j.cmi.2022.05.005;2022;['Journal Article']
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;35533972;RESULT;An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-β-1a, and hydroxychloroquine in hospitalized patients with COVID-19: final results.;"Ader F; DisCoVeRy Study Group";10.1016/j.cmi.2022.04.016;2022;['Letter', 'Randomized Controlled Trial']
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;34534511;RESULT;Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.;"Ader F; Bouscambert-Duchamp M; Hites M; Peiffer-Smadja N; Poissy J; Belhadi D; Diallo A; Lê MP; Peytavin G; Staub T; Greil R; Guedj J; Paiva JA; Costagliola D; Yazdanpanah Y; Burdet C; Mentré F; DisCoVeRy Study Group";10.1016/S1473-3099(21)00485-0;2022;"['Clinical Trial, Phase III', 'Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;32304640;DERIVED;Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base.;"Taccone FS; Gorham J; Vincent JL";10.1016/S2213-2600(20)30172-7;2020;['Journal Article']
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;34473343;DERIVED;SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.;"Kreuzberger N; Hirsch C; Chai KL; Tomlinson E; Khosravi Z; Popp M; Neidhardt M; Piechotta V; Salomon S; Valk SJ; Monsef I; Schmaderer C; Wood EM; So-Osman C; Roberts DJ; McQuilten Z; Estcourt LJ; Skoetz N";10.1002/14651858.CD013825.pub2;2021;"['Journal Article', ""Research Support, Non-U.S. Gov't"", 'Review', 'Systematic Review']"
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;35643099;RESULT;Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19.;"Ader F; Bouscambert-Duchamp M; Hites M; Peiffer-Smadja N; Mentré F; Burdet C; DisCoVeRy Study Group";10.1016/S1473-3099(22)00295-X;2022;['Letter']
NCT02987530;National Multicenter Trial Evaluating Two Treatments in Patients With Primary Human Immunodeficiency Virus (HIV-1) Infection;ANRS, Emerging Infectious Diseases;Institut National de la Santé Et de la Recherche Médicale, France;COMPLETED;INTERVENTIONAL;False;2016-12-09;2017-04-11;2020-01-31;;;;;;;
NCT05311865;Transmission of Covid-19 During Clubbing Events in Closed Places;ANRS, Emerging Infectious Diseases;Cerballiance | Kappa Santé;COMPLETED;INTERVENTIONAL;False;2022-04-05;2021-09-04;2022-02-26;37795682;PUBMED;A randomised controlled trial to study the transmission of SARS-CoV-2 and other respiratory viruses during indoor clubbing events (ANRS0066s ITOC study).;"Luong Nguyen LB; Goupil de Bouillé J; Menant L; Noret M; Dumas A; Salmona M; Le Goff J; Delaugerre C; Crépey P; Zeggagh J; ITOC Study Group";10.1093/cid/ciad603;2023;['Journal Article']
NCT05311865;Transmission of Covid-19 During Clubbing Events in Closed Places;ANRS, Emerging Infectious Diseases;Cerballiance | Kappa Santé;COMPLETED;INTERVENTIONAL;False;2022-04-05;2021-09-04;2022-02-26;36438274;PUBMED;Transmission of SARS-CoV-2 during indoor clubbing events: A clustered randomized, controlled, multicentre trial protocol.;"Goupil de Bouillé J; Luong Nguyen LB; Crépey P; Garlantezec R; Doré V; Dumas A; Ben Mechlia M; Tattevin P; Gaudart J; Spire B; Lert F; Yazdanpanah Y; Delaugerre C; Noret M; Zeggagh J";10.3389/fpubh.2022.981213;2022;"['Clinical Trial Protocol', 'Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT00122616;Efficacy of Pegylated Interferon on Liver Fibrosis in Co-infected Patient With HIV and Hepatitis C;French National Agency for Research on AIDS and Viral Hepatitis;Hoffmann-La Roche;COMPLETED;INTERVENTIONAL;False;2005-07-22;2003-11;2009-03;23800784;DERIVED;The effects of a maintenance therapy with peg-interferon alpha-2a on liver fibrosis in HIV/HCV co-infected patients: a randomized controlled trial.;"Chapplain JM; Bellissant E; Guyader D; Molina JM; Poizot-Martin I; Perré P; Pialoux G; Turlin B; Mouchel C; Renault A; Michelet C; ANRS HC-12 Study Group";10.1016/j.jinf.2013.05.007;2013;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT02428816;Evaluation of a Multimodal Neuroimaging Method for Diagnosis in Parkinsonian Syndromes;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-04-29;2013-01-24;2016-07-28;;;;;;;
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;24793938;BACKGROUND;B-cell responses after intranasal vaccination with the novel attenuated Bordetella pertussis vaccine strain BPZE1 in a randomized phase I clinical trial.;"Jahnmatz M; Amu S; Ljungman M; Wehlin L; Chiodi F; Mielcarek N; Locht C; Thorstensson R";10.1016/j.vaccine.2014.04.048;2014;['Clinical Trial, Phase I', 'Journal Article', 'Randomized Controlled Trial']
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;24950361;BACKGROUND;Heterologous prime-boost immunization with live attenuated B. pertussis BPZE1 followed by acellular pertussis vaccine in mice.;"Feunou PF; Kammoun H; Debrie AS; Locht C";10.1016/j.vaccine.2014.06.019;2014;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;22814407;BACKGROUND;Dual mechanism of protection by live attenuated Bordetella pertussis BPZE1 against Bordetella bronchiseptica in mice.;"Kammoun H; Feunou PF; Foligne B; Debrie AS; Raze D; Mielcarek N; Locht C";10.1016/j.vaccine.2012.07.005;2012;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;24421886;BACKGROUND;"A phase I clinical study of a live attenuated Bordetella pertussis vaccine--BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers.";"Thorstensson R; Trollfors B; Al-Tawil N; Jahnmatz M; Bergström J; Ljungman M; Törner A; Wehlin L; Van Broekhoven A; Bosman F; Debrie AS; Mielcarek N; Locht C";10.1371/journal.pone.0083449;2014;"['Clinical Trial, Phase I', 'Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;21430219;BACKGROUND;Attenuated Bordetella pertussis vaccine candidate BPZE1 promotes human dendritic cell CCL21-induced migration and drives a Th1/Th17 response.;"Fedele G; Bianco M; Debrie AS; Locht C; Ausiello CM";10.4049/jimmunol.1003765;2011;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;21147936;BACKGROUND;A live, attenuated Bordetella pertussis vaccine provides long-term protection against virulent challenge in a murine model.;"Skerry CM; Mahon BP";10.1128/CVI.00371-10;2011;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;31945015;DERIVED;Live attenuated pertussis vaccine BPZE1 induces a broad antibody response in humans.;"Lin A; Apostolovic D; Jahnmatz M; Liang F; Ols S; Tecleab T; Wu C; van Hage M; Solovay K; Rubin K; Locht C; Thorstensson R; Thalen M; Loré K";10.1172/JCI135020;2020;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;19625486;BACKGROUND;A live attenuated Bordetella pertussis candidate vaccine does not cause disseminating infection in gamma interferon receptor knockout mice.;"Skerry CM; Cassidy JP; English K; Feunou-Feunou P; Locht C; Mahon BP";10.1128/CVI.00082-09;2009;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;32687804;DERIVED;Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation study.;"Jahnmatz M; Richert L; Al-Tawil N; Storsaeter J; Colin C; Bauduin C; Thalen M; Solovay K; Rubin K; Mielcarek N; Thorstensson R; Locht C; BPZE1 study team";10.1016/S1473-3099(20)30274-7;2020;"['Clinical Trial, Phase I', 'Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;20708998;BACKGROUND;Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1.;"Feunou PF; Kammoun H; Debrie AS; Mielcarek N; Locht C";10.1016/j.vaccine.2010.08.017;2010;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;20419113;BACKGROUND;T- and B-cell-mediated protection induced by novel, live attenuated pertussis vaccine in mice. Cross protection against parapertussis.;"Feunou PF; Bertout J; Locht C";10.1371/journal.pone.0010178;2010;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;18762220;BACKGROUND;Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1.;"Feunou PF; Ismaili J; Debrie AS; Huot L; Hot D; Raze D; Lemoine Y; Locht C";10.1016/j.vaccine.2008.08.018;2008;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;20107007;BACKGROUND;Dose response of attenuated Bordetella pertussis BPZE1-induced protection in mice.;"Mielcarek N; Debrie AS; Mahieux S; Locht C";10.1128/CVI.00322-09;2010;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT00120757;Efficacy of Alendronate Versus Placebo in the Treatment of HIV-associated Osteoporosis (ANRS120);French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2005-07-19;2004-10;2008-11;22353022;DERIVED;Effect of alendronate on HIV-associated osteoporosis: a randomized, double-blind, placebo-controlled, 96-week trial (ANRS 120).;"Rozenberg S; Lanoy E; Bentata M; Viard JP; Valantin MA; Missy P; Darasteanu I; Roux C; Kolta S; Costagliola D; ANRS 120 Fosivir Study Group";10.1089/AID.2011.0224;2012;"['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT02566148;Life Course, HIV and Hepatitis B Among African Migrants Living in Ile-de-France;ANRS, Emerging Infectious Diseases;Ministry of Health, France | Institut de Recherche pour le Developpement | Institut National de la Santé Et de la Recherche Médicale, France | Institut national de prevention et d'education pour la sante;COMPLETED;OBSERVATIONAL;False;2015-10-02;2012-02;2013-05;29982518;DERIVED;Refusal to provide healthcare to sub-Saharan migrants in France: a comparison according to their HIV and HBV status.;"Vignier N; Dray Spira R; Pannetier J; Ravalihasy A; Gosselin A; Lert F; Lydie N; Bouchaud O; Desgrees Du Lou A; Chauvin P; PARCOURS Study Group";10.1093/eurpub/cky118;2018;"['Comparative Study', 'Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT02566148;Life Course, HIV and Hepatitis B Among African Migrants Living in Ile-de-France;ANRS, Emerging Infectious Diseases;Ministry of Health, France | Institut de Recherche pour le Developpement | Institut National de la Santé Et de la Recherche Médicale, France | Institut national de prevention et d'education pour la sante;COMPLETED;OBSERVATIONAL;False;2015-10-02;2012-02;2013-05;29307383;DERIVED;Prevalence and circumstances of forced sex and post-migration HIV acquisition in sub-Saharan African migrant women in France: an analysis of the ANRS-PARCOURS retrospective population-based study.;"Pannetier J; Ravalihasy A; Lydié N; Lert F; Desgrées du Loû A; Parcours study group";10.1016/S2468-2667(17)30211-6;2018;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT02566148;Life Course, HIV and Hepatitis B Among African Migrants Living in Ile-de-France;ANRS, Emerging Infectious Diseases;Ministry of Health, France | Institut de Recherche pour le Developpement | Institut National de la Santé Et de la Recherche Médicale, France | Institut national de prevention et d'education pour la sante;COMPLETED;OBSERVATIONAL;False;2015-10-02;2012-02;2013-05;29437866;DERIVED;How to use sequence analysis for life course epidemiology? An example on HIV-positive Sub-Saharan migrants in France.;"Gosselin A; Desgrées du Loû A; Lelièvre E; PARCOURS Study Group";10.1136/jech-2017-209739;2018;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;27895016;DERIVED;Are Prophylactic and Therapeutic Target Concentrations Different?: the Case of Lopinavir-Ritonavir or Lamivudine Administered to Infants for Prevention of Mother-to-Child HIV-1 Transmission during Breastfeeding.;"Foissac F; Blume J; Tréluyer JM; Tylleskär T; Kankasa C; Meda N; Tumwine JK; Singata-Madliki M; Harper K; Illamola SM; Bouazza N; Nagot N; Van de Perre P; Blanche S; Hirt D";10.1128/AAC.01869-16;2017;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;32991450;DERIVED;Antiretroviral treatment and its impact on oral health outcomes in 5 to 7 year old Ugandan children: A 6 year follow-up visit from the ANRS 12174 randomized trial.;"Birungi N; Fadnes LT; Engebretsen IMS; Tumwine JK; Åstrøm AN; for ANRS 12174 AND 12341 study groups";10.1097/MD.0000000000022352;2020;['Clinical Trial', 'Journal Article', 'Randomized Controlled Trial']
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;31994250;DERIVED;Association of maternal HIV-1 severity with dental caries: an observational study of uninfected 5- to 7-yr-old children of HIV-1-infected mothers without severe immune suppression.;"Birungi N; Fadnes LT; Engebretsen IMS; Lie SA; Tumwine JK; Åstrøm AN; ANRS 12174 and 12341 study groups";10.1111/eos.12669;2020;"['Journal Article', 'Observational Study', ""Research Support, Non-U.S. Gov't""]"
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;17825642;BACKGROUND;Prevention of human immunodeficiency virus-1 transmission to the infant through breastfeeding: new developments.;"Kourtis AP; Jamieson DJ; de Vincenzi I; Taylor A; Thigpen MC; Dao H; Farley T; Fowler MG";10.1016/j.ajog.2007.03.003;2007;['Journal Article', 'Review']
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;32067040;DERIVED;Clinical and Biological Factors Associated With Early Epstein-Barr Virus Infection in Human Immunodeficiency Virus-Exposed Uninfected Infants in Eastern Uganda.;"Montoya-Ferrer A; Sanosyan A; Fayd'herbe de Maudave A; Pisoni A; Bollore K; Molès JP; Peries M; Tylleskar T; Tumwine JK; Ndeezi G; Gorgolas M; Nagot N; van de Perre P; Tuaillon E";10.1093/cid/ciaa161;2021;['Journal Article']
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;28469697;DERIVED;Breastfeeding patterns and its determinants among mothers living with Human Immuno-deficiency Virus -1 in four African countries participating in the ANRS 12174 trial.;"Somé EN; Engebretsen IMS; Nagot N; Meda N; Lombard C; Vallo R; Peries M; Kankasa C; Tumwine JK; Hofmeyr GJ; Singata M; Harper K; Van De Perre P; Tylleskar T; ANRS 12174 Trial Group";10.1186/s13006-017-0112-2;2016;['Journal Article']
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;30814028;DERIVED;Growth in HIV-1-exposed but uninfected infants treated with lopinavir-ritonavir versus lamivudine: a secondary analysis of the ANRS 12174 trial.;"Blanche S; Tylleskär T; Peries M; Kankasa C; Engebretsen I; Meda N; Tumwine JK; Singata-Madliki M; Mwiya M; Van de Perre P; Nagot N; ANRS 12174 Trial Group";10.1016/S2352-3018(18)30361-8;2019;"['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;26603917;DERIVED;Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial.;"Nagot N; Kankasa C; Tumwine JK; Meda N; Hofmeyr GJ; Vallo R; Mwiya M; Kwagala M; Traore H; Sunday A; Singata M; Siuluta C; Some E; Rutagwera D; Neboua D; Ndeezi G; Jackson D; Maréchal V; Neveu D; Engebretsen IMS; Lombard C; Blanche S; Sommerfelt H; Rekacewicz C; Tylleskär T; Van de Perre P; ANRS 12174 Trial Group";10.1016/S0140-6736(15)00984-8;2016;"['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;34425825;PUBMED;The prevalence and socio-behavioural and clinical covariates of oral health related quality of life in Ugandan mothers with and without HIV-1.;"Birungi N; Fadnes LT; Engebretsen IMS; Tumwine JK; Åstrøm AN; ANRS 12174 and 12341 study groups";10.1186/s12955-021-01844-3;2021;['Journal Article']
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;31633158;DERIVED;Lopinavir-Ritonavir Impairs Adrenal Function in Infants.;"Kariyawasam D; Peries M; Foissac F; Eymard-Duvernay S; Tylleskär T; Singata-Madliki M; Kankasa C; Meda N; Tumwine J; Mwiya M; Engebretsen I; Flück CE; Hartmann MF; Wudy SA; Hirt D; Treluyer JM; Molès JP; Blanche S; Van De Perre P; Polak M; Nagot N; ANRS 12174 Trial Group";10.1093/cid/ciz888;2020;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;23039034;DERIVED;Lopinavir/Ritonavir versus Lamivudine peri-exposure prophylaxis to prevent HIV-1 transmission by breastfeeding: the PROMISE-PEP trial Protocol ANRS 12174.;"Nagot N; Kankasa C; Meda N; Hofmeyr J; Nikodem C; Tumwine JK; Karamagi C; Sommerfelt H; Neveu D; Tylleskär T; Van de Perre P; PROMISE-PEP group";10.1186/1471-2334-12-246;2012;"['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;32228542;DERIVED;Caries experience and oral health related quality of life in a cohort of Ugandan HIV-1 exposed uninfected children compared with a matched cohort of HIV unexposed uninfected children.;"Birungi N; Fadnes LT; Engebretsen IMS; Lie SA; Tumwine JK; Åstrøm AN; ANRS 12174 and 12341 study groups";10.1186/s12889-020-08564-1;2020;['Comparative Study', 'Journal Article']
NCT01693835;"""Cancersensor"": Circadian Rhythms";Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-09-26;2012-08;2014-06;;;;;;;
NCT04470648;COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey;Institut National de la Santé Et de la Recherche Médicale, France;Samusocial de Paris | Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2020-07-14;2020-07-22;2021-08-22;32371096;RESULT;SARS-CoV-2 was already spreading in France in late December 2019.;"Deslandes A; Berti V; Tandjaoui-Lambotte Y; Alloui C; Carbonnelle E; Zahar JR; Brichler S; Cohen Y";10.1016/j.ijantimicag.2020.106006;2020;['Journal Article']
NCT04470648;COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey;Institut National de la Santé Et de la Recherche Médicale, France;Samusocial de Paris | Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2020-07-14;2020-07-22;2021-08-22;32046819;RESULT;Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20-28 January 2020.;"Backer JA; Klinkenberg D; Wallinga J";10.2807/1560-7917.ES.2020.25.5.2000062;2020;['Journal Article']
NCT04470648;COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey;Institut National de la Santé Et de la Recherche Médicale, France;Samusocial de Paris | Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2020-07-14;2020-07-22;2021-08-22;32338732;RESULT;Prevalence of SARS-CoV-2 Infection in Residents of a Large Homeless Shelter in Boston.;"Baggett TP; Keyes H; Sporn N; Gaeta JM";10.1001/jama.2020.6887;2020;['Journal Article']
NCT04470648;COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey;Institut National de la Santé Et de la Recherche Médicale, France;Samusocial de Paris | Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2020-07-14;2020-07-22;2021-08-22;32070465;RESULT;First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures, January 2020.;"Bernard Stoecklin S; Rolland P; Silue Y; Mailles A; Campese C; Simondon A; Mechain M; Meurice L; Nguyen M; Bassi C; Yamani E; Behillil S; Ismael S; Nguyen D; Malvy D; Lescure FX; Georges S; Lazarus C; Tabaï A; Stempfelet M; Enouf V; Coignard B; Levy-Bruhl D; Investigation team";10.2807/1560-7917.ES.2020.25.6.2000094;2020;['Case Reports', 'Journal Article']
NCT04470648;COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey;Institut National de la Santé Et de la Recherche Médicale, France;Samusocial de Paris | Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2020-07-14;2020-07-22;2021-08-22;31978945;RESULT;A Novel Coronavirus from Patients with Pneumonia in China, 2019.;"Zhu N; Zhang D; Wang W; Li X; Yang B; Song J; Zhao X; Huang B; Shi W; Lu R; Niu P; Zhan F; Ma X; Wang D; Xu W; Wu G; Gao GF; Tan W; China Novel Coronavirus Investigating and Research Team";10.1056/NEJMoa2001017;2020;['Journal Article']
NCT04470648;COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey;Institut National de la Santé Et de la Recherche Médicale, France;Samusocial de Paris | Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2020-07-14;2020-07-22;2021-08-22;32109013;RESULT;Clinical Characteristics of Coronavirus Disease 2019 in China.;"Guan WJ; Ni ZY; Hu Y; Liang WH; Ou CQ; He JX; Liu L; Shan H; Lei CL; Hui DSC; Du B; Li LJ; Zeng G; Yuen KY; Chen RC; Tang CL; Wang T; Chen PY; Xiang J; Li SY; Wang JL; Liang ZJ; Peng YX; Wei L; Liu Y; Hu YH; Peng P; Wang JM; Liu JY; Chen Z; Li G; Zheng ZJ; Qiu SQ; Luo J; Ye CJ; Zhu SY; Zhong NS; China Medical Treatment Expert Group for Covid-19";10.1056/NEJMoa2002032;2020;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT04470648;COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey;Institut National de la Santé Et de la Recherche Médicale, France;Samusocial de Paris | Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2020-07-14;2020-07-22;2021-08-22;31995857;RESULT;Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia.;"Li Q; Guan X; Wu P; Wang X; Zhou L; Tong Y; Ren R; Leung KSM; Lau EHY; Wong JY; Xing X; Xiang N; Wu Y; Li C; Chen Q; Li D; Liu T; Zhao J; Liu M; Tu W; Chen C; Jin L; Yang R; Wang Q; Zhou S; Wang R; Liu H; Luo Y; Liu Y; Shao G; Li H; Tao Z; Yang Y; Deng Z; Liu B; Ma Z; Zhang Y; Shi G; Lam TTY; Wu JT; Gao GF; Cowling BJ; Yang B; Leung GM; Feng Z";10.1056/NEJMoa2001316;2020;"['Journal Article', 'Research Support, N.I.H., Extramural', ""Research Support, Non-U.S. Gov't""]"
NCT04470648;COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey;Institut National de la Santé Et de la Recherche Médicale, France;Samusocial de Paris | Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2020-07-14;2020-07-22;2021-08-22;32224310;RESULT;Clinical and virological data of the first cases of COVID-19 in Europe: a case series.;"Lescure FX; Bouadma L; Nguyen D; Parisey M; Wicky PH; Behillil S; Gaymard A; Bouscambert-Duchamp M; Donati F; Le Hingrat Q; Enouf V; Houhou-Fidouh N; Valette M; Mailles A; Lucet JC; Mentre F; Duval X; Descamps D; Malvy D; Timsit JF; Lina B; van-der-Werf S; Yazdanpanah Y";10.1016/S1473-3099(20)30200-0;2020;"['Journal Article', 'Observational Study', ""Research Support, Non-U.S. Gov't""]"
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;ANRS, Emerging Infectious Diseases;National Institute on Drug Abuse (NIDA);COMPLETED;OBSERVATIONAL;True;2015-10-12;2014-09;2016-06;26075647;BACKGROUND;Can HIV and Hepatitis C Virus Infection be Eliminated Among Persons Who Inject Drugs?;"Perlman DC; Des Jarlais DC; Feelemyer J";10.1080/10550887.2015.1059111;2015;['Journal Article', 'Research Support, N.I.H., Extramural']
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;ANRS, Emerging Infectious Diseases;National Institute on Drug Abuse (NIDA);COMPLETED;OBSERVATIONAL;True;2015-10-12;2014-09;2016-06;27006257;RESULT;Prospects for ending the HIV epidemic among persons who inject drugs in Haiphong, Vietnam.;"Des Jarlais DC; Thi Huong D; Thi Hai Oanh K; Khuê Pham M; Thi Giang H; Thi Tuyet Thanh N; Arasteh K; Feelemyer J; Hammett T; Peries M; Michel L; Vu Hai V; Roustide MJ; Moles JP; Laureillard D; Nagot N; DRIVE Study Team";10.1016/j.drugpo.2016.02.021;2016;"['Journal Article', ""Research Support, Non-U.S. Gov't"", 'Research Support, N.I.H., Extramural']"
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;ANRS, Emerging Infectious Diseases;National Institute on Drug Abuse (NIDA);COMPLETED;OBSERVATIONAL;True;2015-10-12;2014-09;2016-06;27178119;RESULT;Integrated respondent-driven sampling and peer support for persons who inject drugs in Haiphong, Vietnam: a case study with implications for interventions.;"Des Jarlais D; Duong HT; Pham Minh K; Khuat OH; Nham TT; Arasteh K; Feelemyer J; Heckathorn DD; Peries M; Moles JP; Laureillard D; Nagot N; (The Drive Study Team)";10.1080/09540121.2016.1178698;2016;['Journal Article']
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;ANRS, Emerging Infectious Diseases;National Institute on Drug Abuse (NIDA);COMPLETED;OBSERVATIONAL;True;2015-10-12;2014-09;2016-06;26080690;BACKGROUND;HIV, Hepatitis C, and Abstinence from Alcohol Among Injection and Non-injection Drug Users.;"Elliott JC; Hasin DS; Stohl M; Des Jarlais DC";10.1007/s10461-015-1113-z;2016;"['Journal Article', 'Research Support, N.I.H., Extramural', ""Research Support, Non-U.S. Gov't""]"
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;ANRS, Emerging Infectious Diseases;National Institute on Drug Abuse (NIDA);COMPLETED;OBSERVATIONAL;True;2015-10-12;2014-09;2016-06;28612212;RESULT;Risk Behaviors for HIV and HCV Infection Among People Who Inject Drugs in Hai Phong, Viet Nam, 2014.;"Duong HT; Jarlais DD; Khuat OHT; Arasteh K; Feelemyer J; Khue PM; Giang HT; Laureillard D; Hai VV; Vallo R; Michel L; Moles JP; Nagot N; Drive Study Group";10.1007/s10461-017-1814-6;2018;['Journal Article']
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;ANRS, Emerging Infectious Diseases;National Institute on Drug Abuse (NIDA);COMPLETED;OBSERVATIONAL;True;2015-10-12;2014-09;2016-06;26050614;BACKGROUND;An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: Structural barriers and public health potential.;"Perlman DC; Jordan AE; Uuskula A; Huong DT; Masson CL; Schackman BR; Des Jarlais DC";10.1016/j.drugpo.2015.04.015;2015;['Journal Article', 'Research Support, N.I.H., Extramural']
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;ANRS, Emerging Infectious Diseases;National Institute on Drug Abuse (NIDA);COMPLETED;OBSERVATIONAL;True;2015-10-12;2014-09;2016-06;28800503;RESULT;Intravenous heroin use in Haiphong, Vietnam: Need for comprehensive care including methamphetamine use-related interventions.;"Michel L; Des Jarlais DC; Duong Thi H; Khuat Thi Hai O; Pham Minh K; Peries M; Vallo R; Nham Thi Tuyet T; Hoang Thi G; Le Sao M; Feelemyer J; Vu Hai V; Moles JP; Laureillard D; Nagot N; DRIVE Study Team";10.1016/j.drugalcdep.2017.07.004;2017;['Journal Article']
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;ANRS, Emerging Infectious Diseases;National Institute on Drug Abuse (NIDA);COMPLETED;OBSERVATIONAL;True;2015-10-12;2014-09;2016-06;26032121;BACKGROUND;Design and baseline findings of a large-scale rapid response to an HIV outbreak in people who inject drugs in Athens, Greece: the ARISTOTLE programme.;"Hatzakis A; Sypsa V; Paraskevis D; Nikolopoulos G; Tsiara C; Micha K; Panopoulos A; Malliori M; Psichogiou M; Pharris A; Wiessing L; van de Laar M; Donoghoe M; Heckathorn DD; Friedman SR; Des Jarlais DC";10.1111/add.12999;2015;"['Journal Article', 'Research Support, N.I.H., Extramural', ""Research Support, Non-U.S. Gov't""]"
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;ANRS, Emerging Infectious Diseases;National Institute on Drug Abuse (NIDA);COMPLETED;OBSERVATIONAL;True;2015-10-12;2014-09;2016-06;25540950;BACKGROUND;AIDS, people who use drugs, and altruism: reflection on a personal image.;Des Jarlais DC;10.3109/10826084.2015.978185;2015;['Journal Article']
NCT01693848;"""Cancersensor"" Metastasis Resection";Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-09-26;2012-09;2014-11;;;;;;;
NCT01895920;Viral Biofilms: Hijacking T Cell Extracellular Matrix to Regulate HIV-1 Spread?;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2013-07-11;2013-01;2018-02;;;;;;;
NCT01039220;Incidence of H1N1v Influenza-like Illness and Risk Factors for Serious Influenza Forms in HIV Infected Patients;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2009-12-24;2009-12;2010-11;;;;;;;
NCT00820118;Early and Intermittent Antiretroviral Therapy in Naive HIV Infected Adults;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2009-01-09;2009-05;2012-05;26568566;DERIVED;Immunity, inflammation and reservoir in patients at an early stage of HIV infection on intermittent ART (ANRS 141 TIPI Trial).;"Piroth L; Moinot L; Yeni P; Avettand-Fénoel V; Reynes J; Girard PM; Marchou B; Georget A; Rouzioux C; Autran B; Duvillard L; Chêne G; Fagard C; ANRS 141 TIPI Trial Study Group";10.1093/jac/dkv369;2016;"['Clinical Trial, Phase II', 'Journal Article', 'Multicenter Study', ""Research Support, Non-U.S. Gov't""]"
NCT01801618;National Evaluation of PI-based 2nd Line Efficacy in Cambodia;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2013-03-01;2013-02;2014-12;29662875;PUBMED;Positive Virological Outcomes of HIV-Infected Patients on Protease Inhibitor-Based Second-Line Regimen in Cambodia: The ANRS 12276 2PICAM Study.;"Ségéral O; Nerrienet E; Neth S; Spire B; Khol V; Ferradini L; Sarun S; Mom C; Ngin S; Charpentier C; Men P; Mora M; Mean Chhi V; Ly P; Saphonn V";10.3389/fpubh.2018.00063;2018;['Journal Article']
NCT02405013;Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus-infected Patients in West and Central Africa;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2015-04-01;2015-10;2017-11;36686592;PUBMED;Patient-reported outcomes with direct-acting antiviral treatment for hepatitis C in West and Central Africa (TAC ANRS 12311 trial).;"Marcellin F; Mourad A; Lemoine M; Kouanfack C; Seydi M; Carrieri P; Attia A; Protopopescu C; Lacombe K; Boyer S";10.1016/j.jhepr.2022.100665;2023;['Journal Article']
NCT01779713;Transcriptomic Signature of Vasospasm Consecutive to Sub-arachnoid Aneurismal Hemorrhage;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2013-01-30;2013-02-04;2016-07-04;30354977;DERIVED;Whole-Blood miRNA Sequencing Profiling for Vasospasm in Patients With Aneurysmal Subarachnoid Hemorrhage.;"Pulcrano-Nicolas AS; Proust C; Clarençon F; Jacquens A; Perret C; Roux M; Shotar E; Thibord F; Puybasset L; Garnier S; Degos V; Trégouët DA";10.1161/STROKEAHA.118.021101;2018;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;21971357;RESULT;Early antiretroviral therapy in HIV-1-infected infants, 1996-2008: treatment response and duration of first-line regimens.;"Judd A; European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord";10.1097/QAD.0b013e32834d614c;2011;['Comparative Study', 'Journal Article']
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;22427678;RESULT;Relationships between HIV disease history and blood HIV-1 DNA load in perinatally infected adolescents and young adults: the ANRS-EP38-IMMIP study.;"Avettand-Fenoel V; Blanche S; Le Chenadec J; Scott-Algara D; Dollfus C; Viard JP; Bouallag N; Benmebarek Y; Rivière Y; Warszawski J; Rouzioux C; Buseyne F";10.1093/infdis/jis233;2012;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;17712765;RESULT;Long-term nonprogression of HIV infection in children: evaluation of the ANRS prospective French Pediatric Cohort.;"Warszawski J; Lechenadec J; Faye A; Dollfus C; Firtion G; Meyer L; Douard D; Monpoux F; Tricoire J; Benmebarek Y; Rouzioux C; Blanche S";10.1086/521165;2007;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;24253249;RESULT;Naive T lymphocytes and recent thymic emigrants are associated with HIV-1 disease history in french adolescents and young adults infected in the perinatal period: the ANRS-EP38-IMMIP study.;"Blanche S; Scott-Algara D; Le Chenadec J; Didier C; Montange T; Avettand-Fenoel V; Rouzioux C; Mélard A; Viard JP; Dollfus C; Bouallag N; Warszawski J; Buseyne F";10.1093/cid/cit729;2014;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;19194272;RESULT;Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants.;"Goetghebuer T; Haelterman E; Le Chenadec J; Dollfus C; Gibb D; Judd A; Green H; Galli L; Ramos JT; Giaquinto C; Warszawski J; Levy J; European Infant Collaboration group";10.1097/QAD.0b013e328326ca37;2009;"['Journal Article', 'Multicenter Study', ""Research Support, Non-U.S. Gov't""]"
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;22198788;RESULT;Short- and long-term immunological and virological outcome in HIV-infected infants according to the age at antiretroviral treatment initiation.;"Goetghebuer T; Le Chenadec J; Haelterman E; Galli L; Dollfus C; Thorne C; Judd A; Keiser O; Ramos JT; Levy J; Warszawski J; European Infant Collaboration Group";10.1093/cid/cir950;2012;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;20536367;RESULT;Long-term outcomes in adolescents perinatally infected with HIV-1 and followed up since birth in the French perinatal cohort (EPF/ANRS CO10).;"Dollfus C; Le Chenadec J; Faye A; Blanche S; Briand N; Rouzioux C; Warszawski J";10.1086/653674;2010;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;26762993;RESULT;HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report.;"Frange P; Faye A; Avettand-Fenoël V; Bellaton E; Descamps D; Angin M; David A; Caillat-Zucman S; Peytavin G; Dollfus C; Le Chenadec J; Warszawski J; Rouzioux C; Sáez-Cirión A; ANRS EPF-CO10 Pediatric Cohort and the ANRS EP47 VISCONTI study group";10.1016/S2352-3018(15)00232-5;2016;"['Case Reports', 'Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;24945880;RESULT;Interruption of cART in clinical practice is associated with an increase in the long-term risk of subsequent immunosuppression in HIV-1-infected children.;"Aupiais C; Faye A; Le Chenadec J; Rouzioux C; Bouallag N; Laurent C; Blanche S; Dollfus C; Warszawski J; ANRS EPF-CO10 French Pediatric Cohort";10.1097/INF.0000000000000450;2014;"['Journal Article', 'Multicenter Study', ""Research Support, Non-U.S. Gov't""]"
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;21511330;RESULT;Risk of triple-class virological failure in children with HIV: a retrospective cohort study.;"Pursuing Later Treatment Options II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE); Castro H; Judd A; Gibb DM; Butler K; Lodwick RK; van Sighem A; Ramos JT; Warsawski J; Thorne C; Noguera-Julian A; Obel N; Costagliola D; Tookey PA; Colin C; Kjaer J; Grarup J; Chene G; Phillips A";10.1016/S0140-6736(11)60208-0;2011;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;18614870;RESULT;Response to combination antiretroviral therapy: variation by age.;"Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group; Sabin CA; Smith CJ; d'Arminio Monforte A; Battegay M; Gabiano C; Galli L; Geelen S; Gibb D; Guiguet M; Judd A; Leport C; Dabis F; Pantazis N; Porter K; Raffi F; Thorne C; Torti C; Walker S; Warszawski J; Wintergerst U; Chene G; Lundgren J";10.1097/QAD.0b013e3282f88d02;2008;"['Journal Article', 'Multicenter Study', ""Research Support, Non-U.S. Gov't""]"
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;24705410;RESULT;Low birth weight in perinatally HIV-exposed uninfected infants: observations in urban settings in Cameroon.;"Sofeu CL; Warszawski J; Ateba Ndongo F; Penda IC; Tetang Ndiang S; Guemkam G; Makwet N; Owona F; Kfutwah A; Tchendjou P; Texier G; Tchuente M; Faye A; Tejiokem MC; ANRS-PEDIACAM Study Group";10.1371/journal.pone.0093554;2014;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT03071458;Mutational Landscape in Hepatocellular Carcinoma;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2017-03-07;2008-01;2015-05;;;;;;;
NCT02886416;Co-adaptation Between Human Immunodeficiency Virus (HIV) and Cluster of Differentiation 8 (CD8) Cellular Immunity;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2016-09-01;2016-08;2017-04;;;;;;;
NCT01899196;Epicardial Adipose Tissue And Coronary Risk In HIV-Infected Patients;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2013-07-15;2013-07;2016-03;;;;;;;
NCT00944541;Evaluation of Maraviroc Intensification in HIV Infected Patients With Insufficient Immune Restoration;French National Agency for Research on AIDS and Viral Hepatitis;Pfizer;COMPLETED;INTERVENTIONAL;False;2009-07-23;2009-09;2011-01;;;;;;;
NCT02160119;Emotional and Change-related Attention in Autism;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2014-06-10;2014-05-27;2018-05-27;;;;;;;
NCT00158496;Chronic Hepatitis C Treatment by Pegylated Interferon and Ribavirin in Naive Egyptian Patients (ANRS 1211);French National Agency for Research on AIDS and Viral Hepatitis;Hoffmann-La Roche;COMPLETED;INTERVENTIONAL;False;2005-09-12;2002-08;2005-01;16956918;BACKGROUND;Metabolic and cardiovascular risk profiles and hepatitis C virus infection in rural Egypt.;"Marzouk D; Sass J; Bakr I; El Hosseiny M; Abdel-Hamid M; Rekacewicz C; Chaturvedi N; Mohamed MK; Fontanet A";10.1136/gut.2006.091983;2007;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT00158496;Chronic Hepatitis C Treatment by Pegylated Interferon and Ribavirin in Naive Egyptian Patients (ANRS 1211);French National Agency for Research on AIDS and Viral Hepatitis;Hoffmann-La Roche;COMPLETED;INTERVENTIONAL;False;2005-09-12;2002-08;2005-01;16434426;BACKGROUND;Higher clearance of hepatitis C virus infection in females compared with males.;"Bakr I; Rekacewicz C; El Hosseiny M; Ismail S; El Daly M; El-Kafrawy S; Esmat G; Hamid MA; Mohamed MK; Fontanet A";10.1136/gut.2005.078147;2006;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT00158496;Chronic Hepatitis C Treatment by Pegylated Interferon and Ribavirin in Naive Egyptian Patients (ANRS 1211);French National Agency for Research on AIDS and Viral Hepatitis;Hoffmann-La Roche;COMPLETED;INTERVENTIONAL;False;2005-09-12;2002-08;2005-01;16019104;BACKGROUND;Changing pattern of hepatitis C virus spread in rural areas of Egypt.;"Arafa N; El Hoseiny M; Rekacewicz C; Bakr I; El-Kafrawy S; El Daly M; Aoun S; Marzouk D; Mohamed MK; Fontanet A";10.1016/j.jhep.2005.03.021;2005;['Journal Article']
NCT00158496;Chronic Hepatitis C Treatment by Pegylated Interferon and Ribavirin in Naive Egyptian Patients (ANRS 1211);French National Agency for Research on AIDS and Viral Hepatitis;Hoffmann-La Roche;COMPLETED;INTERVENTIONAL;False;2005-09-12;2002-08;2005-01;16847958;BACKGROUND;HCV-related morbidity in a rural community of Egypt.;"Mohamed MK; Bakr I; El-Hoseiny M; Arafa N; Hassan A; Ismail S; Anwar M; Attala M; Rekacewicz C; Zalata K; Abdel-Hamid M; Esmat G; Fontanet A";10.1002/jmv.20679;2006;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT02192658;Disability and HIV: Vulnerability of People With Disabilities to HIV Infection in Sub-Saharan Africa;ANRS, Emerging Infectious Diseases;Handicap International | Institut de Recherche pour le Developpement | Institut de Formation et de Recherche Démographique | Forum Camerounais de Psychologie | Centre de Recherche Internationale pour la Santé de l'Université de Ouagadougou;COMPLETED;OBSERVATIONAL;False;2014-07-17;2014-11;2016-07;26846895;DERIVED;HandiVIH--A population-based survey to understand the vulnerability of people with disabilities to HIV and other sexual and reproductive health problems in Cameroon: protocol and methodological considerations.;"De Beaudrap P; Pasquier E; Tchoumkeu A; Touko A; Essomba F; Brus A; Desgrées du Loû A; Aderemi TJ; Hanass-Hancock J; Eide AH; Mont D; Mac-Seing M; Beninguisse G";10.1136/bmjopen-2015-008934;2016;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT00383734;Safety and Efficacy of Intradermal Injections of Newfill Versus Eutrophill in the Treatment of Facial Lipoatrophy in HIV-infected Patients ANRS 132 SMILE;French National Agency for Research on AIDS and Viral Hepatitis;Procitech | Sanofi;COMPLETED;INTERVENTIONAL;False;2006-10-03;2006-12;2010-09;23432777;DERIVED;Polylactic acid vs. polyacrylamide hydrogel for treatment of facial lipoatrophy: a randomized controlled trial [Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS) 132 SMILE].;"Lafaurie M; Dolivo M; Girard PM; May T; Bouchaud O; Carbonnel E; Madelaine I; Loze B; Porcher R; Molina JM; ANRS 132 SMILE study group";10.1111/hiv.12021;2013;['Clinical Trial', 'Comparative Study', 'Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT02051413;Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder (MDD) (DEPARRESTCLIN);Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-01-31;2014-02-18;2018-05;;;;;;;
NCT03109067;Genetic and Metabolism of Post-prandial HDL Particles;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2017-04-12;2011-09-21;2015-11-21;;;;;;;
NCT02073604;Role of the SMA During Unimanual and Bimanual Movements Preparation: the Mirror Movements Paradigm;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-02-27;2014-03;2016-02;;;;;;;
NCT01490489;EG-VEGF : Potential Marker of Pre-eclampsia and / or Intrauterine Growth Restriction;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-12-13;2011-07-11;2015-03-13;19602057;RESULT;Role of EG-VEGF in human placentation: Physiological and pathological implications.;"Hoffmann P; Saoudi Y; Benharouga M; Graham CH; Schaal JP; Mazouni C; Feige JJ; Alfaidy N";10.1111/j.1582-4934.2008.00554.x;2009;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01490489;EG-VEGF : Potential Marker of Pre-eclampsia and / or Intrauterine Growth Restriction;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-12-13;2011-07-11;2015-03-13;16384869;RESULT;Expression and oxygen regulation of endocrine gland-derived vascular endothelial growth factor/prokineticin-1 and its receptors in human placenta during early pregnancy.;"Hoffmann P; Feige JJ; Alfaidy N";10.1210/en.2005-0912;2006;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01490489;EG-VEGF : Potential Marker of Pre-eclampsia and / or Intrauterine Growth Restriction;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-12-13;2011-07-11;2015-03-13;17531315;RESULT;Placental expression of EG-VEGF and its receptors PKR1 (prokineticin receptor-1) and PKR2 throughout mouse gestation.;"Hoffmann P; Feige JJ; Alfaidy N";10.1016/j.placenta.2007.03.008;2007;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01335529;Boceprevir in HIV-HCV Coinfected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin;ANRS, Emerging Infectious Diseases;Rennes University Hospital | Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2011-04-14;2011-05;2014-05;27077673;DERIVED;Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study.;"Poizot-Martin I; Bellissant E; Garraffo R; Colson P; Piroth L; Solas C; Renault A; Bourlière M; Halfon P; Ghosn J; Alric L; Naqvi A; Carrieri P; Molina JM; ANRS HC27 BOCEPREVIH Study Group";10.1080/15284336.2015.1135553;2016;['Clinical Trial, Phase II', 'Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT00545194;Cervical Ripening Before Induction of Labour at Term: a Randomised Comparison of Prostin vs Propess;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2007-10-17;2002-01;2004-10;11236117;BACKGROUND;In vivo controlled release of PGE2 from a vaginal insert (0.8 mm, 10 mg) during induction of labour.;"Lyrenäs S; Clason I; Ulmsten U";10.1111/j.1471-0528.2001.00039.x;2001;['Journal Article']
NCT00545194;Cervical Ripening Before Induction of Labour at Term: a Randomised Comparison of Prostin vs Propess;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2007-10-17;2002-01;2004-10;17071427;BACKGROUND;Induction of labour at term with vaginal prostaglandins preparations: a randomised controlled trial of Prostin vs Propess.;"El-Shawarby SA; Connell RJ";10.1080/01443610600903362;2006;['Comparative Study', 'Journal Article', 'Randomized Controlled Trial']
NCT00545194;Cervical Ripening Before Induction of Labour at Term: a Randomised Comparison of Prostin vs Propess;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2007-10-17;2002-01;2004-10;16553177;BACKGROUND;Randomized study on removable PGE2 vaginal insert versus PGE2 cervical gel for cervical priming and labor induction in low-Bishop-score pregnancy.;"Strobelt N; Meregalli V; Ratti M; Mariani S; Zani G; Morana S";10.1080/00016340500523685;2006;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT03298360;A Chronological Study of the Formation of HIV Cellular Reservoirs Through the Expression of Surface Markers on CD4 + T Lymphocytes, Including CD32a;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-10-02;2018-06-28;2020-06-25;;;;;;;
NCT01508494;Cognitive Rehabilitation and Galantamine for Post Stroke Cognitive Impairment;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-01-12;2011-06-29;2016-06-22;;;;;;;
NCT00573001;Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA);French National Agency for Research on AIDS and Viral Hepatitis;Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba | Gilead Sciences | Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-12-13;2008-07;2011-12;;;;;;;
NCT00236340;Syringe or Continuous Amnioreduction for Symptomatic Polyhydramnios. A Prospective Randomized Study.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2005-10-12;2002-01;2005-02;11438952;BACKGROUND;Rapid and radical amniodrainage in the treatment of severe twin-twin transfusion syndrome.;"Jauniaux E; Holmes A; Hyett J; Yates R; Rodeck C";10.1002/pd.96;2001;['Journal Article']
NCT00236340;Syringe or Continuous Amnioreduction for Symptomatic Polyhydramnios. A Prospective Randomized Study.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2005-10-12;2002-01;2005-02;7970458;BACKGROUND;Large-volume therapeutic amniocentesis in the treatment of hydramnios.;"Elliott JP; Sawyer AT; Radin TG; Strong RE";;1994;['Journal Article']
NCT00236340;Syringe or Continuous Amnioreduction for Symptomatic Polyhydramnios. A Prospective Randomized Study.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2005-10-12;2002-01;2005-02;9464739;BACKGROUND;Therapeutic amniocentesis using a vacuum bottle aspiration system.;"Dolinger MB; Donnenfeld AE";10.1016/s0029-7844(97)00584-x;1998;['Journal Article']
NCT00236340;Syringe or Continuous Amnioreduction for Symptomatic Polyhydramnios. A Prospective Randomized Study.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2005-10-12;2002-01;2005-02;14770396;BACKGROUND;Procedure-related complications of rapid amniodrainage in the treatment of polyhydramnios.;"Leung WC; Jouannic JM; Hyett J; Rodeck C; Jauniaux E";10.1002/uog.972;2004;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT02542891;European Comparative Effectiveness Research on Internet-based Depression Treatment;Institut National de la Santé Et de la Recherche Médicale, France;European Commission | Fondation FondaMental | Assistance Publique - Hôpitaux de Paris;COMPLETED;INTERVENTIONAL;False;2015-09-07;2015-09;2018-09-15;34874888;DERIVED;Examining the Theoretical Framework of Behavioral Activation for Major Depressive Disorder: Smartphone-Based Ecological Momentary Assessment Study.;"van Genugten CR; Schuurmans J; Hoogendoorn AW; Araya R; Andersson G; Baños R; Botella C; Cerga Pashoja A; Cieslak R; Ebert DD; García-Palacios A; Hazo JB; Herrero R; Holtzmann J; Kemmeren L; Kleiboer A; Krieger T; Smoktunowicz E; Titzler I; Topooco N; Urech A; Smit JH; Riper H";10.2196/32007;2021;['Journal Article']
NCT02542891;European Comparative Effectiveness Research on Internet-based Depression Treatment;Institut National de la Santé Et de la Recherche Médicale, France;European Commission | Fondation FondaMental | Assistance Publique - Hôpitaux de Paris;COMPLETED;INTERVENTIONAL;False;2015-09-07;2015-09;2018-09-15;27488181;DERIVED;European COMPARative Effectiveness research on blended Depression treatment versus treatment-as-usual (E-COMPARED): study protocol for a randomized controlled, non-inferiority trial in eight European countries.;"Kleiboer A; Smit J; Bosmans J; Ruwaard J; Andersson G; Topooco N; Berger T; Krieger T; Botella C; Baños R; Chevreul K; Araya R; Cerga-Pashoja A; Cieślak R; Rogala A; Vis C; Draisma S; van Schaik A; Kemmeren L; Ebert D; Berking M; Funk B; Cuijpers P; Riper H";10.1186/s13063-016-1511-1;2016;['Equivalence Trial', 'Journal Article', 'Multicenter Study', 'Pragmatic Clinical Trial', 'Randomized Controlled Trial']
NCT03671291;Missed Opportunities to Pre-exposure Prophylaxis for HIV Infection on Person Newly Diagnosed With HIV;French National Agency for Research on AIDS and Viral Hepatitis;University Hospital, Marseille | University Hospital, Grenoble | Centre Hospitalier Universitaire de Nice | University Hospital, Montpellier | Hospital Purpan | University Hospital, Bordeaux | Hôpital de la Croix-Rousse | Centre Hospitalier Universitaire Dijon | University Hospital of Saint-Etienne | University Hospital, Clermont-Ferrand | Centre Hospitalier Universitaire de Besancon | Tourcoing Hospital | University Hospital, Strasbourg | Nantes University Hospital | Centre Hospitalier Régional d'Orléans | Rennes University Hospital | Saint Antoine University Hospital | Tenon Hospital, Paris | Saint-Louis Hospital, Paris, France | Hôpital Necker-Enfants Malades | Bicetre Hospital | Pitié-Salpêtrière Hospital | Bichat Hospital | University Hospital Center of Martinique;COMPLETED;INTERVENTIONAL;False;2018-09-14;2019-04-03;2021-10-03;;;;;;;
NCT01066962;Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects;ANRS, Emerging Infectious Diseases;NEAT - European AIDS Treatment Network;COMPLETED;INTERVENTIONAL;False;2010-02-10;2010-08;2013-10;33794182;DERIVED;Epigenetic age acceleration changes 2 years after antiretroviral therapy initiation in adults with HIV: a substudy of the NEAT001/ANRS143 randomised trial.;"Esteban-Cantos A; Rodríguez-Centeno J; Barruz P; Alejos B; Saiz-Medrano G; Nevado J; Martin A; Gayá F; De Miguel R; Bernardino JI; Montejano R; Mena-Garay B; Cadiñanos J; Florence E; Mulcahy F; Banhegyi D; Antinori A; Pozniak A; Wallet C; Raffi F; Rodés B; Arribas JR; NEAT001/ANRS143 Study Group";10.1016/S2352-3018(21)00006-0;2021;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01066962;Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects;ANRS, Emerging Infectious Diseases;NEAT - European AIDS Treatment Network;COMPLETED;INTERVENTIONAL;False;2010-02-10;2010-08;2013-10;30365452;DERIVED;Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 Trial.;"Ammassari A; Stöhr W; Antinori A; Molina JM; Schwimmer C; Domingo P; Thalme A; Di Pietro M; Wallet C; Pozniak A; Richert L; Raffi F; NEAT001/ANRS143 Trial Study Group";10.1097/QAI.0000000000001834;2018;"['Clinical Trial, Phase III', 'Comparative Study', 'Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT01066962;Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects;ANRS, Emerging Infectious Diseases;NEAT - European AIDS Treatment Network;COMPLETED;INTERVENTIONAL;False;2010-02-10;2010-08;2013-10;26520926;DERIVED;Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial.;"Bernardino JI; Mocroft A; Mallon PW; Wallet C; Gerstoft J; Russell C; Reiss P; Katlama C; De Wit S; Richert L; Babiker A; Buño A; Castagna A; Girard PM; Chene G; Raffi F; Arribas JR; NEAT001/ANRS143 Study Group";10.1016/S2352-3018(15)00181-2;2015;"['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT01066962;Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects;ANRS, Emerging Infectious Diseases;NEAT - European AIDS Treatment Network;COMPLETED;INTERVENTIONAL;False;2010-02-10;2010-08;2013-10;25103176;DERIVED;Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial.;"Raffi F; Babiker AG; Richert L; Molina JM; George EC; Antinori A; Arribas JR; Grarup J; Hudson F; Schwimmer C; Saillard J; Wallet C; Jansson PO; Allavena C; Van Leeuwen R; Delfraissy JF; Vella S; Chêne G; Pozniak A; NEAT001/ANRS143 Study Group";10.1016/S0140-6736(14)61170-3;2014;"['Comparative Study', 'Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT01703962;Non Invasive IDentification of Gliomas With IDH1 Mutation;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-10-11;2012-03-14;2014-03-20;37668523;PUBMED;Neurochemical Differences between 1p/19q Codeleted and Noncodeleted IDH-mutant Gliomas by in Vivo MR Spectroscopy.;"Branzoli F; Liserre R; Deelchand DK; Poliani PL; Bielle F; Nichelli L; Sanson M; Lehéricy S; Marjańska M";10.1148/radiol.223255;2023;"['Journal Article', 'Observational Study', ""Research Support, Non-U.S. Gov't"", 'Research Support, N.I.H., Extramural']"
NCT03642704;HIV Diagnosis and Treatment at Birth for Newborn With High Risk HIV Exposure;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-08-22;2017-02-22;2019-09-17;;;;;;;
NCT01086904;Safety and Efficacy of an Inactivated and Non Adjuvanted Vaccine Against Influenza A in Renal Transplant Recipients;Institut National de la Santé Et de la Recherche Médicale, France;MCM Vaccines B.V.;COMPLETED;INTERVENTIONAL;False;2010-03-15;2009-11;2010-05;;;;;;;
NCT01127204;Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age;ANRS, Emerging Infectious Diseases;European and Developing Countries Clinical Trials Partnership (EDCTP) | Public Research Centre Health, Luxembourg | Ministry of Foreign Affairs, Luxembourg | University of Ouagadougou, Burkina Faso | Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire | Ministry of Health, Rwanda | Institut National de la Santé Et de la Recherche Médicale, France | University of Bordeaux | Institut de Sante Publique, d'Epidémiologie et de Développement | Université Montpellier | University of Paris 5 - Rene Descartes | Queen Fabiola Children's University Hospital;COMPLETED;INTERVENTIONAL;False;2010-05-20;2011-06;2015-04;28483965;DERIVED;Pharmacokinetics of Efavirenz at a High Dose of 25 Milligrams per Kilogram per Day in Children 2 to 3 Years Old.;"Pressiat C; Amorissani-Folquet M; Yonaba C; Treluyer JM; Dahourou DL; Eboua F; Blanche S; Mea-Assande V; Bouazza N; Foissac F; Malateste K; Ouedraogo S; Lui G; Leroy V; Hirt D";10.1128/AAC.00297-17;2017;['Journal Article']
NCT01127204;Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age;ANRS, Emerging Infectious Diseases;European and Developing Countries Clinical Trials Partnership (EDCTP) | Public Research Centre Health, Luxembourg | Ministry of Foreign Affairs, Luxembourg | University of Ouagadougou, Burkina Faso | Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire | Ministry of Health, Rwanda | Institut National de la Santé Et de la Recherche Médicale, France | University of Bordeaux | Institut de Sante Publique, d'Epidémiologie et de Développement | Université Montpellier | University of Paris 5 - Rene Descartes | Queen Fabiola Children's University Hospital;COMPLETED;INTERVENTIONAL;False;2010-05-20;2011-06;2015-04;31334298;DERIVED;Cost-Effectiveness of Preemptive Switching to Efavirenz-Based Antiretroviral Therapy for Children With Human Immunodeficiency Virus.;"Desmonde S; Frank SC; Coovadia A; Dahourou DL; Hou T; Abrams EJ; Amorissani-Folquet M; Walensky RP; Strehlau R; Penazzato M; Freedberg KA; Kuhn L; Leroy V; Ciaranello AL";10.1093/ofid/ofz276;2019;['Journal Article']
NCT01127204;Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age;ANRS, Emerging Infectious Diseases;European and Developing Countries Clinical Trials Partnership (EDCTP) | Public Research Centre Health, Luxembourg | Ministry of Foreign Affairs, Luxembourg | University of Ouagadougou, Burkina Faso | Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire | Ministry of Health, Rwanda | Institut National de la Santé Et de la Recherche Médicale, France | University of Bordeaux | Institut de Sante Publique, d'Epidémiologie et de Développement | Université Montpellier | University of Paris 5 - Rene Descartes | Queen Fabiola Children's University Hospital;COMPLETED;INTERVENTIONAL;False;2010-05-20;2011-06;2015-04;28800382;DERIVED;Suboptimal cotrimoxazole prophylactic concentrations in HIV-infected children according to the WHO guidelines.;"Pressiat C; Mea-Assande V; Yonaba C; Treluyer JM; Dahourou DL; Amorissani-Folquet M; Blanche S; Eboua F; Ye D; Lui G; Malateste K; Zheng Y; Leroy V; Hirt D; MONOD Study Group";10.1111/bcp.13397;2017;['Clinical Trial, Phase III', 'Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT01127204;Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age;ANRS, Emerging Infectious Diseases;European and Developing Countries Clinical Trials Partnership (EDCTP) | Public Research Centre Health, Luxembourg | Ministry of Foreign Affairs, Luxembourg | University of Ouagadougou, Burkina Faso | Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire | Ministry of Health, Rwanda | Institut National de la Santé Et de la Recherche Médicale, France | University of Bordeaux | Institut de Sante Publique, d'Epidémiologie et de Développement | Université Montpellier | University of Paris 5 - Rene Descartes | Queen Fabiola Children's University Hospital;COMPLETED;INTERVENTIONAL;False;2010-05-20;2011-06;2015-04;28453240;DERIVED;Virological response and resistances over 12 months among HIV-infected children less than two years receiving first-line lopinavir/ritonavir-based antiretroviral therapy in Cote d'Ivoire and Burkina Faso: the MONOD ANRS 12206 cohort.;"Amani-Bosse C; Dahourou DL; Malateste K; Amorissani-Folquet M; Coulibaly M; Dattez S; Emieme A; Barry M; Rouzioux C; N'gbeche S; Yonaba C; Timité-Konan M; Mea V; Ouédraogo S; Blanche S; Meda N; Seguin-Devaux C; Leroy V";10.7448/IAS.20.01.21362;2017;['Journal Article']
NCT01127204;Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age;ANRS, Emerging Infectious Diseases;European and Developing Countries Clinical Trials Partnership (EDCTP) | Public Research Centre Health, Luxembourg | Ministry of Foreign Affairs, Luxembourg | University of Ouagadougou, Burkina Faso | Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire | Ministry of Health, Rwanda | Institut National de la Santé Et de la Recherche Médicale, France | University of Bordeaux | Institut de Sante Publique, d'Epidémiologie et de Développement | Université Montpellier | University of Paris 5 - Rene Descartes | Queen Fabiola Children's University Hospital;COMPLETED;INTERVENTIONAL;False;2010-05-20;2011-06;2015-04;34723858;DERIVED;High nevirapine levels in breast milk and consequences in HIV-infected child when initiated on antiretroviral therapy.;"Pressiat C; Toni TD; Treluyer JM; Yonaba C; Dahourou DL; Malateste K; Seguin-Devaux C; Leroy V; Hirt D; MONOD ANRS Study Group";10.1097/QAD.0000000000003043;2021;"['Letter', ""Research Support, Non-U.S. Gov't""]"
NCT01127204;Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age;ANRS, Emerging Infectious Diseases;European and Developing Countries Clinical Trials Partnership (EDCTP) | Public Research Centre Health, Luxembourg | Ministry of Foreign Affairs, Luxembourg | University of Ouagadougou, Burkina Faso | Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire | Ministry of Health, Rwanda | Institut National de la Santé Et de la Recherche Médicale, France | University of Bordeaux | Institut de Sante Publique, d'Epidémiologie et de Développement | Université Montpellier | University of Paris 5 - Rene Descartes | Queen Fabiola Children's University Hospital;COMPLETED;INTERVENTIONAL;False;2010-05-20;2011-06;2015-04;27015798;DERIVED;Missed opportunities of inclusion in a cohort of HIV-infected children to initiate antiretroviral treatment before the age of two in West Africa, 2011 to 2013.;"Dahourou DL; Amorissani-Folquet M; Coulibaly M; Avit-Edi D; Meda N; Timite-Konan M; Arendt V; Ye D; Amani-Bosse C; Salamon R; Lepage P; Leroy V; Monod Anrs 12206 Study Group";10.7448/IAS.19.1.20601;2016;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01127204;Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age;ANRS, Emerging Infectious Diseases;European and Developing Countries Clinical Trials Partnership (EDCTP) | Public Research Centre Health, Luxembourg | Ministry of Foreign Affairs, Luxembourg | University of Ouagadougou, Burkina Faso | Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire | Ministry of Health, Rwanda | Institut National de la Santé Et de la Recherche Médicale, France | University of Bordeaux | Institut de Sante Publique, d'Epidémiologie et de Développement | Université Montpellier | University of Paris 5 - Rene Descartes | Queen Fabiola Children's University Hospital;COMPLETED;INTERVENTIONAL;False;2010-05-20;2011-06;2015-04;28434406;DERIVED;Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.;"Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V; MONOD Study Group";10.1186/s12916-017-0842-4;2017;['Clinical Trial, Phase III', 'Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT01771562;Nutritional and Metabolic Disorders in HIV Infected Children and Adolescent;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2013-01-18;2013-04;2016-04;27881690;DERIVED;Acceptability of Outpatient Ready-To-Use Food-Based Protocols in HIV-Infected Senegalese Children and Adolescents Within the MAGGSEN Cohort Study.;"Cames C; Varloteaux M; Have NN; Diom AB; Msellati P; Mbaye N; Mbodj H; Sy Signate H; Diack A; ANRS 12279 MAGGSEN Cohort Study Group";10.1177/0379572116679053;2017;['Journal Article']
NCT01771562;Nutritional and Metabolic Disorders in HIV Infected Children and Adolescent;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2013-01-18;2013-04;2016-04;30081838;DERIVED;Low prevalence of lipodystrophy in HIV-infected Senegalese children on long-term antiretroviral treatment: the ANRS 12279 MAGGSEN Pediatric Cohort Study.;"Cames C; Pascal L; Ba A; Mbodj H; Ouattara B; Diallo NF; Msellati P; Mbaye N; Sy Signate H; Blanche S; Diack A; MAGGSEN Cohort Study Group";10.1186/s12879-018-3282-7;2018;['Journal Article']
NCT00196612;Once Daily Antiretroviral Therapy in HIV Infected Adults Treated With HAART;French National Agency for Research on AIDS and Viral Hepatitis;Triangle Pharmaceuticals | Gilead Sciences | Bristol-Myers Squibb | Dupont Applied Biosciences;COMPLETED;INTERVENTIONAL;False;2005-09-20;2001-04;2004-09;15717256;RESULT;Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial.;"Molina JM; Journot V; Morand-Joubert L; Yéni P; Rozenbaum W; Rancinan C; Fournier S; Morlat P; Palmer P; Dupont B; Goujard C; Dellamonica P; Collin F; Poizot-Martin I; Chene G; ALIZE (Agence Nationale de Recherches sur le SIDA 099) Study Team";10.1086/428091;2005;"['Clinical Trial', 'Comparative Study', 'Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT01226446;Efficacy of Vitamin D on Top of Pegylated Interferon and Ribavirin in Patients With Chronic Viral Hepatitis C Null-Responders;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2010-10-22;2010-11;2013-01;25987791;DERIVED;Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study.;"Terrier B; Lapidus N; Pol S; Serfaty L; Ratziu V; Asselah T; Thibault V; Souberbielle JC; Carrat F; Cacoub P";10.3748/wjg.v21.i18.5647;2015;['Clinical Trial', 'Journal Article', 'Multicenter Study']
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;19533496;BACKGROUND;Apathy after acquired brain impairment: a systematic review of non-pharmacological interventions.;"Lane-Brown AT; Tate RL";10.1080/09602010902949207;2009;"['Journal Article', ""Research Support, Non-U.S. Gov't"", 'Review', 'Systematic Review']"
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;16207933;BACKGROUND;Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits.;"Levy R; Dubois B";10.1093/cercor/bhj043;2006;"['Journal Article', ""Research Support, Non-U.S. Gov't"", 'Review']"
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;10941190;BACKGROUND;Negative symptoms: the 'pathology' of motivation and goal-directed behaviour.;"Brown RG; Pluck G";10.1016/s0166-2236(00)01626-x;2000;['Journal Article', 'Review']
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;12461757;BACKGROUND;The apathy inventory: assessment of apathy and awareness in Alzheimer's disease, Parkinson's disease and mild cognitive impairment.;"Robert PH; Clairet S; Benoit M; Koutaich J; Bertogliati C; Tible O; Caci H; Borg M; Brocker P; Bedoucha P";10.1002/gps.755;2002;"['Journal Article', ""Research Support, Non-U.S. Gov't"", 'Validation Study']"
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;10678322;BACKGROUND;Group differences in the relationship between apathy and depression.;"Marin RS; Firinciogullari S; Biedrzycki RC";10.1097/00005053-199404000-00008;1994;"['Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]"
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;1821241;BACKGROUND;Apathy: a neuropsychiatric syndrome.;Marin RS;10.1176/jnp.3.3.243;1991;"['Journal Article', ""Research Support, U.S. Gov't, P.H.S."", 'Review']"
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;16421064;BACKGROUND;Reduced daytime activity in patients with acquired brain damage and apathy: a study with ambulatory actigraphy.;"Müller U; Czymmek J; Thöne-Otto A; Von Cramon DY";10.1080/02699050500443467;2006;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;19933975;BACKGROUND;Subthalamic nucleus stimulation in Parkinson disease induces apathy: a PET study.;"Le Jeune F; Drapier D; Bourguignon A; Péron J; Mesbah H; Drapier S; Sauleau P; Haegelen C; Travers D; Garin E; Malbert CH; Millet B; Vérin M";10.1212/WNL.0b013e3181c34b34;2009;['Clinical Trial', 'Journal Article']
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;19713543;BACKGROUND;A longitudinal view of apathy and its impact after stroke.;"Mayo NE; Fellows LK; Scott SC; Cameron J; Wood-Dauphinee S";10.1161/STROKEAHA.109.554410;2009;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;15897497;BACKGROUND;Does bilateral stimulation of the subthalamic nucleus aggravate apathy in Parkinson's disease?;"Czernecki V; Pillon B; Houeto JL; Welter ML; Mesnage V; Agid Y; Dubois B";10.1136/jnnp.2003.033258;2005;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;18307266;BACKGROUND;The Lille Apathy Rating Scale: validation of a caregiver-based version.;"Dujardin K; Sockeel P; Delliaux M; Destée A; Defebvre L";10.1002/mds.21968;2008;['Journal Article']
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;10436334;BACKGROUND;The clinical picture of frontotemporal dementia: diagnosis and follow-up.;"Pasquier F; Lebert F; Lavenu I; Guillaume B";10.1159/000051206;1999;['Journal Article']
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;17131230;BACKGROUND;Apathy and the basal ganglia.;"Levy R; Czernecki V";10.1007/s00415-006-7012-5;2006;['Journal Article', 'Review']
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;17027767;BACKGROUND;Negative symptoms: A review of schizophrenia, melancholic depression and Parkinson's disease.;"Winograd-Gurvich C; Fitzgerald PB; Georgiou-Karistianis N; Bradshaw JL; White OB";10.1016/j.brainresbull.2006.06.007;2006;['Journal Article', 'Review']
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;21895376;BACKGROUND;The SEA (Social cognition and Emotional Assessment): a clinical neuropsychological tool for early diagnosis of frontal variant of frontotemporal lobar degeneration.;"Funkiewiez A; Bertoux M; de Souza LC; Lévy R; Dubois B";10.1037/a0025318;2012;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT04133012;Cartography of Virologic Reservoir Related to Antiretroviral Concentrations in HIV-1 Chronic Patients Treated by a First Line Treatment Containing Dolutegravir and Associated Nucleoside / Nucleotide Reverse Transcriptase Inhibitors Backbone;ANRS, Emerging Infectious Diseases;ViiV Healthcare;COMPLETED;INTERVENTIONAL;False;2019-10-21;2020-02-10;2023-06-09;;;;;;;
NCT01100281;Prefrontal Cortex and Abstract Thinking;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2010-04-08;2010-04;2011-04;;;;;;;
NCT01647295;Social Interactions: Ocular Explorations and Pupillometry in Autism;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-07-23;2013-02-25;2019-06-18;;;;;;;
NCT00424814;Prevention of HIV1 Mother to Child Transmission Without Nucleoside Analogue Reverse Transcriptase Inhibitors in the Pre-partum Phase. ANRS 135 Primeva;ANRS, Emerging Infectious Diseases;Abbott;COMPLETED;INTERVENTIONAL;False;2007-01-22;2007-03;2012-11;25838291;DERIVED;In utero exposure to zidovudine and heart anomalies in the ANRS French perinatal cohort and the nested PRIMEVA randomized trial.;"Sibiude J; Le Chenadec J; Bonnet D; Tubiana R; Faye A; Dollfus C; Mandelbrot L; Delmas S; Lelong N; Khoshnood B; Warszawski J; Blanche S; French National Agency for Research on AIDS and Viral Hepatitis French Perinatal Cohort/Protease Inhibitor Monotherapy Evaluation Trial";10.1093/cid/civ260;2015;"['Clinical Trial', 'Journal Article', 'Observational Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00424814;Prevention of HIV1 Mother to Child Transmission Without Nucleoside Analogue Reverse Transcriptase Inhibitors in the Pre-partum Phase. ANRS 135 Primeva;ANRS, Emerging Infectious Diseases;Abbott;COMPLETED;INTERVENTIONAL;False;2007-01-22;2007-03;2012-11;23766338;DERIVED;Lopinavir/ritonavir monotherapy as a nucleoside analogue-sparing strategy to prevent HIV-1 mother-to-child transmission: the ANRS 135 PRIMEVA phase 2/3 randomized trial.;"Tubiana R; Mandelbrot L; Le Chenadec J; Delmas S; Rouzioux C; Hirt D; Treluyer JM; Ekoukou D; Bui E; Chaix ML; Blanche S; Warszawski J; ANRS 135 PRIMEVA (Protease Inhibitor Monotherapy Evaluation) Study Group";10.1093/cid/cit390;2013;"['Clinical Trial, Phase II', 'Clinical Trial, Phase III', 'Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT02488395;Superior Colliculus Activity in Parkinson Disease: a Potential Marker?;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2015-07-02;2015-10-07;2018-01-19;6774653;RESULT;Visual-motor function of the primate superior colliculus.;"Wurtz RH; Albano JE";10.1146/annurev.ne.03.030180.001201;1980;['Comparative Study', 'Journal Article', 'Review']
NCT02488395;Superior Colliculus Activity in Parkinson Disease: a Potential Marker?;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2015-07-02;2015-10-07;2018-01-19;23916713;RESULT;Enhanced visual responses in the superior colliculus and subthalamic nucleus in an animal model of Parkinson's disease.;"Rolland M; Carcenac C; Overton PG; Savasta M; Coizet V";10.1016/j.neuroscience.2013.07.047;2013;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT02488395;Superior Colliculus Activity in Parkinson Disease: a Potential Marker?;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2015-07-02;2015-10-07;2018-01-19;22639796;RESULT;Linking visual response properties in the superior colliculus to saccade behavior.;"Marino RA; Levy R; Boehnke S; White BJ; Itti L; Munoz DP";10.1111/j.1460-9568.2012.08079.x;2012;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT00658346;Molecular Diversity of HIV-1 Group O Strains and Treatment Management in Cameroon;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2008-04-15;2010-06;2016-09;31063537;DERIVED;Comparative Immunovirological and Clinical Responses to Antiretroviral Therapy Between HIV-1 Group O and HIV-1 Group M Infected Patients.;"Kouanfack C; Unal G; Schaeffer L; Kfutwah A; Aghokeng A; Mougnutou R; Tchemgui-Noumsi N; Alessandri-Gradt E; Delaporte E; Simon F; Vray M; Plantier JC; ANRS 12168 DynaMO Study";10.1093/cid/ciz371;2020;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01188512;First Adult Safety Trial on Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;European Union | Swedish Institute for Infectious Disease Control | Innogenetics;COMPLETED;INTERVENTIONAL;False;2010-08-25;2010-08;2012-01;24793938;DERIVED;B-cell responses after intranasal vaccination with the novel attenuated Bordetella pertussis vaccine strain BPZE1 in a randomized phase I clinical trial.;"Jahnmatz M; Amu S; Ljungman M; Wehlin L; Chiodi F; Mielcarek N; Locht C; Thorstensson R";10.1016/j.vaccine.2014.04.048;2014;['Clinical Trial, Phase I', 'Journal Article', 'Randomized Controlled Trial']
NCT01188512;First Adult Safety Trial on Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;European Union | Swedish Institute for Infectious Disease Control | Innogenetics;COMPLETED;INTERVENTIONAL;False;2010-08-25;2010-08;2012-01;24421886;DERIVED;"A phase I clinical study of a live attenuated Bordetella pertussis vaccine--BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers.";"Thorstensson R; Trollfors B; Al-Tawil N; Jahnmatz M; Bergström J; Ljungman M; Törner A; Wehlin L; Van Broekhoven A; Bosman F; Debrie AS; Mielcarek N; Locht C";10.1371/journal.pone.0083449;2014;"['Clinical Trial, Phase I', 'Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT01188512;First Adult Safety Trial on Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;European Union | Swedish Institute for Infectious Disease Control | Innogenetics;COMPLETED;INTERVENTIONAL;False;2010-08-25;2010-08;2012-01;20184606;BACKGROUND;Attenuated Bordetella pertussis vaccine strain BPZE1 modulates allergen-induced immunity and prevents allergic pulmonary pathology in a murine model.;"Kavanagh H; Noone C; Cahill E; English K; Locht C; Mahon BP";10.1111/j.1365-2222.2010.03459.x;2010;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01188512;First Adult Safety Trial on Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;European Union | Swedish Institute for Infectious Disease Control | Innogenetics;COMPLETED;INTERVENTIONAL;False;2010-08-25;2010-08;2012-01;24261996;DERIVED;Attenuated Bordetella pertussis vaccine protects against respiratory syncytial virus disease via an IL-17-dependent mechanism.;"Schnoeller C; Roux X; Sawant D; Raze D; Olszewska W; Locht C; Openshaw PJ";10.1164/rccm.201307-1227OC;2014;['Evaluation Study', 'Journal Article']
NCT01188512;First Adult Safety Trial on Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;European Union | Swedish Institute for Infectious Disease Control | Innogenetics;COMPLETED;INTERVENTIONAL;False;2010-08-25;2010-08;2012-01;19625486;BACKGROUND;A live attenuated Bordetella pertussis candidate vaccine does not cause disseminating infection in gamma interferon receptor knockout mice.;"Skerry CM; Cassidy JP; English K; Feunou-Feunou P; Locht C; Mahon BP";10.1128/CVI.00082-09;2009;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01188512;First Adult Safety Trial on Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;European Union | Swedish Institute for Infectious Disease Control | Innogenetics;COMPLETED;INTERVENTIONAL;False;2010-08-25;2010-08;2012-01;16839199;BACKGROUND;Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough.;"Mielcarek N; Debrie AS; Raze D; Bertout J; Rouanet C; Younes AB; Creusy C; Engle J; Goldman WE; Locht C";10.1371/journal.ppat.0020065;2006;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01188512;First Adult Safety Trial on Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;European Union | Swedish Institute for Infectious Disease Control | Innogenetics;COMPLETED;INTERVENTIONAL;False;2010-08-25;2010-08;2012-01;18762220;BACKGROUND;Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1.;"Feunou PF; Ismaili J; Debrie AS; Huot L; Hot D; Raze D; Lemoine Y; Locht C";10.1016/j.vaccine.2008.08.018;2008;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01188512;First Adult Safety Trial on Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;European Union | Swedish Institute for Infectious Disease Control | Innogenetics;COMPLETED;INTERVENTIONAL;False;2010-08-25;2010-08;2012-01;20107007;BACKGROUND;Dose response of attenuated Bordetella pertussis BPZE1-induced protection in mice.;"Mielcarek N; Debrie AS; Mahieux S; Locht C";10.1128/CVI.00322-09;2010;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT04945655;Impact of a School- and Primary Care-based Multicomponent Intervention on HPV Vaccination Acceptability;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2021-06-30;2021-11-15;2023-04-30;35332045;DERIVED;Impact of a school-based and primary care-based multicomponent intervention on HPV vaccination coverage among French adolescents: a cluster randomised controlled trial protocol (the PrevHPV study).;"Bocquier A; Michel M; Giraudeau B; Bonnay S; Gagneux-Brunon A; Gauchet A; Gilberg S; Le Duc-Banaszuk AS; Mueller JE; Chevreul K; Thilly N; PrevHPV Study group";10.1136/bmjopen-2021-057943;2022;"['Clinical Trial Protocol', 'Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01942655;IL-23/IL-12 Imbalance and T Lymphocyte Polarization in HIV Infection;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2013-09-16;2014-06-01;2018-03-01;;;;;;;
NCT01332955;Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen;ANRS, Emerging Infectious Diseases;Janssen-Cilag Ltd.;COMPLETED;INTERVENTIONAL;False;2011-04-11;2011-04;2013-09;25139963;DERIVED;Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.;"Cotte L; Braun J; Lascoux-Combe C; Vincent C; Valantin MA; Sogni P; Lacombe K; Neau D; Aumaitre H; Batisse D; de Truchis P; Gervais A; Michelet C; Morlat P; Vittecoq D; Rosa I; Bertucci I; Chevaliez S; Aboulker JP; Molina JM; French National Agency for Research on AIDS and Viral Hepatitis (ANRS) HC26 Study Group";10.1093/cid/ciu659;2014;"['Clinical Trial, Phase II', 'Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01552044;Effect of Spironolactone in Treating Chronic Non-resolutive Central Serous Chorioretinitis;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-03-13;2012-01;2013-02;;;;;;;
NCT02592174;Prevalence, Characteristics and Risk Factors of HIV-Associated Neurocognitive Disorders in Subjects Between the Ages of 55 and 70 Years: An Exposed/Unexposed Cross Sectional Study;ANRS, Emerging Infectious Diseases;Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2015-10-30;2016-01-26;2017-10-27;31755936;DERIVED;Increased Prevalence of Neurocognitive Impairment in Aging People Living With Human Immunodeficiency Virus: The ANRS EP58 HAND 55-70 Study.;"Makinson A; Dubois J; Eymard-Duvernay S; Leclercq P; Zaegel-Faucher O; Bernard L; Vassallo M; Barbuat C; Gény C; Thouvenot E; Costagliola D; Ozguler A; Zins M; Simony M; Reynes J; Berr C";10.1093/cid/ciz670;2020;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT02100774;Effect of Genetic Variants on Fat-soluble Vitamin Bioavailability;Institut National de la Santé Et de la Recherche Médicale, France;Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement;COMPLETED;OBSERVATIONAL;False;2014-04-01;2009-01;2013-12;21957063;BACKGROUND;Genetic variations involved in interindividual variability in carotenoid status.;Borel P;10.1002/mnfr.201100322;2012;['Journal Article', 'Review']
NCT02100774;Effect of Genetic Variants on Fat-soluble Vitamin Bioavailability;Institut National de la Santé Et de la Recherche Médicale, France;Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement;COMPLETED;OBSERVATIONAL;False;2014-04-01;2009-01;2013-12;24808487;DERIVED;Interindividual variability of lutein bioavailability in healthy men: characterization, genetic variants involved, and relation with fasting plasma lutein concentration.;"Borel P; Desmarchelier C; Nowicki M; Bott R; Morange S; Lesavre N";10.3945/ajcn.114.085720;2014;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT02100774;Effect of Genetic Variants on Fat-soluble Vitamin Bioavailability;Institut National de la Santé Et de la Recherche Médicale, France;Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement;COMPLETED;OBSERVATIONAL;False;2014-04-01;2009-01;2013-12;26063065;DERIVED;A Combination of Single-Nucleotide Polymorphisms Is Associated with Interindividual Variability in Dietary β-Carotene Bioavailability in Healthy Men.;"Borel P; Desmarchelier C; Nowicki M; Bott R";10.3945/jn.115.212837;2015;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT02100774;Effect of Genetic Variants on Fat-soluble Vitamin Bioavailability;Institut National de la Santé Et de la Recherche Médicale, France;Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement;COMPLETED;OBSERVATIONAL;False;2014-04-01;2009-01;2013-12;27798339;DERIVED;A Combination of Single-Nucleotide Polymorphisms Is Associated with Interindividual Variability in Cholecalciferol Bioavailability in Healthy Men.;"Desmarchelier C; Borel P; Goncalves A; Kopec R; Nowicki M; Morange S; Lesavre N; Portugal H; Reboul E";10.3945/jn.116.237115;2016;['Journal Article']
NCT00490074;Study to Compare the Immunogenicity and Safety of Two HIV Preventive Vaccinations in Healthy Volunteers;French National Agency for Research on AIDS and Viral Hepatitis;EuroVacc Foundation;COMPLETED;INTERVENTIONAL;False;2007-06-22;2007-07;2009-10;;;;;;;
NCT01882062;Proof of Concept of an Anaplerotic Study Using Brain Phosphorus Magnetic Resonance Spectroscopy in Huntington Disease;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2013-06-20;2013-05;2013-07;25568297;RESULT;Triheptanoin improves brain energy metabolism in patients with Huntington disease.;"Adanyeguh IM; Rinaldi D; Henry PG; Caillet S; Valabregue R; Durr A; Mochel F";10.1212/WNL.0000000000001214;2015;"['Clinical Trial', 'Journal Article', 'Research Support, N.I.H., Extramural', ""Research Support, Non-U.S. Gov't""]"
NCT01525472;Accelerated Aging of the Cells of Visceral Adipose Tissue in Morbid Obese Subjects;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-02-03;2012-02-13;2015-10-20;;;;;;;
NCT02650427;A Pilot Study to Evaluate the Safety of a 3 Weeks Sitagliptin Treatment in HCC Patients Undergoing Liver Resection;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-01-08;2016-02;2018-09;;;;;;;
NCT01473472;On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2011-11-17;2012-01;2016-12-15;28747274;DERIVED;Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.;"Molina JM; Charreau I; Spire B; Cotte L; Chas J; Capitant C; Tremblay C; Rojas-Castro D; Cua E; Pasquet A; Bernaud C; Pintado C; Delaugerre C; Sagaon-Teyssier L; Mestre SL; Chidiac C; Pialoux G; Ponscarme D; Fonsart J; Thompson D; Wainberg MA; Doré V; Meyer L; ANRS IPERGAY Study Group";10.1016/S2352-3018(17)30089-9;2017;"['Journal Article', 'Multicenter Study', 'Observational Study', ""Research Support, Non-U.S. Gov't""]"
NCT01473472;On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2011-11-17;2012-01;2016-12-15;26624850;DERIVED;On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.;"Molina JM; Capitant C; Spire B; Pialoux G; Cotte L; Charreau I; Tremblay C; Le Gall JM; Cua E; Pasquet A; Raffi F; Pintado C; Chidiac C; Chas J; Charbonneau P; Delaugerre C; Suzan-Monti M; Loze B; Fonsart J; Peytavin G; Cheret A; Timsit J; Girard G; Lorente N; Préau M; Rooney JF; Wainberg MA; Thompson D; Rozenbaum W; Doré V; Marchand L; Simon MC; Etien N; Aboulker JP; Meyer L; Delfraissy JF; ANRS IPERGAY Study Group";10.1056/NEJMoa1506273;2015;"['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT01473472;On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2011-11-17;2012-01;2016-12-15;29229440;DERIVED;Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial.;"Molina JM; Charreau I; Chidiac C; Pialoux G; Cua E; Delaugerre C; Capitant C; Rojas-Castro D; Fonsart J; Bercot B; Bébéar C; Cotte L; Robineau O; Raffi F; Charbonneau P; Aslan A; Chas J; Niedbalski L; Spire B; Sagaon-Teyssier L; Carette D; Mestre SL; Doré V; Meyer L; ANRS IPERGAY Study Group";10.1016/S1473-3099(17)30725-9;2018;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT01473472;On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2011-11-17;2012-01;2016-12-15;36601747;PUBMED;Hepatitis A and B vaccine uptake and immunisation among men who have sex with men seeking PrEP: a substudy of the ANRS IPERGAY trial.;"Le Turnier P; Charreau I; Gabassi A; Carette D; Cotte L; Pialoux G; Tremblay C; Spire B; Chaix ML; Meyer L; Capitant C; Delaugerre C; Raffi F; Molina JM; ANRS IPERGAY study group";10.1136/sextrans-2022-055634;2023;"['Clinical Trial', ""Research Support, Non-U.S. Gov't"", 'Letter']"
NCT01473472;On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2011-11-17;2012-01;2016-12-15;31784343;DERIVED;On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial.;"Antoni G; Tremblay C; Delaugerre C; Charreau I; Cua E; Rojas Castro D; Raffi F; Chas J; Huleux T; Spire B; Capitant C; Cotte L; Meyer L; Molina JM; ANRS IPERGAY study group";10.1016/S2352-3018(19)30341-8;2020;"['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT02267304;Double Blind Randomized, Monocentric, Cross-over, Placebo-controlled Study to Evaluate the Effect of Morphine and Naloxone on Motivation (MBBAnalgesic);Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-10-17;2013-10-30;2016-08-30;;;;;;;
NCT04780191;Investigation of Treatment Using the MyoRegulator® Device in Patients With Spasticity in the Lower Limb Due to Stroke;Institut National de la Santé Et de la Recherche Médicale, France;PathMaker Neurosystems Inc.;COMPLETED;INTERVENTIONAL;False;2021-03-03;2018-07-19;2021-01-19;32232101;BACKGROUND;Non-invasive treatment of patients with upper extremity spasticity following stroke using paired trans-spinal and peripheral direct current stimulation.;"Paget-Blanc A; Chang JL; Saul M; Lin R; Ahmed Z; Volpe BT";10.1186/s42234-019-0028-9;2019;['Journal Article']
NCT00495326;Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146 CARINEMO);French National Agency for Research on AIDS and Viral Hepatitis;Medecins Sans Frontieres, Netherlands;COMPLETED;INTERVENTIONAL;False;2007-07-03;2007-12;2011-04;24663014;DERIVED;Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.;"Bhatt NB; Barau C; Amin A; Baudin E; Meggi B; Silva C; Furlan V; Grinsztejn B; Barrail-Tran A; Bonnet M; Taburet AM; ANRS 12146-CARINEMO Study Group";10.1128/AAC.02379-13;2014;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00495326;Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146 CARINEMO);French National Agency for Research on AIDS and Viral Hepatitis;Medecins Sans Frontieres, Netherlands;COMPLETED;INTERVENTIONAL;False;2007-07-03;2007-12;2011-04;23433590;DERIVED;Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial.;"Bonnet M; Bhatt N; Baudin E; Silva C; Michon C; Taburet AM; Ciaffi L; Sobry A; Bastos R; Nunes E; Rouzioux C; Jani I; Calmy A; CARINEMO study group";10.1016/S1473-3099(13)70007-0;2013;"['Comparative Study', 'Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT03459157;Access to PrEP for MSM: Acceptability and Feasibility in Community-based Clinics in West Africa (CohMSM-PrEP);ANRS, Emerging Infectious Diseases;Expertise France | Université Montpellier | SESSTIM (IRD, Inserm, Université Aix-Marseille) | Coalition Internationale Sida | Institut de Médecine Tropicale, Anvers, Belgique | ARCAD-SIDA MALI | Association African Solidarité | Centre de Recherche Internationale pour la Santé, Université de Ouagadougou | Espace Confiance, Côte d'Ivoire | Espoir Vie-Togo - ONG | Laboratoire BIOLIM, Université de Lomé;COMPLETED;INTERVENTIONAL;False;2018-03-08;2017-11-20;2021-06-30;34048794;DERIVED;HIV pre-exposure prophylaxis for men who have sex with men in west Africa: a multicountry demonstration study.;"Laurent C; Dembélé Keita B; Yaya I; Le Guicher G; Sagaon-Teyssier L; Agboyibor MK; Coulibaly A; Traoré I; Malan JB; De Baetselier I; Eubanks A; Riegel L; Rojas Castro D; Fayé-Ketté H; Koné A; Diandé S; Dagnra CA; Serrano L; Diallo F; Mensah E; Dah TTE; Anoma C; Vuylsteke B; Spire B; CohMSM-PrEP Study Group";10.1016/S2352-3018(21)00005-9;2021;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01620957;Longitudinal Study of the Default-mode Network Connectivity in Brain Injured Patients Recovering From Coma;Institut National de la Santé Et de la Recherche Médicale, France;University Hospital, Toulouse | Association des Traumatisés du Crane et de la Face, Paris, France;COMPLETED;OBSERVATIONAL;False;2012-06-15;2012-07-10;2017-07;;;;;;;
NCT00339157;Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2006-06-20;2006-06;2008-07;21173013;DERIVED;A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial).;"Quartier P; Allantaz F; Cimaz R; Pillet P; Messiaen C; Bardin C; Bossuyt X; Boutten A; Bienvenu J; Duquesne A; Richer O; Chaussabel D; Mogenet A; Banchereau J; Treluyer JM; Landais P; Pascual V";10.1136/ard.2010.134254;2011;"['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT01555450;Study of Patient Navigation to Reduce Social Inequalities;Institut National de la Santé Et de la Recherche Médicale, France;National Cancer Institute, France;COMPLETED;INTERVENTIONAL;False;2012-03-15;2011-03;2013-11;29909873;DERIVED;Cost-Effectiveness Analysis of a Navigation Program for Colorectal Cancer Screening to Reduce Social Health Inequalities: A French Cluster Randomized Controlled Trial.;"De Mil R; Guillaume E; Guittet L; Dejardin O; Bouvier V; Pornet C; Christophe V; Notari A; Delattre-Massy H; De Seze C; Peng J; Launoy G; Berchi C";10.1016/j.jval.2017.09.020;2018;"['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT01555450;Study of Patient Navigation to Reduce Social Inequalities;Institut National de la Santé Et de la Recherche Médicale, France;National Cancer Institute, France;COMPLETED;INTERVENTIONAL;False;2012-03-15;2011-03;2013-11;28823681;DERIVED;Patient navigation to reduce social inequalities in colorectal cancer screening participation: A cluster randomized controlled trial.;"Guillaume E; Dejardin O; Bouvier V; De Mil R; Berchi C; Pornet C; Christophe V; Notari A; Delattre Massy H; De Seze C; Peng J; Guittet L; Launoy G";10.1016/j.ypmed.2017.08.012;2017;['Journal Article', 'Randomized Controlled Trial']
NCT01555450;Study of Patient Navigation to Reduce Social Inequalities;Institut National de la Santé Et de la Recherche Médicale, France;National Cancer Institute, France;COMPLETED;INTERVENTIONAL;False;2012-03-15;2011-03;2013-11;21256688;BACKGROUND;[Social inequalities in health from observational studies to intervention: can the patient navigator reduce social inequalities in cancer patients?].;"Dejardin O; Berchi C; Mignon A; Pornet C; Guillaume E; Guittet L; Bouvier V; Sailly M; Salinas A; Christophe V; Launoy G";10.1016/j.respe.2010.10.008;2011;['English Abstract', 'Journal Article', 'Review']
NCT01348308;Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients;ANRS, Emerging Infectious Diseases;Pfizer;COMPLETED;INTERVENTIONAL;False;2011-05-05;2011-09;2016-03;32040959;DERIVED;Addition of Maraviroc Versus Placebo to Standard Antiretroviral Therapy for Initial Treatment of Advanced HIV Infection: A Randomized Trial.;"Lévy Y; Lelièvre JD; Assoumou L; Aznar E; Pulido F; Tambussi G; Crespo M; Meybeck A; Molina JM; Delaugerre C; Izopet J; Peytavin G; Cardon F; Diallo A; Lancar R; Béniguel L; Costagliola D";10.7326/M19-2133;2020;"['Clinical Trial, Phase III', 'Comparative Study', 'Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT01696708;Utilization of 31P-Nuclear Magnetic Resonance Spectroscopy to Monitor Brain Energy Deficit in Huntington Disease;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-10-01;2012-12-06;2015-11;25568297;DERIVED;Triheptanoin improves brain energy metabolism in patients with Huntington disease.;"Adanyeguh IM; Rinaldi D; Henry PG; Caillet S; Valabregue R; Durr A; Mochel F";10.1212/WNL.0000000000001214;2015;"['Clinical Trial', 'Journal Article', 'Research Support, N.I.H., Extramural', ""Research Support, Non-U.S. Gov't""]"
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;ANRS, Emerging Infectious Diseases;Africa Centre For Health and Population Studies | University of KwaZulu;COMPLETED;INTERVENTIONAL;False;2012-01-13;2012-03;2016-06;29199100;DERIVED;Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial.;"Iwuji CC; Orne-Gliemann J; Larmarange J; Balestre E; Thiebaut R; Tanser F; Okesola N; Makowa T; Dreyer J; Herbst K; McGrath N; Bärnighausen T; Boyer S; De Oliveira T; Rekacewicz C; Bazin B; Newell ML; Pillay D; Dabis F; ANRS 12249 TasP Study Group";10.1016/S2352-3018(17)30205-9;2018;"['Clinical Trial, Phase IV', 'Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;ANRS, Emerging Infectious Diseases;Africa Centre For Health and Population Studies | University of KwaZulu;COMPLETED;INTERVENTIONAL;False;2012-01-13;2012-03;2016-06;25880823;DERIVED;Addressing social issues in a universal HIV test and treat intervention trial (ANRS 12249 TasP) in South Africa: methods for appraisal.;"Orne-Gliemann J; Larmarange J; Boyer S; Iwuji C; McGrath N; Bärnighausen T; Zuma T; Dray-Spira R; Spire B; Rochat T; Lert F; Imrie J; ANRS 12249 TasP Group";10.1186/s12889-015-1344-y;2015;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;ANRS, Emerging Infectious Diseases;Africa Centre For Health and Population Studies | University of KwaZulu;COMPLETED;INTERVENTIONAL;False;2012-01-13;2012-03;2016-06;23880306;DERIVED;Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa: study protocol for a cluster randomised controlled trial.;"Iwuji CC; Orne-Gliemann J; Tanser F; Boyer S; Lessells RJ; Lert F; Imrie J; Bärnighausen T; Rekacewicz C; Bazin B; Newell ML; Dabis F; ANRS 12249 TasP Study Group";10.1186/1745-6215-14-230;2013;"['Comparative Study', 'Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;ANRS, Emerging Infectious Diseases;Africa Centre For Health and Population Studies | University of KwaZulu;COMPLETED;INTERVENTIONAL;False;2012-01-13;2012-03;2016-06;27504637;DERIVED;Uptake of Home-Based HIV Testing, Linkage to Care, and Community Attitudes about ART in Rural KwaZulu-Natal, South Africa: Descriptive Results from the First Phase of the ANRS 12249 TasP Cluster-Randomised Trial.;"Iwuji CC; Orne-Gliemann J; Larmarange J; Okesola N; Tanser F; Thiebaut R; Rekacewicz C; Newell ML; Dabis F; ANRS 12249 TasP trial group";10.1371/journal.pmed.1002107;2016;['Journal Article', 'Randomized Controlled Trial']
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;ANRS, Emerging Infectious Diseases;Africa Centre For Health and Population Studies | University of KwaZulu;COMPLETED;INTERVENTIONAL;False;2012-01-13;2012-03;2016-06;30027600;DERIVED;The impact of population dynamics on the population HIV care cascade: results from the ANRS 12249 Treatment as Prevention trial in rural KwaZulu-Natal (South Africa).;"Larmarange J; Diallo MH; McGrath N; Iwuji C; Plazy M; Thiébaut R; Tanser F; Bärnighausen T; Pillay D; Dabis F; Orne-Gliemann J; ANRS 12249 TasP Study Group";10.1002/jia2.25128;2018;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;ANRS, Emerging Infectious Diseases;Africa Centre For Health and Population Studies | University of KwaZulu;COMPLETED;INTERVENTIONAL;False;2012-01-13;2012-03;2016-06;28329393;DERIVED;Virological Outcomes of Second-line Protease Inhibitor-Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis.;"Collier D; Iwuji C; Derache A; de Oliveira T; Okesola N; Calmy A; Dabis F; Pillay D; Gupta RK; French National Agency for AIDS and Viral Hepatitis Research (ANRS) 12249 Treatment as Prevention (TasP) Study Group";10.1093/cid/cix015;2017;['Journal Article']
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;ANRS, Emerging Infectious Diseases;Africa Centre For Health and Population Studies | University of KwaZulu;COMPLETED;INTERVENTIONAL;False;2012-01-13;2012-03;2016-06;30412926;DERIVED;"""If you are here at the clinic, you do not know how many people need help in the community"": Perspectives of home-based HIV services from health care workers in rural KwaZulu-Natal, South Africa in the era of universal test-and-treat.";"Perriat D; Plazy M; Gumede D; Boyer S; Pillay D; Dabis F; Seeley J; Orne-Gliemann J; ANRS 12249 TasP Study Group";10.1371/journal.pone.0202473;2018;"['Clinical Trial', 'Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;ANRS, Emerging Infectious Diseases;Africa Centre For Health and Population Studies | University of KwaZulu;COMPLETED;INTERVENTIONAL;False;2012-01-13;2012-03;2016-06;30321314;DERIVED;Impact of Next-generation Sequencing Defined Human Immunodeficiency Virus Pretreatment Drug Resistance on Virological Outcomes in the ANRS 12249 Treatment-as-Prevention Trial.;"Derache A; Iwuji CC; Baisley K; Danaviah S; Marcelin AG; Calvez V; de Oliveira T; Dabis F; Porter K; Pillay D";10.1093/cid/ciy881;2019;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;ANRS, Emerging Infectious Diseases;Africa Centre For Health and Population Studies | University of KwaZulu;COMPLETED;INTERVENTIONAL;False;2012-01-13;2012-03;2016-06;31637821;DERIVED;Temporal trends of population viral suppression in the context of Universal Test and Treat: the ANRS 12249 TasP trial in rural South Africa.;"Larmarange J; Diallo MH; McGrath N; Iwuji C; Plazy M; Thiébaut R; Tanser F; Bärnighausen T; Orne-Gliemann J; Pillay D; Dabis F; ANRS 12249 TasP Study Group";10.1002/jia2.25402;2019;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;ANRS, Emerging Infectious Diseases;Africa Centre For Health and Population Studies | University of KwaZulu;COMPLETED;INTERVENTIONAL;False;2012-01-13;2012-03;2016-06;32970730;DERIVED;Test but not treat: Community members' experiences with barriers and facilitators to universal antiretroviral therapy uptake in rural KwaZulu-Natal, South Africa.;"Iwuji C; Chimukuche RS; Zuma T; Plazy M; Larmarange J; Orne-Gliemann J; Siedner M; Shahmanesh M; Seeley J";10.1371/journal.pone.0239513;2020;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;ANRS, Emerging Infectious Diseases;Africa Centre For Health and Population Studies | University of KwaZulu;COMPLETED;INTERVENTIONAL;False;2012-01-13;2012-03;2016-06;29890048;DERIVED;Universal test and treat is not associated with sub-optimal antiretroviral therapy adherence in rural South Africa: the ANRS 12249 TasP trial.;"Iwuji C; McGrath N; Calmy A; Dabis F; Pillay D; Newell ML; Baisley K; Porter K";10.1002/jia2.25112;2018;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT01874808;From Movement Preparation to Gait Execution in ALS;Institut National de la Santé Et de la Recherche Médicale, France;Université Paris Ouest-EA 2931-CEntre de Recherches sur le Sport et le Mouvement;COMPLETED;OBSERVATIONAL;False;2013-06-11;2013-06-21;2015-12-21;;;;;;;
NCT02126384;Identifocation the B Cell Subsets Responsible for Anti-pneumococcal Response;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-04-30;2014-11-18;2016-04-05;;;;;;;
NCT03150290;Brown Adipose Tissue in ALS;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2017-05-12;2017-10-26;2019-04-01;;;;;;;
NCT03519503;Infant Peri-Exposure Prophylaxis to Prevent HIV-1 Transmission by Breastfeeding: Mechanisms & Safety;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2018-05-09;2017-02-27;2018-02-15;21602695;BACKGROUND;Antiretroviral drugs for preventing mother-to-child transmission of HIV: a review of potential effects on HIV-exposed but uninfected children.;"Heidari S; Mofenson L; Cotton MF; Marlink R; Cahn P; Katabira E";10.1097/QAI.0b013e318221c56a;2011;['Journal Article', 'Review']
NCT03519503;Infant Peri-Exposure Prophylaxis to Prevent HIV-1 Transmission by Breastfeeding: Mechanisms & Safety;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2018-05-09;2017-02-27;2018-02-15;26603917;BACKGROUND;Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial.;"Nagot N; Kankasa C; Tumwine JK; Meda N; Hofmeyr GJ; Vallo R; Mwiya M; Kwagala M; Traore H; Sunday A; Singata M; Siuluta C; Some E; Rutagwera D; Neboua D; Ndeezi G; Jackson D; Maréchal V; Neveu D; Engebretsen IMS; Lombard C; Blanche S; Sommerfelt H; Rekacewicz C; Tylleskär T; Van de Perre P; ANRS 12174 Trial Group";10.1016/S0140-6736(15)00984-8;2016;"['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT03519503;Infant Peri-Exposure Prophylaxis to Prevent HIV-1 Transmission by Breastfeeding: Mechanisms & Safety;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2018-05-09;2017-02-27;2018-02-15;22814853;BACKGROUND;HIV-1 reservoirs in breast milk and challenges to elimination of breast-feeding transmission of HIV-1.;"Van de Perre P; Rubbo PA; Viljoen J; Nagot N; Tylleskär T; Lepage P; Vendrell JP; Tuaillon E";10.1126/scitranslmed.3003327;2012;"['Journal Article', ""Research Support, Non-U.S. Gov't"", 'Review']"
NCT00465790;Research of Biomarkers in Parkinson Disease;Institut National de la Santé Et de la Recherche Médicale, France;European Union;COMPLETED;OBSERVATIONAL;False;2007-04-25;2007-10;2012-06;;;;;;;
NCT00122603;Dual Boosted Protease Inhibitor Regimens Without Any Additional Antiretroviral Therapy in HIV-1 Infected Patients (ANRS127);French National Agency for Research on AIDS and Viral Hepatitis;Bristol-Myers Squibb | GlaxoSmithKline | Hoffmann-La Roche;COMPLETED;INTERVENTIONAL;False;2005-07-22;2005-12;2007-08;19420019;DERIVED;Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.;"Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P; ANRS 127 Study Group";10.1093/jac/dkp146;2009;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT02314208;Therapeutic Metabolic Intervention in Patients With Spastic Paraplegia SPG5;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-12-11;2015-01;2018-01-01;;;;;;;
NCT00121121;Safety of Intradermal Versus Intramuscular Administration of HIV Lipopeptides in HIV Uninfected Adult Volunteers;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2005-07-21;2004-07;2005-12;17712402;DERIVED;Cellular immune responses induced with dose-sparing intradermal administration of HIV vaccine to HIV-uninfected volunteers in the ANRS VAC16 trial.;"Launay O; Durier C; Desaint C; Silbermann B; Jackson A; Pialoux G; Bonnet B; Poizot-Martin I; Gonzalez-Canali G; Cuzin L; Figuereido S; Surenaud M; Ben Hamouda N; Gahery H; Choppin J; Salmon D; Guérin C; Bourgault Villada I; Guillet JG; ANRS VAC16 Study Group";10.1371/journal.pone.0000725;2007;"['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT01432821;Blinking and Yawning in Epilepsy: The Role of Dopamine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-09-13;2011-09;2014-12;2271377;RESULT;Apomorphine-induced blinking and yawning in healthy volunteers.;"Blin O; Masson G; Azulay JP; Fondarai J; Serratrice G";10.1111/j.1365-2125.1990.tb03848.x;1990;['Clinical Trial', 'Comparative Study', 'Journal Article', 'Randomized Controlled Trial']
NCT01432821;Blinking and Yawning in Epilepsy: The Role of Dopamine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-09-13;2011-09;2014-12;15249613;RESULT;PET evidence for a role of the basal ganglia in patients with ring chromosome 20 epilepsy.;"Biraben A; Semah F; Ribeiro MJ; Douaud G; Remy P; Depaulis A";10.1212/01.wnl.0000132840.40838.13;2004;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01432821;Blinking and Yawning in Epilepsy: The Role of Dopamine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-09-13;2011-09;2014-12;15777732;RESULT;Lamotrigine, carbamazepine and phenytoin differentially alter extracellular levels of 5-hydroxytryptamine, dopamine and amino acids.;"Ahmad S; Fowler LJ; Whitton PS";10.1016/j.eplepsyres.2005.02.002;2005;['Comparative Study', 'Journal Article']
NCT01432821;Blinking and Yawning in Epilepsy: The Role of Dopamine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-09-13;2011-09;2014-12;12914551;RESULT;Pharmacokinetic-pharmacodynamic study of apomorphine's effect on growth hormone secretion in healthy subjects.;"Aymard G; Berlin I; de Brettes B; Diquet B";10.1046/j.1472-8206.2003.00152.x;2003;['Clinical Trial', 'Journal Article', 'Randomized Controlled Trial']
NCT01432821;Blinking and Yawning in Epilepsy: The Role of Dopamine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-09-13;2011-09;2014-12;15037514;RESULT;Effect of acute and chronic lamotrigine on basal and stimulated extracellular 5-hydroxytryptamine and dopamine in the hippocampus of the freely moving rat.;"Ahmad S; Fowler LJ; Whitton PS";10.1038/sj.bjp.0705737;2004;['Comparative Study', 'Journal Article']
NCT02071784;Imaging Study of Neurovascular Coupling in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL);Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2014-02-26;2014-07-08;2016-10-24;;;;;;;
NCT02738502;Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors;ANRS, Emerging Infectious Diseases;Institut National de la Santé Et de la Recherche Médicale, France;COMPLETED;INTERVENTIONAL;False;2016-04-14;2016-07-06;2020-07-16;26709605;BACKGROUND;Efficacy of protease inhibitor monotherapy vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials.;"Arribas JR; Girard PM; Paton N; Winston A; Marcelin AG; Elbirt D; Hill A; Hadacek MB";10.1111/hiv.12348;2016;['Comparative Study', 'Journal Article', 'Meta-Analysis']
NCT02738502;Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors;ANRS, Emerging Infectious Diseases;Institut National de la Santé Et de la Recherche Médicale, France;COMPLETED;INTERVENTIONAL;False;2016-04-14;2016-07-06;2020-07-16;26197844;BACKGROUND;No perinatal HIV-1 transmission from women with effective antiretroviral therapy starting before conception.;"Mandelbrot L; Tubiana R; Le Chenadec J; Dollfus C; Faye A; Pannier E; Matheron S; Khuong MA; Garrait V; Reliquet V; Devidas A; Berrebi A; Allisy C; Elleau C; Arvieux C; Rouzioux C; Warszawski J; Blanche S; ANRS-EPF Study Group";10.1093/cid/civ578;2015;"['Journal Article', 'Multicenter Study', 'Observational Study', ""Research Support, Non-U.S. Gov't""]"
NCT02738502;Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors;ANRS, Emerging Infectious Diseases;Institut National de la Santé Et de la Recherche Médicale, France;COMPLETED;INTERVENTIONAL;False;2016-04-14;2016-07-06;2020-07-16;26854809;BACKGROUND;Risk of cancer in children exposed to didanosine in utero.;"Hleyhel M; Goujon S; Delteil C; Vasiljevic A; Luzi S; Stephan JL; Reliquet V; Jannier S; Tubiana R; Dollfus C; Faye A; Mandelbrot L; Clavel J; Warszawski J; Blanche S; ANRS French Perinatal Cohort Study Group";10.1097/QAD.0000000000001051;2016;"['Journal Article', 'Multicenter Study', ""Research Support, Non-U.S. Gov't""]"
NCT02738502;Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors;ANRS, Emerging Infectious Diseases;Institut National de la Santé Et de la Recherche Médicale, France;COMPLETED;INTERVENTIONAL;False;2016-04-14;2016-07-06;2020-07-16;22160145;BACKGROUND;Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study.;"Valantin MA; Lambert-Niclot S; Flandre P; Morand-Joubert L; Cabiè A; Meynard JL; Ponscarme D; Ajana F; Slama L; Curjol A; Cuzin L; Schneider L; Taburet AM; Marcelin AG; Katlama C; MONOI ANRS 136 Study Group";10.1093/jac/dkr504;2012;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT02738502;Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors;ANRS, Emerging Infectious Diseases;Institut National de la Santé Et de la Recherche Médicale, France;COMPLETED;INTERVENTIONAL;False;2016-04-14;2016-07-06;2020-07-16;23559464;BACKGROUND;Genotoxic signature in cord blood cells of newborns exposed in utero to a Zidovudine-based antiretroviral combination.;"André-Schmutz I; Dal-Cortivo L; Six E; Kaltenbach S; Cocchiarella F; Le Chenadec J; Cagnard N; Cordier AG; Benachi A; Mandelbrot L; Azria E; Bouallag N; Luce S; Ternaux B; Reimann C; Revy P; Radford-Weiss I; Leschi C; Recchia A; Mavilio F; Cavazzana M; Blanche S";10.1093/infdis/jit149;2013;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT02738502;Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors;ANRS, Emerging Infectious Diseases;Institut National de la Santé Et de la Recherche Médicale, France;COMPLETED;INTERVENTIONAL;False;2016-04-14;2016-07-06;2020-07-16;22848481;BACKGROUND;Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks.;"Lambert-Niclot S; Flandre P; Valantin MA; Soulie C; Fourati S; Wirden M; Sayon S; Pakianather S; Bocket L; Masquelier B; Dos Santos G; Katlama C; Calvez V; Marcelin AG";10.1371/journal.pone.0041390;2012;"['Comparative Study', 'Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT02738502;Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors;ANRS, Emerging Infectious Diseases;Institut National de la Santé Et de la Recherche Médicale, France;COMPLETED;INTERVENTIONAL;False;2016-04-14;2016-07-06;2020-07-16;23766338;BACKGROUND;Lopinavir/ritonavir monotherapy as a nucleoside analogue-sparing strategy to prevent HIV-1 mother-to-child transmission: the ANRS 135 PRIMEVA phase 2/3 randomized trial.;"Tubiana R; Mandelbrot L; Le Chenadec J; Delmas S; Rouzioux C; Hirt D; Treluyer JM; Ekoukou D; Bui E; Chaix ML; Blanche S; Warszawski J; ANRS 135 PRIMEVA (Protease Inhibitor Monotherapy Evaluation) Study Group";10.1093/cid/cit390;2013;"['Clinical Trial, Phase II', 'Clinical Trial, Phase III', 'Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT02992184;PoC-HCV Genedrive Viral Detection Assay Validation Study;ANRS, Emerging Infectious Diseases;EPISTEM;COMPLETED;OBSERVATIONAL;False;2016-12-14;2016-09;2016-12;29615488;DERIVED;Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus.;"Llibre A; Shimakawa Y; Mottez E; Ainsworth S; Buivan TP; Firth R; Harrison E; Rosenberg AR; Meritet JF; Fontanet A; Castan P; Madejón A; Laverick M; Glass A; Viana R; Pol S; McClure CP; Irving WL; Miele G; Albert ML; Duffy D";10.1136/gutjnl-2017-315783;2018;"['Clinical Trial', 'Journal Article', ""Research Support, Non-U.S. Gov't"", 'Validation Study']"
NCT01514890;French Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon and Ribavirin;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2012-01-23;2011-02;2014-03;24704719;DERIVED;Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.;"Hézode C; Fontaine H; Dorival C; Zoulim F; Larrey D; Canva V; De Ledinghen V; Poynard T; Samuel D; Bourliere M; Alric L; Raabe JJ; Zarski JP; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Chazouilleres O; Abergel A; Guyader D; Metivier S; Tran A; Di Martino V; Causse X; Dao T; Lucidarme D; Portal I; Cacoub P; Gournay J; Grando-Lemaire V; Hillon P; Attali P; Fontanges T; Rosa I; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP; CUPIC Study Group";10.1053/j.gastro.2014.03.051;2014;['Journal Article', 'Multicenter Study']
NCT01514890;French Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon and Ribavirin;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2012-01-23;2011-02;2014-03;25556540;DERIVED;Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy.;"Sultanik P; Mallet V; Lagaye S; Casrouge A; Dorival C; Barthe Y; Fontaine H; Hézode C; Mottez E; Bronowicki JP; Carrat F; Theodorou I; Abel L; Gayat E; Fontanet A; Pol S; Albert ML; ANRS CO20-CUPIC";10.1111/liv.12759;2015;"['Clinical Trial', 'Journal Article', 'Multicenter Study', ""Research Support, Non-U.S. Gov't""]"
NCT01514890;French Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon and Ribavirin;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2012-01-23;2011-02;2014-03;23669289;DERIVED;Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.;"Hézode C; Fontaine H; Dorival C; Larrey D; Zoulim F; Canva V; de Ledinghen V; Poynard T; Samuel D; Bourlière M; Zarski JP; Raabe JJ; Alric L; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Métivier S; Tran A; Serfaty L; Abergel A; Causse X; Di Martino V; Guyader D; Lucidarme D; Grando-Lemaire V; Hillon P; Feray C; Dao T; Cacoub P; Rosa I; Attali P; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP; CUPIC Study Group";10.1016/j.jhep.2013.04.035;2013;"['Clinical Trial', 'Journal Article', 'Multicenter Study', ""Research Support, Non-U.S. Gov't""]"
NCT02212379;Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL;ANRS, Emerging Infectious Diseases;Merck Sharp & Dohme LLC | Janssen-Cilag Ltd.;COMPLETED;INTERVENTIONAL;True;2014-08-08;2015-01;2018-04;31269208;PUBMED;Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study.;"Katlama C; Assoumou L; Valantin MA; Soulié C; Martinez E; Béniguel L; Bouchaud O; Raffi F; Molina JM; Fellahi S; Peytavin G; Marcelin AG; Kolta S; Capeau J; Gibowski S; Cardon F; Reynes J; Costagliola D; members of the ANRS 163 ETRAL study";10.1093/jac/dkz224;2019;"['Journal Article', 'Multicenter Study', ""Research Support, Non-U.S. Gov't""]"
NCT03652090;Primary Nasal Cell Culture as a Tool for Personalized Therapy in Cystic Fibrosis;Institut National de la Santé Et de la Recherche Médicale, France;ABCF2;COMPLETED;OBSERVATIONAL;False;2018-08-29;2010-09-01;2016-03-03;;;;;;;
NCT00196664;Efficacy of Paroxetine in the Prevention of Depressive Syndrome in Patients With Chronic Hepatitis C Treated by PEG-Interferon Alfa Plus Ribavirin;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2005-09-20;2005-10;2009-02;;;;;;;
NCT03335995;Stroke Prognosis in Intensive CarE;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2017-11-08;2017-10-18;2020-11-18;32026446;DERIVED;Outcomes of Acute Stroke Patients Requiring Mechanical Ventilation: Study Protocol for the SPICE Multicenter Prospective Observational Study.;"Sonneville R; Mazighi M; Bresson D; Crassard I; Crozier S; de Montmollin E; Degos V; Faugeras F; Gayat E; Josse L; Lamy C; Magalhaes E; Maldjian A; Ruckly S; Servan J; Vassel P; Vigué B; Timsit JF; Woimant F; SPICE investigators";10.1007/s12028-019-00907-0;2020;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT03335995;Stroke Prognosis in Intensive CarE;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2017-11-08;2017-10-18;2020-11-18;37497675;PUBMED;One-Year Outcomes in Patients With Acute Stroke Requiring Mechanical Ventilation.;"Sonneville R; Mazighi M; Collet M; Gayat E; Degos V; Duranteau J; Grégoire C; Sharshar T; Naim G; Cortier D; Jost PH; Foucrier A; Bagate F; de Montmollin E; Papin G; Magalhaes E; Guidet B; Ben Hadj Salem O; Benghanem S; le Guennec L; Delpierre E; Legriel S; Megarbane B; Toumert K; Tran M; Geri G; Monchi M; Bodiguel E; Mariotte E; Demoule A; Zarka J; Diehl JL; Roux D; Barré E; Tanaka S; Osman D; Pasquier P; Lamara F; Crassard I; Boursin P; Ruckly S; Staiquly Q; Timsit JF; Woimant F; SPICE Investigators";10.1161/STROKEAHA.123.042910;2023;"['Multicenter Study', 'Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT00946595;Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients;French National Agency for Research on AIDS and Viral Hepatitis;Abbott | Gilead Sciences;COMPLETED;INTERVENTIONAL;False;2009-07-27;2009-11;2014-01;30968368;DERIVED;Cost-Effectiveness Analysis of Lopinavir/Ritonavir Monotherapy Versus Standard Combination Antiretroviral Therapy in HIV-1 Infected Patients with Viral Suppression in France (ANRS 140 DREAM).;"Garay OU; Nishimwe ML; Bousmah MA; Janah A; Girard PM; Chêne G; Moinot L; Sagaon-Teyssier L; Meynard JL; Spire B; Boyer S";10.1007/s41669-019-0130-7;2019;['Journal Article']
NCT00946595;Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients;French National Agency for Research on AIDS and Viral Hepatitis;Abbott | Gilead Sciences;COMPLETED;INTERVENTIONAL;False;2009-07-27;2009-11;2014-01;29767684;DERIVED;Ultrasensitive Human Immunodeficiency Virus Type 1 Viral Load as a Marker of Treatment Choice for Simplification Strategies.;"Lambert-Niclot S; Grude M; Meynard JL; Marcelin AG; Valantin MA; Flandre P; Izopet J; Moinot L; Bouteloup V; Calvez V; Katlama C; Girard PM; Morand-Joubert L";10.1093/cid/ciy382;2018;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT02469350;Serious Game for Parkinson's Disease Patients;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-06-11;2015-06;2017-10-04;29636105;DERIVED;The feasibility and positive effects of a customised videogame rehabilitation programme for freezing of gait and falls in Parkinson's disease patients: a pilot study.;"Nuic D; Vinti M; Karachi C; Foulon P; Van Hamme A; Welter ML";10.1186/s12984-018-0375-x;2018;"['Clinical Trial', 'Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;30010022;RESULT;Adaptive optics ophthalmoscopy: Application to age-related macular degeneration and vascular diseases.;"Paques M; Meimon S; Rossant F; Rosenbaum D; Mrejen S; Sennlaub F; Grieve K";10.1016/j.preteyeres.2018.07.001;2018;"['Journal Article', ""Research Support, Non-U.S. Gov't"", 'Review']"
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;28900746;RESULT;Electrophysiological features and multimodal imaging in ritonavir-related maculopathy.;"Faure C; Paques M; Audo I";10.1007/s10633-017-9612-z;2017;['Case Reports', 'Journal Article']
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;27065002;RESULT;Effects of age, blood pressure and antihypertensive treatments on retinal arterioles remodeling assessed by adaptive optics.;"Rosenbaum D; Mattina A; Koch E; Rossant F; Gallo A; Kachenoura N; Paques M; Redheuil A; Girerd X";10.1097/HJH.0000000000000894;2016;['Journal Article']
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;30947025;RESULT;Vision loss after chemotherapy: an irinotecan-induced retinopathy.;"Boilève A; Jozwiak M; Malka D; Boige V; Le Roy F; Paques M; Ducreux M";10.1016/j.ejca.2019.02.015;2019;['Case Reports', 'Letter']
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;26523388;RESULT;The Negative Cone Mosaic: A New Manifestation of the Optical Stiles-Crawford Effect in Normal Eyes.;"Miloudi C; Rossant F; Bloch I; Chaumette C; Leseigneur A; Sahel JA; Meimon S; Mrejen S; Paques M";10.1167/iovs.15-17022;2015;"['Clinical Trial', 'Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;26418443;DERIVED;CONE DENSITY LOSS ON ADAPTIVE OPTICS IN EARLY MACULAR TELANGIECTASIA TYPE 2.;"Jacob J; Krivosic V; Paques M; Tadayoni R; Gaudric A";10.1097/IAE.0000000000000737;2016;['Journal Article']
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;23620431;RESULT;Adaptive optics imaging of geographic atrophy.;"Gocho K; Sarda V; Falah S; Sahel JA; Sennlaub F; Benchaboune M; Ullern M; Paques M";10.1167/iovs.12-10672;2013;"['Controlled Clinical Trial', 'Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;25997175;RESULT;Venous Nicking Without Arteriovenous Contact: The Role of the Arteriolar Microenvironment in Arteriovenous Nickings.;"Paques M; Brolly A; Benesty J; Lermé N; Koch E; Rossant F; Bloch I; Girmens JF";10.1001/jamaophthalmol.2015.1132;2015;"['Journal Article', 'Observational Study', ""Research Support, Non-U.S. Gov't""]"
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;24576889;RESULT;Retinal vasculitis imaging by adaptive optics.;"Errera MH; Coisy S; Fardeau C; Sahel JA; Kallel S; Westcott M; Bodaghi B; Paques M";10.1016/j.ophtha.2013.12.036;2014;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;24337723;RESULT;Functional and high resolution retinal imaging assessment in a case of ocular siderosis.;"Faure C; Gocho K; Le Mer Y; Sahel JA; Paques M; Audo I";10.1007/s10633-013-9421-y;2014;['Case Reports', 'Journal Article']
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;27009576;RESULT;Relationships between retinal arteriole anatomy and aortic geometry and function and peripheral resistance in hypertensives.;"Rosenbaum D; Kachenoura N; Koch E; Paques M; Cluzel P; Redheuil A; Girerd X";10.1038/hr.2016.26;2016;['Journal Article']
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;31568064;RESULT;IN VIVO OBSERVATION OF RETINAL VASCULAR DEPOSITS USING ADAPTIVE OPTICS IMAGING IN FABRY DISEASE.;"Sodi A; Germain DP; Bacherini D; Finocchio L; Pacini B; Marziali E; Lenzetti C; Tanini I; Koraichi F; Coriat C; Nencini P; Olivotto I; Virgili G; Rizzo S; Paques M";10.1097/IAE.0000000000002648;2020;['Journal Article', 'Multicenter Study']
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;24406779;RESULT;Morphometric analysis of small arteries in the human retina using adaptive optics imaging: relationship with blood pressure and focal vascular changes.;"Koch E; Rosenbaum D; Brolly A; Sahel JA; Chaumet-Riffaud P; Girerd X; Rossant F; Paques M";10.1097/HJH.0000000000000095;2014;"['Clinical Trial', 'Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;29369084;RESULT;DIRECTIONAL VARIABILITY OF FUNDUS REFLECTANCE IN ACUTE MACULAR NEURORETINOPATHY: EVIDENCE FOR A CONTRIBUTION OF THE STILES-CRAWFORD EFFECT.;"Bottin C; Grieve K; Rossant F; Pedinielli A; Mrejen S; Paques M";10.1097/ICB.0000000000000701;2018;['Case Reports', 'Journal Article']
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;25077537;RESULT;High-resolution imaging of gunn's dots.;"Paques M; Miloudi C; Kulcsar C; Leseigneur A; Chaumette C; Koch E";10.1097/IAE.0000000000000269;2015;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;26344727;RESULT;Functional and high-resolution retinal imaging monitoring photoreceptor damage in acute macular neuroretinopathy.;"Audo I; Gocho K; Rossant F; Mohand-Saïd S; Loquin K; Bloch I; Sahel JA; Paques M";10.1007/s00417-015-3136-6;2016;['Case Reports', 'Journal Article']
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;31972545;RESULT;IGF-1 is an independent predictor of retinal arterioles remodeling in subjects with uncontrolled acromegaly.;"Gallo A; Chaigneau E; Jublanc C; Rosenbaum D; Mattina A; Paques M; Rossant F; Girerd X; Leban M; Bruckert E";10.1530/EJE-19-0390;2020;['Journal Article']
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;31922497;RESULT;ATTENUATION OUTER RETINAL BANDS ON OPTICAL COHERENCE TOMOGRAPHY FOLLOWING MACULAR EDEMA: A Possible Manifestation of Photoreceptor Misalignment.;"Paques M; Rossant F; Finocchio L; Grieve K; Sahel JA; Pedinielli A; Mrejen S";10.1097/IAE.0000000000002738;2020;['Journal Article']
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;31573376;RESULT;High-Resolution Imaging of Retinal Vasculitis by Flood Illumination Adaptive Optics Ophthalmoscopy: A Follow-up Study.;"Errera MH; Laguarrigue M; Rossant F; Koch E; Chaumette C; Fardeau C; Westcott M; Sahel JA; Bodaghi B; Benesty J; Paques M";10.1080/09273948.2019.1646773;2020;['Journal Article']
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;25284764;RESULT;Meaning of visualizing retinal cone mosaic on adaptive optics images.;"Jacob J; Paques M; Krivosic V; Dupas B; Couturier A; Kulcsar C; Tadayoni R; Massin P; Gaudric A";10.1016/j.ajo.2014.09.043;2015;['Case Reports', 'Journal Article', 'Observational Study']
NCT00122538;Once-daily Highly Active Antiretroviral Treatment Regimen Administration in HIV-1 Infected Children in Burkina Faso (ANRS 12103 BURKINAME);French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2005-07-22;2006-02;2009-05;23719348;DERIVED;A novel pharmacokinetic approach to predict virologic failure in HIV-1-infected paediatric patients.;"Bouazza N; Tréluyer JM; Msellati P; Van de Perre P; Diagbouga S; Nacro B; Hien H; Zoure E; Rouet F; Ouiminga A; Blanche S; Hirt D; Urien S";10.1097/QAD.0b013e32835caad1;2013;"['Clinical Trial, Phase II', 'Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT00122538;Once-daily Highly Active Antiretroviral Treatment Regimen Administration in HIV-1 Infected Children in Burkina Faso (ANRS 12103 BURKINAME);French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2005-07-22;2006-02;2009-05;20516271;DERIVED;Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children?;"Bouazza N; Hirt D; Bardin C; Diagbouga S; Nacro B; Hien H; Zoure E; Rouet F; Ouiminga A; Blanche S; Van De Perre P; Tréluyer JM; Msellati P; Urien S";10.1128/AAC.00306-10;2010;['Clinical Trial, Phase II', 'Journal Article']
NCT00122538;Once-daily Highly Active Antiretroviral Treatment Regimen Administration in HIV-1 Infected Children in Burkina Faso (ANRS 12103 BURKINAME);French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2005-07-22;2006-02;2009-05;21857286;DERIVED;Short-term virological efficacy, immune reconstitution, tolerance, and adherence of once-daily dosing of didanosine, lamivudine, and efavirenz in HIV-1-infected African children: ANRS 12103 Burkiname.;"Barro M; Some J; Foulongne V; Diasso Y; Zouré E; Hien H; François R; Michel S; Drabo A; Tamboura H; Ouiminga A; Diagbouga S; Hien A; Yaméogo S; Van De Perre P; Nacro B; Msellati P";10.1097/QAI.0b013e31821fd64f;2011;"['Clinical Trial, Phase II', 'Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01426243;The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient.;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2011-08-31;2011-07;2017-12;30096071;DERIVED;Immunogenicity and safety of yellow fever vaccine in HIV-1-infected patients.;"Colin de Verdiere N; Durier C; Samri A; Meiffredy V; Launay O; Matheron S; Mercier-Delarue S; Even S; Aboulker JP; Molina JM; Autran B; Simon F; ANRS EP46 NOVAA Group";10.1097/QAD.0000000000001963;2018;"['Comparative Study', 'Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01426243;The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient.;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2011-08-31;2011-07;2017-12;26314624;PUBMED;Molecular characterization of the 17D-204 yellow fever vaccine.;"Salmona M; Gazaignes S; Mercier-Delarue S; Garnier F; Korimbocus J; Colin de Verdière N; LeGoff J; Roques P; Simon F";10.1016/j.vaccine.2015.08.055;2015;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT04824638;BNT162b2 Vaccination With 2 Doses in COVID-19 Negative Volunteers and With a Single Dose in COVID-19 Positive Volunteers;ANRS, Emerging Infectious Diseases;Institut National de la Santé Et de la Recherche Médicale, France;COMPLETED;INTERVENTIONAL;False;2021-04-01;2021-03-08;2023-12-02;;;;;;;
NCT02113943;Double Blind Randomized, Monocentric, Cross-over, Placebo-controlled Study to Evaluate the Effect of Citalopram on Motivation;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-04-15;2014-04;2014-06;;;;;;;
NCT00299143;Pilot Study on Shear-induced Platelet Aggregation in Acute Coronary Syndromes;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2006-03-06;2005-06;2010-06;;;;;;;
NCT03870438;Prevention of Mother-to-child Transmission of HIV-1 Using a Responsive Intervention;ANRS, Emerging Infectious Diseases;University Teaching Hospital, Lusaka, Zambia | Centre Muraz | Institut National de la Santé Et de la Recherche Médicale, France | University of Bergen;COMPLETED;INTERVENTIONAL;False;2019-03-12;2019-12-14;2022-10-31;38484756;PUBMED;Optimised prevention of postnatal HIV transmission in Zambia and Burkina Faso (PROMISE-EPI): a phase 3, open-label, randomised controlled trial.;"Kankasa C; Mennecier A; Sakana BLD; Molès JP; Mwiya M; Chunda-Liyoka C; D'Ottavi M; Tassembedo S; Wilfred-Tonga MM; Fao P; Rutagwera D; Matoka B; Kania D; Taofiki OA; Tylleskär T; Van de Perre P; Nagot N; PROMISE-EPI Trial Group";10.1016/S0140-6736(23)02464-9;2024;['Journal Article']
NCT03870438;Prevention of Mother-to-child Transmission of HIV-1 Using a Responsive Intervention;ANRS, Emerging Infectious Diseases;University Teaching Hospital, Lusaka, Zambia | Centre Muraz | Institut National de la Santé Et de la Recherche Médicale, France | University of Bergen;COMPLETED;INTERVENTIONAL;False;2019-03-12;2019-12-14;2022-10-31;33872801;BACKGROUND;Design and challenges of a large HIV prevention clinical study on mother-to-child transmission: ANRS 12397 PROMISE-EPI study in Zambia and Burkina Faso.;"Mennecier A; Kankasa C; Fao P; Moles JP; Eymard-Duvernay S; Mwiya M; Kania D; Chunda-Liyoka C; Sakana L; Rutagwera D; Tassembedo S; Wilfred-Tonga MM; Mosqueira B; Tylleskär T; Nagot N; Van de Perre P; ANRS 12397 Study group";10.1016/j.cct.2021.106402;2021;"['Clinical Trial Protocol', 'Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT03870438;Prevention of Mother-to-child Transmission of HIV-1 Using a Responsive Intervention;ANRS, Emerging Infectious Diseases;University Teaching Hospital, Lusaka, Zambia | Centre Muraz | Institut National de la Santé Et de la Recherche Médicale, France | University of Bergen;COMPLETED;INTERVENTIONAL;False;2019-03-12;2019-12-14;2022-10-31;26603917;BACKGROUND;Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial.;"Nagot N; Kankasa C; Tumwine JK; Meda N; Hofmeyr GJ; Vallo R; Mwiya M; Kwagala M; Traore H; Sunday A; Singata M; Siuluta C; Some E; Rutagwera D; Neboua D; Ndeezi G; Jackson D; Maréchal V; Neveu D; Engebretsen IMS; Lombard C; Blanche S; Sommerfelt H; Rekacewicz C; Tylleskär T; Van de Perre P; ANRS 12174 Trial Group";10.1016/S0140-6736(15)00984-8;2016;"['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT01605890;Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients;ANRS, Emerging Infectious Diseases;Gilead Sciences | Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;True;2012-05-25;2012-07;2015-12;29590335;DERIVED;First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2).;"Matheron S; Descamps D; Gallien S; Besseghir A; Sellier P; Blum L; Mortier E; Charpentier C; Tubiana R; Damond F; Peytavin G; Ponscarme D; Collin F; Brun-Vezinet F; Chene G; France REcherche Nord&Sud Sida-Hiv Hépatites (ANRS) 159 HIV-2 Trial Study Group";10.1093/cid/ciy245;2018;"['Clinical Trial, Phase II', 'Journal Article', 'Multicenter Study', ""Research Support, Non-U.S. Gov't""]"
NCT00391638;Efficacy and Tolerance of Peg-interferon Alpha 2a Added to Tenofovir and Emtricitabine in AgHBe Positive HBV-HIV Co-infected Patients;French National Agency for Research on AIDS and Viral Hepatitis;Gilead Sciences | Roche Pharma AG;COMPLETED;INTERVENTIONAL;False;2006-10-24;2007-01;2012-10;;;;;;;
NCT02323308;Isolated Anti-HBc Serological Profile in HIV Infected Patients: Immunological, Virological Characteristics and Response to Hepatitis B Vaccination;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2014-12-23;2010-12;2014-06;;;;;;;
NCT02384967;Evaluation of a Dose Reduction of Darunavir (400 mg/d) in Virologically Suppressed HIV-1 Patients;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2015-03-10;2015-03;2016-10;29905808;DERIVED;Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study.;"Lê MP; Chaix ML; Chevret S; Bertrand J; Raffi F; Gallien S; El Abbassi EMB; Katlama C; Delobel P; Yazdanpanah Y; Saillard J; Molina JM; Peytavin G; ANRS 165 DARULIGHT Study Group";10.1093/jac/dky193;2018;"['Clinical Trial, Phase II', 'Journal Article', 'Multicenter Study', ""Research Support, Non-U.S. Gov't""]"
NCT00988767;Safety and Immunogenicity of a Naked DNA-based Vaccine Therapy in Patients With Chronic Hepatitis B;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2009-10-02;2001-02;2004-10;15382173;BACKGROUND;Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers.;"Mancini-Bourgine M; Fontaine H; Scott-Algara D; Pol S; Bréchot C; Michel ML";10.1002/hep.20408;2004;"['Clinical Trial', 'Clinical Trial, Phase I', 'Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT00988767;Safety and Immunogenicity of a Naked DNA-based Vaccine Therapy in Patients With Chronic Hepatitis B;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2009-10-02;2001-02;2004-10;16310901;RESULT;Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers.;"Mancini-Bourgine M; Fontaine H; Bréchot C; Pol S; Michel ML";10.1016/j.vaccine.2005.08.013;2006;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT00988767;Safety and Immunogenicity of a Naked DNA-based Vaccine Therapy in Patients With Chronic Hepatitis B;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2009-10-02;2001-02;2004-10;20090916;DERIVED;Changes to the natural killer cell repertoire after therapeutic hepatitis B DNA vaccination.;"Scott-Algara D; Mancini-Bourgine M; Fontaine H; Pol S; Michel ML";10.1371/journal.pone.0008761;2010;"['Clinical Trial, Phase I', 'Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT00323804;Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.;ANRS, Emerging Infectious Diseases;Merck Sharp & Dohme LLC | Rennes University Hospital;COMPLETED;INTERVENTIONAL;False;2006-05-10;2006-05;2013-03;;;;;;;
NCT04849767;National Survey About Trajectory and Life Conditions of HIV Trans People in France;ANRS, Emerging Infectious Diseases;Institut National de la Santé Et de la Recherche Médicale, France;COMPLETED;OBSERVATIONAL;False;2021-04-19;2020-10-01;2023-12-31;34916316;DERIVED;Living conditions, HIV and gender affirmation care pathways of transgender people living with HIV in France: a nationwide, comprehensive, cross-sectional, community-based research protocol (ANRS Trans&HIV).;"Mora M; Rincon G; Bourrelly M; Maradan G; Freire Maresca A; Michard F; Rouveix E; Pannetier J; Leriche D; Alain T; Yazdanpanah Y; Michels D; Spire B";10.1136/bmjopen-2021-052691;2021;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT03047967;Effects of Prenatal Tobacco Smoke Exposure on Lung Function and Respiratory Epithelium Functionality in Newborns;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2017-02-09;2017-11-10;2019-02-09;;;;;;;
NCT00120367;Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125);French National Agency for Research on AIDS and Viral Hepatitis;Hoffmann-La Roche | Gilead Sciences;COMPLETED;INTERVENTIONAL;False;2005-07-18;2005-04;2007-12;21738597;DERIVED;Improved survival of HIV-1-infected patients with progressive multifocal leukoencephalopathy receiving early 5-drug combination antiretroviral therapy.;"Gasnault J; Costagliola D; Hendel-Chavez H; Dulioust A; Pakianather S; Mazet AA; de Goer de Herve MG; Lancar R; Lascaux AS; Porte L; Delfraissy JF; Taoufik Y; ANRS 125 Trial Team";10.1371/journal.pone.0020967;2011;"['Clinical Trial', 'Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01038401;Residual Replication of HIV-1 in the Gut Associated Lymphoid Tissue (GALT) of Patients on Highly Active Antiretroviral Therapy (HAART): the ANRS EP 44 Study;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2009-12-24;2008-09;2010-05;;;;;;;
NCT04484740;Penetration of the Innovative Antibiotic Gepotidacin Into Prostate and Tonsillar Tissue;Institut National de la Santé Et de la Recherche Médicale, France;Medical University of Vienna;COMPLETED;INTERVENTIONAL;False;2020-07-24;2021-01-29;2023-05-27;;;;;;;
NCT03078439;EPIPAGE2 Cohort Study Follow up at Five and a Half Years;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2017-03-13;2016-09-02;2018-01-08;38408861;PUBMED;Birth weight and head circumference discordance and outcome in preterms: results from the EPIPAGE-2 cohort.;"Guellec I; Brunet A; Lapillonne A; Taine M; Torchin H; Favrais G; Gascoin G; Simon L; Heude B; Scherdel P; Kayem G; Delorme P; Jarreau PH; Ancel PY";10.1136/archdischild-2023-326336;2024;['Journal Article']
NCT00148863;Interferon Gamma With Peg-Interferon Alpha 2a and Ribavirin in Non Responders Patients With Chronic Hepatitis C;French National Agency for Research on AIDS and Viral Hepatitis;InterMune | Hoffmann-La Roche;COMPLETED;INTERVENTIONAL;False;2005-09-08;2004-06;2007-08;23190183;DERIVED;Interferon-gamma with peginterferon alpha-2a and ribavirin in nonresponder patients with chronic hepatitis C (ANRS HC16 GAMMATRI).;"Couzigou P; Pérusat S; Bourlière M; Trimoulet P; Poynard T; Leroy V; Marcellin P; Foucher J; Bronowicki JP; Chêne G; ANRS HC16 GAMMATRI Trial Group";10.1111/jgh.12060;2013;"['Clinical Trial, Phase II', 'Journal Article', 'Multicenter Study', ""Research Support, Non-U.S. Gov't""]"
NCT01548586;Effect of Transcranial Direct Current Stimulation (tDCS) on the Excitability of the Diaphragmatic Primary Motor Cortex;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;INTERVENTIONAL;False;2012-03-08;2012-01;2012-05;11723286;BACKGROUND;Sustained excitability elevations induced by transcranial DC motor cortex stimulation in humans.;"Nitsche MA; Paulus W";10.1212/wnl.57.10.1899;2001;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01548586;Effect of Transcranial Direct Current Stimulation (tDCS) on the Excitability of the Diaphragmatic Primary Motor Cortex;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;INTERVENTIONAL;False;2012-03-08;2012-01;2012-05;16002441;BACKGROUND;Modulating parameters of excitability during and after transcranial direct current stimulation of the human motor cortex.;"Nitsche MA; Seeber A; Frommann K; Klein CC; Rochford C; Nitsche MS; Fricke K; Liebetanz D; Lang N; Antal A; Paulus W; Tergau F";10.1113/jphysiol.2005.092429;2005;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01548586;Effect of Transcranial Direct Current Stimulation (tDCS) on the Excitability of the Diaphragmatic Primary Motor Cortex;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;INTERVENTIONAL;False;2012-03-08;2012-01;2012-05;8756819;BACKGROUND;Impairment of central motor conduction to the diaphragm in stroke.;"Similowski T; Catala M; Rancurel G; Derenne JP";10.1164/ajrccm.154.2.8756819;1996;"['Comparative Study', 'Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01548586;Effect of Transcranial Direct Current Stimulation (tDCS) on the Excitability of the Diaphragmatic Primary Motor Cortex;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;INTERVENTIONAL;False;2012-03-08;2012-01;2012-05;15634731;BACKGROUND;Effects of non-invasive cortical stimulation on skilled motor function in chronic stroke.;"Hummel F; Celnik P; Giraux P; Floel A; Wu WH; Gerloff C; Cohen LG";10.1093/brain/awh369;2005;"['Clinical Trial', 'Controlled Clinical Trial', 'Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01548586;Effect of Transcranial Direct Current Stimulation (tDCS) on the Excitability of the Diaphragmatic Primary Motor Cortex;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;INTERVENTIONAL;False;2012-03-08;2012-01;2012-05;20161639;BACKGROUND;Focal and bi-directional modulation of lower limb motor cortex using anodal transcranial direct current stimulation.;"Madhavan S; Stinear JW";10.1016/j.brs.2009.06.005;2010;"['Journal Article', 'Research Support, N.I.H., Extramural', ""Research Support, Non-U.S. Gov't""]"
NCT01548586;Effect of Transcranial Direct Current Stimulation (tDCS) on the Excitability of the Diaphragmatic Primary Motor Cortex;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;INTERVENTIONAL;False;2012-03-08;2012-01;2012-05;22085959;BACKGROUND;Transcranial direct current stimulation--update 2011.;"Nitsche MA; Paulus W";10.3233/RNN-2011-0618;2011;"['Historical Article', 'Journal Article', ""Research Support, Non-U.S. Gov't"", 'Review']"
NCT01548586;Effect of Transcranial Direct Current Stimulation (tDCS) on the Excitability of the Diaphragmatic Primary Motor Cortex;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;INTERVENTIONAL;False;2012-03-08;2012-01;2012-05;10990547;BACKGROUND;Excitability changes induced in the human motor cortex by weak transcranial direct current stimulation.;"Nitsche MA; Paulus W";10.1111/j.1469-7793.2000.t01-1-00633.x;2000;"['Clinical Trial', 'Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01548586;Effect of Transcranial Direct Current Stimulation (tDCS) on the Excitability of the Diaphragmatic Primary Motor Cortex;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;INTERVENTIONAL;False;2012-03-08;2012-01;2012-05;19805746;BACKGROUND;Impact of transcranial direct current stimulation on spinal network excitability in humans.;"Roche N; Lackmy A; Achache V; Bussel B; Katz R";10.1113/jphysiol.2009.177550;2009;['Journal Article']
NCT01548586;Effect of Transcranial Direct Current Stimulation (tDCS) on the Excitability of the Diaphragmatic Primary Motor Cortex;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;INTERVENTIONAL;False;2012-03-08;2012-01;2012-05;15272049;BACKGROUND;Demonstration of a second rapidly conducting cortico-diaphragmatic pathway in humans.;"Sharshar T; Hopkinson NS; Jonville S; Prigent H; Carlier R; Dayer MJ; Swallow EB; Lofaso F; Moxham J; Polkey MI";10.1113/jphysiol.2004.061150;2004;['Comparative Study', 'Journal Article']
NCT00302822;Intensification With Enfuvirtide in Naive HIV-infected Patients (ANRS130);French National Agency for Research on AIDS and Viral Hepatitis;Hoffmann-La Roche | Gilead Sciences;COMPLETED;INTERVENTIONAL;False;2006-03-15;2006-04;2009-12;;;;;;;
NCT00196625;Salvage Therapy With Amprenavir, Lopinavir and Ritonavir in HIV-Infected Patients in Virological Failure.;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2005-09-20;2000-11;2002-02;15456093;RESULT;Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.;"Raguin G; Chêne G; Morand-Joubert L; Taburet AM; Droz C; Le Tiec C; Clavel F; Girard PM; Puzzle 1 Study Group";;2004;"['Clinical Trial', 'Clinical Trial, Phase II', 'Comparative Study', 'Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00196625;Salvage Therapy With Amprenavir, Lopinavir and Ritonavir in HIV-Infected Patients in Virological Failure.;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2005-09-20;2000-11;2002-02;15060509;RESULT;Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus.;"Taburet AM; Raguin G; Le Tiec C; Droz C; Barrail A; Vincent I; Morand-Joubert L; Chêne G; Clavel F; Girard PM";10.1016/j.clpt.2003.12.013;2004;"['Clinical Trial', 'Comparative Study', 'Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT01188525;Pharmacokinetic Study to Characterize Individual Metabolic Profile;Institut National de la Santé Et de la Recherche Médicale, France;Nuclear Energy Commission (CEA);COMPLETED;INTERVENTIONAL;False;2010-08-25;2010-08;2011-07;;;;;;;
NCT00670839;Trial Comparing Two Strategies of Vaccination Against Hepatitis B in HIV-infected Patients Non Responding to Primary Immunization (B-BOOST);ANRS, Emerging Infectious Diseases;MCM Vaccines B.V.;COMPLETED;INTERVENTIONAL;False;2008-05-02;2008-05;2013-02;26257021;DERIVED;Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial.;"Rey D; Piroth L; Wendling MJ; Miailhes P; Michel ML; Dufour C; Haour G; Sogni P; Rohel A; Ajana F; Billaud E; Molina JM; Launay O; Carrat F; ANRS HB04 B-BOOST study group";10.1016/S1473-3099(15)00220-0;2015;"['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00158522;Efficacy of Pegylated Interferon Alone in Egyptian Patients With Acute Hepatitis C (ANRS 1213);French National Agency for Research on AIDS and Viral Hepatitis;Hoffmann-La Roche;COMPLETED;INTERVENTIONAL;False;2005-09-12;2003-02;2007-12;15977225;BACKGROUND;Surveillance of acute hepatitis C in Cairo, Egypt.;"El Gaafary MM; Rekacewicz C; Abdel-Rahman AG; Allam MF; El Hosseiny M; Hamid MA; Colombani F; Sultan Y; El-Aidy S; Fontanet A; Mohamed MK";10.1002/jmv.20392;2005;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT00158522;Efficacy of Pegylated Interferon Alone in Egyptian Patients With Acute Hepatitis C (ANRS 1213);French National Agency for Research on AIDS and Viral Hepatitis;Hoffmann-La Roche;COMPLETED;INTERVENTIONAL;False;2005-09-12;2003-02;2007-12;16434426;BACKGROUND;Higher clearance of hepatitis C virus infection in females compared with males.;"Bakr I; Rekacewicz C; El Hosseiny M; Ismail S; El Daly M; El-Kafrawy S; Esmat G; Hamid MA; Mohamed MK; Fontanet A";10.1136/gut.2005.078147;2006;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT00196586;Efficacy and Safety of Addition of IL-2 to Pegylated Interferon Alpha 2a and Ribavirin in HIV/HCV Coinfected Patients;French National Agency for Research on AIDS and Viral Hepatitis;Hoffmann-La Roche;COMPLETED;INTERVENTIONAL;False;2005-09-20;2003-04;2006-11;;;;;;;
NCT04808986;Seroprevalence of IgG Antibodies to SARS-CoV-2 (COVID-19) in Primary Health Care Workers and Their Household Contacts;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2021-03-22;2021-05-10;2021-10-12;;;;;;;
NCT02626286;Feasibility and Interest of a HIV Quarterly Preventive Global Care in Men Who Have Sex With Men in Sub-Saharan Africa;ANRS, Emerging Infectious Diseases;Expertise France | Université Montpellier | IRD Unité SESSTIM (IRD, Inserm, Université Aix-Marseille) | Coalition Internationale Sida | ARCAD-SIDA MALI | Espace Confiance, Côte d'Ivoire | Programme PAC-CI, Abidjan, Côte d'Ivoire | Association African Solidarité | Centre de Recherche Internationale pour la Santé, Ouagadougou, Burkina Faso | Espoir Vie-Togo - ONG;COMPLETED;INTERVENTIONAL;False;2015-12-10;2015-06;2021-01-05;33753460;DERIVED;Decrease in incidence of sexually transmitted infections symptoms in men who have sex with men enrolled in a quarterly HIV prevention and care programme in West Africa (CohMSM ANRS 12324-Expertise France).;"Yaya I; Diallo F; Kouamé MJ; Agboyibor MK; Traoré I; Coulibaly A; Maiga K; Mora M; Palvadeau P; Dah ETT; Mensah E; Anoma C; Dembélé Keita B; Spire B; Laurent C; CohMSM Study Group";10.1136/sextrans-2020-054755;2022;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT02626286;Feasibility and Interest of a HIV Quarterly Preventive Global Care in Men Who Have Sex With Men in Sub-Saharan Africa;ANRS, Emerging Infectious Diseases;Expertise France | Université Montpellier | IRD Unité SESSTIM (IRD, Inserm, Université Aix-Marseille) | Coalition Internationale Sida | ARCAD-SIDA MALI | Espace Confiance, Côte d'Ivoire | Programme PAC-CI, Abidjan, Côte d'Ivoire | Association African Solidarité | Centre de Recherche Internationale pour la Santé, Ouagadougou, Burkina Faso | Espoir Vie-Togo - ONG;COMPLETED;INTERVENTIONAL;False;2015-12-10;2015-06;2021-01-05;34352834;DERIVED;Rapid antiretroviral therapy initiation and its effect on treatment response in MSM in West Africa.;"Dah TTE; Yaya I; Mensah E; Coulibaly A; Kouamé JM; Traoré I; Mora M; Palvadeau P; Anoma C; Keita BD; Spire B; Laurent C; CohMSM Study Group";10.1097/QAD.0000000000003046;2021;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT02626286;Feasibility and Interest of a HIV Quarterly Preventive Global Care in Men Who Have Sex With Men in Sub-Saharan Africa;ANRS, Emerging Infectious Diseases;Expertise France | Université Montpellier | IRD Unité SESSTIM (IRD, Inserm, Université Aix-Marseille) | Coalition Internationale Sida | ARCAD-SIDA MALI | Espace Confiance, Côte d'Ivoire | Programme PAC-CI, Abidjan, Côte d'Ivoire | Association African Solidarité | Centre de Recherche Internationale pour la Santé, Ouagadougou, Burkina Faso | Espoir Vie-Togo - ONG;COMPLETED;INTERVENTIONAL;False;2015-12-10;2015-06;2021-01-05;34022820;DERIVED;Adherence to quarterly HIV prevention services and its impact on HIV incidence in men who have sex with men in West Africa (CohMSM ANRS 12324 - Expertise France).;"Dah TTE; Yaya I; Sagaon-Teyssier L; Coulibaly A; Kouamé MJ; Agboyibor MK; Maiga K; Traoré I; Mora M; Palvadeau P; Rojas-Castro D; Diallo F; Mensah E; Anoma C; Keita BD; Spire B; Laurent C; CohMSM Study Group";10.1186/s12889-021-10994-4;2021;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01207986;Early Lung Cancer Diagnosis in HIV Infected Population With an Important Smoking History With Low Dose CT: a Pilot Study;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2010-09-23;2011-02;2014-08;;;;;;;
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;20041309;BACKGROUND;Prevalence and incidence of HCV infection among Vietnam heroin users with recent onset of injection.;"Clatts MC; Colón-López V; Giang LM; Goldsamt LA";10.1007/s11524-009-9417-9;2010;"['Journal Article', 'Research Support, N.I.H., Extramural', ""Research Support, Non-U.S. Gov't""]"
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;27667367;BACKGROUND;EASL Recommendations on Treatment of Hepatitis C 2016.;European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu;10.1016/j.jhep.2016.09.001;2017;['Journal Article', 'Practice Guideline']
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;22098550;BACKGROUND;Liver disease in Viet Nam: screening, surveillance, management and education: a 5-year plan and call to action.;"Gish RG; Bui TD; Nguyen CT; Nguyen DT; Tran HV; Tran DM; Trinh HN; International Group for Liver Health in Viet Nam";10.1111/j.1440-1746.2011.06974.x;2012;"['Journal Article', ""Research Support, Non-U.S. Gov't"", 'Review']"
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;27178119;BACKGROUND;Integrated respondent-driven sampling and peer support for persons who inject drugs in Haiphong, Vietnam: a case study with implications for interventions.;"Des Jarlais D; Duong HT; Pham Minh K; Khuat OH; Nham TT; Arasteh K; Feelemyer J; Heckathorn DD; Peries M; Moles JP; Laureillard D; Nagot N; (The Drive Study Team)";10.1080/09540121.2016.1178698;2016;['Journal Article']
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;25920094;BACKGROUND;From non-A, non-B hepatitis to hepatitis C virus cure.;"Pawlotsky JM; Feld JJ; Zeuzem S; Hoofnagle JH";10.1016/j.jhep.2015.02.006;2015;['Journal Article', 'Review']
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;27427455;BACKGROUND;The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia.;"Altice FL; Azbel L; Stone J; Brooks-Pollock E; Smyrnov P; Dvoriak S; Taxman FS; El-Bassel N; Martin NK; Booth R; Stöver H; Dolan K; Vickerman P";10.1016/S0140-6736(16)30856-X;2016;"['Journal Article', 'Research Support, N.I.H., Extramural', ""Research Support, U.S. Gov't, Non-P.H.S."", 'Review']"
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;22564041;BACKGROUND;Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings.;"Vickerman P; Martin N; Turner K; Hickman M";10.1111/j.1360-0443.2012.03932.x;2012;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;27148964;BACKGROUND;High Proportion of HIV-HCV Coinfected Patients with Advanced Liver Fibrosis Requiring Hepatitis C Treatment in Haiphong, Northern Vietnam (ANRS 12262).;"Nguyen Truong T; Laureillard D; Lacombe K; Duong Thi H; Pham Thi Hanh P; Truong Thi Xuan L; Chu Thi N; Luong Que A; Vu Hai V; Nagot N; Tuaillon E; Dominguez S; Lemoine M";10.1371/journal.pone.0153744;2016;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;27349488;BACKGROUND;Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals.;"Conti F; Buonfiglioli F; Scuteri A; Crespi C; Bolondi L; Caraceni P; Foschi FG; Lenzi M; Mazzella G; Verucchi G; Andreone P; Brillanti S";10.1016/j.jhep.2016.06.015;2016;['Journal Article']
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;33208326;DERIVED;Towards HCV elimination among people who inject drugs in Hai Phong, Vietnam: study protocol for an effectiveness-implementation trial evaluating an integrated model of HCV care (DRIVE-C: DRug use & Infections in ViEtnam-hepatitis C).;"Rapoud D; Quillet C; Pham Minh K; Vu Hai V; Nguyen Thanh B; Nham Thi Tuyet T; Tran Thi H; Molès JP; Vallo R; Michel L; Feelemyer J; Weiss L; Lemoine M; Vickerman P; Fraser H; Duong Thi H; Khuat Thi Hai O; Des Jarlais D; Nagot N; Laureillard D; DRIVE-C Study Group";10.1136/bmjopen-2020-039234;2020;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;20196807;BACKGROUND;Vietnamese community screening for hepatitis B virus and hepatitis C virus.;"Kallman JB; Tran S; Arsalla A; Haddad D; Stepanova M; Fang Y; Wrobel VJ; Srishord M; Younossi ZM";10.1111/j.1365-2893.2010.01278.x;2011;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;23884064;BACKGROUND;Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy.;"Martin NK; Hickman M; Hutchinson SJ; Goldberg DJ; Vickerman P";10.1093/cid/cit296;2013;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;23728143;BACKGROUND;Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements.;"Grebely J; Matthews GV; Lloyd AR; Dore GJ";10.1093/cid/cit377;2013;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;25086286;BACKGROUND;Global epidemiology and genotype distribution of the hepatitis C virus infection.;"Gower E; Estes C; Blach S; Razavi-Shearer K; Razavi H";10.1016/j.jhep.2014.07.027;2014;"['Journal Article', ""Research Support, Non-U.S. Gov't"", 'Review']"
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;23553643;BACKGROUND;Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals.;"Martin NK; Vickerman P; Grebely J; Hellard M; Hutchinson SJ; Lima VD; Foster GR; Dillon JF; Goldberg DJ; Dore GJ; Hickman M";10.1002/hep.26431;2013;"['Journal Article', 'Research Support, N.I.H., Extramural', ""Research Support, Non-U.S. Gov't""]"
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;19839502;BACKGROUND;High prevalence of Hepatitis C virus genotype 6 in Vietnam.;"Pham DA; Leuangwutiwong P; Jittmittraphap A; Luplertlop N; Bach HK; Akkarathamrongsin S; Theamboonlers A; Poovorawan Y";;2009;['Journal Article']
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;20572071;BACKGROUND;Multiple routes of hepatitis C virus transmission among injection drug users in Hai Phong, Northern Vietnam.;"Tanimoto T; Nguyen HC; Ishizaki A; Chung PT; Hoang TT; Nguyen VT; Kageyama S; Oka S; Pham VT; Ichimura H";10.1002/jmv.21787;2010;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;23675659;BACKGROUND;Current and future therapies for hepatitis C virus infection.;"Liang TJ; Ghany MG";10.1056/NEJMra1213651;2013;['Journal Article', 'Review']
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;25245939;BACKGROUND;Prevention, treatment and care of hepatitis C virus infection among people who inject drugs.;"Bruggmann P; Grebely J";10.1016/j.drugpo.2014.08.014;2015;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;23172780;BACKGROUND;Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence.;"Mohd Hanafiah K; Groeger J; Flaxman AD; Wiersma ST";10.1002/hep.26141;2013;['Journal Article', 'Meta-Analysis', 'Review', 'Systematic Review']
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;26298331;BACKGROUND;Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis.;"Smith DJ; Combellick J; Jordan AE; Hagan H";10.1016/j.drugpo.2015.07.004;2015;['Journal Article', 'Meta-Analysis', 'Research Support, N.I.H., Extramural', 'Review', 'Systematic Review']
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;22828983;BACKGROUND;Epidemiology, responses, and way forward: the silent epidemic of viral hepatitis and HIV coinfection in Vietnam.;"Sereno L; Mesquita F; Kato M; Jacka D; Nguyen TT; Nguyen TN";10.1177/1545109712453939;2012;"['Journal Article', ""Research Support, Non-U.S. Gov't"", 'Review']"
NCT04684758;HIV Acquisition and Life Course of Born-abroad Men Who Have Sex With Men Living in Ile-de-France: the GANYMEDE Study;ANRS, Emerging Infectious Diseases;Institut National de la Santé Et de la Recherche Médicale, France;COMPLETED;OBSERVATIONAL;False;2020-12-28;2021-04-14;2022-06-30;;;;;;;
NCT00121758;AIDS Vaccine Study Comparing Immunogenicity and Safety of 3 Doses of Lipopeptides Versus Placebo in Non Infected HIV Volunteers;French National Agency for Research on AIDS and Viral Hepatitis;Aventis Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2005-07-21;2004-09;2007-12;20625264;DERIVED;Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial.;"Salmon-Céron D; Durier C; Desaint C; Cuzin L; Surenaud M; Hamouda NB; Lelièvre JD; Bonnet B; Pialoux G; Poizot-Martin I; Aboulker JP; Lévy Y; Launay O; ANRS VAC18 trial group";10.1097/QAD.0b013e32833ce566;2010;"['Clinical Trial, Phase II', 'Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00121758;AIDS Vaccine Study Comparing Immunogenicity and Safety of 3 Doses of Lipopeptides Versus Placebo in Non Infected HIV Volunteers;French National Agency for Research on AIDS and Viral Hepatitis;Aventis Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2005-07-21;2004-09;2007-12;23759749;DERIVED;Cytokine and gene transcription profiles of immune responses elicited by HIV lipopeptide vaccine in HIV-negative volunteers.;"Richert L; Hue S; Hocini H; Raimbault M; Lacabaratz C; Surenaud M; Wiedemann A; Tisserand P; Durier C; Salmon D; Lelièvre JD; Chêne G; Thiébaut R; Lévy Y; ANRS Vaccine Network/Vaccine Research Institute";10.1097/QAD.0b013e32835f5b60;2013;"['Clinical Trial, Phase II', 'Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT02527096;A Trial Evaluating Maintenance Therapy With Lamivudine (Epivir®) and Dolutegravir (Tivicay®) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple Highly Active Antiretroviral Therapy (HAART) (ANRS 167 Lamidol);ANRS, Emerging Infectious Diseases;ViiV Healthcare;COMPLETED;INTERVENTIONAL;False;2015-08-18;2015-09-17;2017-03;;;;;;;
NCT00158457;Simple Once Daily Triple Regimen Including Tenofovir, Emtricitabine and Efavirenz in HIV-1 Infected Patients (ANRS 1207);French National Agency for Research on AIDS and Viral Hepatitis;Gilead Sciences | Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba;COMPLETED;INTERVENTIONAL;False;2005-09-12;2004-06;2006-12;;;;;;;
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;16055926;RESULT;Spastin mutations are frequent in sporadic spastic paraparesis and their spectrum is different from that observed in familial cases.;"Depienne C; Tallaksen C; Lephay JY; Bricka B; Poea-Guyon S; Fontaine B; Labauge P; Brice A; Durr A";10.1136/jmg.2005.035311;2006;"['Comparative Study', 'Letter', ""Research Support, Non-U.S. Gov't""]"
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;15365159;RESULT;Mutations in the FGF14 gene are not a major cause of spinocerebellar ataxia in Caucasians.;"Stevanin G; Durr A; Dussert C; Penet C; Brice A";10.1212/01.wnl.0000137020.30604.1e;2004;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;17605047;RESULT;"A novel locus for autosomal dominant ""uncomplicated"" hereditary spastic paraplegia maps to chromosome 8p21.1-q13.3.";"Hanein S; Dürr A; Ribai P; Forlani S; Leutenegger AL; Nelson I; Babron MC; Elleuch N; Depienne C; Charon C; Brice A; Stevanin G";10.1007/s00439-007-0396-1;2007;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;16501573;RESULT;Mutations in voltage-gated potassium channel KCNC3 cause degenerative and developmental central nervous system phenotypes.;"Waters MF; Minassian NA; Stevanin G; Figueroa KP; Bannister JP; Nolte D; Mock AF; Evidente VG; Fee DB; Müller U; Dürr A; Brice A; Papazian DM; Pulst SM";10.1038/ng1758;2006;"['Journal Article', 'Research Support, N.I.H., Extramural', ""Research Support, Non-U.S. Gov't""]"
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;15313841;RESULT;Mutation in the catalytic domain of protein kinase C gamma and extension of the phenotype associated with spinocerebellar ataxia type 14.;"Stevanin G; Hahn V; Lohmann E; Bouslam N; Gouttard M; Soumphonphakdy C; Welter ML; Ollagnon-Roman E; Lemainque A; Ruberg M; Brice A; Durr A";10.1001/archneur.61.8.1242;2004;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;17597328;RESULT;A de novo SPAST mutation leading to somatic mosaicism is associated with a later age at onset in HSP.;"Depienne C; Fedirko E; Faucheux JM; Forlani S; Bricka B; Goizet C; Lesourd S; Stevanin G; Ruberg M; Durr A; Brice A";10.1007/s10048-007-0090-4;2007;"['Case Reports', 'Letter', ""Research Support, Non-U.S. Gov't""]"
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;22491195;DERIVED;Factors influencing disease progression in autosomal dominant cerebellar ataxia and spastic paraplegia.;"Tezenas du Montcel S; Charles P; Goizet C; Marelli C; Ribai P; Vincitorio C; Anheim M; Guyant-Maréchal L; Le Bayon A; Vandenberghe N; Tchikviladzé M; Devos D; Le Ber I; N'Guyen K; Cazeneuve C; Tallaksen C; Brice A; Durr A";10.1001/archneurol.2011.2713;2012;"['Journal Article', 'Multicenter Study', ""Research Support, Non-U.S. Gov't""]"
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;24780882;DERIVED;Prediction of the age at onset in spinocerebellar ataxia type 1, 2, 3 and 6.;"Tezenas du Montcel S; Durr A; Rakowicz M; Nanetti L; Charles P; Sulek A; Mariotti C; Rola R; Schols L; Bauer P; Dufaure-Garé I; Jacobi H; Forlani S; Schmitz-Hübsch T; Filla A; Timmann D; van de Warrenburg BP; Marelli C; Kang JS; Giunti P; Cook A; Baliko L; Melegh B; Boesch S; Szymanski S; Berciano J; Infante J; Buerk K; Masciullo M; Di Fabio R; Depondt C; Ratka S; Stevanin G; Klockgether T; Brice A; Golmard JL";10.1136/jmedgenet-2013-102200;2014;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;18378516;RESULT;Composite cerebellar functional severity score: validation of a quantitative score of cerebellar impairment.;"du Montcel ST; Charles P; Ribai P; Goizet C; Le Bayon A; Labauge P; Guyant-Maréchal L; Forlani S; Jauffret C; Vandenberghe N; N'guyen K; Le Ber I; Devos D; Vincitorio CM; Manto MU; Tison F; Hannequin D; Ruberg M; Brice A; Durr A";10.1093/brain/awn059;2008;"['Journal Article', 'Multicenter Study', ""Research Support, Non-U.S. Gov't"", 'Validation Study']"
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;17098887;RESULT;Exon deletions of SPG4 are a frequent cause of hereditary spastic paraplegia.;"Depienne C; Fedirko E; Forlani S; Cazeneuve C; Ribaï P; Feki I; Tallaksen C; Nguyen K; Stankoff B; Ruberg M; Stevanin G; Durr A; Brice A";10.1136/jmg.2006.046425;2007;"['Comparative Study', 'Letter', ""Research Support, Non-U.S. Gov't""]"
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;16193476;RESULT;New mutations in protein kinase Cgamma associated with spinocerebellar ataxia type 14.;"Klebe S; Durr A; Rentschler A; Hahn-Barma V; Abele M; Bouslam N; Schöls L; Jedynak P; Forlani S; Denis E; Dussert C; Agid Y; Bauer P; Globas C; Wüllner U; Brice A; Riess O; Stevanin G";10.1002/ana.20628;2005;"['Comparative Study', 'Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;18853458;RESULT;Complicated forms of autosomal dominant hereditary spastic paraplegia are frequent in SPG10.;"Goizet C; Boukhris A; Mundwiller E; Tallaksen C; Forlani S; Toutain A; Carriere N; Paquis V; Depienne C; Durr A; Stevanin G; Brice A";10.1002/humu.20920;2009;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;17957230;RESULT;Mental deficiency in three families with SPG4 spastic paraplegia.;"Ribaï P; Depienne C; Fedirko E; Jothy AC; Viveweger C; Hahn-Barma V; Brice A; Durr A";10.1038/sj.ejhg.5201922;2008;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01579435;Experimental Therapeutics in Essential Tremor Using Transcranial Direct Current Stimulation;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-04-18;2012-04;2013-04;;;;;;;
NCT02057796;Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2014-02-07;2014-09;2018-04;36883573;PUBMED;High performance of systematic combined urine LAM test and sputum Xpert MTB/RIF® for tuberculosis screening in severely immunosuppressed ambulatory adults with HIV.;"Bonnet M; Gabillard D; Domoua S; Muzoora C; Messou E; Sovannarith S; Nguyen DB; Badje A; Juchet S; Bunnet D; Borand L; Natukunda N; Tran TH; Anglaret X; Laureillard D; Blanc FX; STATIS ANRS 12290 Trial Team";10.1093/cid/ciad125;2023;['Journal Article']
NCT02057796;Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2014-02-07;2014-09;2018-04;32558469;DERIVED;Systematic or Test-Guided Treatment for Tuberculosis in HIV-Infected Adults.;"Blanc FX; Badje AD; Bonnet M; Gabillard D; Messou E; Muzoora C; Samreth S; Nguyen BD; Borand L; Domergue A; Rapoud D; Natukunda N; Thai S; Juchet S; Eholié SP; Lawn SD; Domoua SK; Anglaret X; Laureillard D; STATIS ANRS 12290 Trial Team";10.1056/NEJMoa1910708;2020;"['Comparative Study', 'Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT01713335;Proteasis Evaluation in COPD;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-10-24;2012-10-18;2017-04;;;;;;;
NCT02073630;Contribution of the Cerebellum In Sensory-motor Adaptation Via Gamma Oscillations: the Case of Dystonia;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-02-27;2014-02;2016-08;;;;;;;
NCT05040048;Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease;Institut National de la Santé Et de la Recherche Médicale, France;Innovative Medicines Initiative | Institut d'Investigacions Biomèdiques August Pi i Sunyer | ICM Co. Ltd. | University Hospital, Bonn | Karolinska Institutet;COMPLETED;OBSERVATIONAL;False;2021-09-10;2015-09-04;2018-02;;;;;;;
NCT03446430;Validation of Laser Doppler Vibrometer (LDV) for Measurement of Arterial Stiffness in Hypertensive Patients;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2018-02-26;2018-06-21;2018-12-04;;;;;;;
NCT01094899;Abnormal Structure and Bone Density in Diabetes;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2010-03-29;2010-03-10;2014-07-10;;;;;;;
NCT03193099;Decoding Presymptomatic White Matter Changes in Huntington Disease;Institut National de la Santé Et de la Recherche Médicale, France;University College, London;COMPLETED;INTERVENTIONAL;False;2017-06-20;2017-07-11;2019-12-30;;;;;;;
NCT03831906;Impact of Systematic Early Tuberculosis Detection Using Xpert MTB/RIF Ultra in Children With Severe Pneumonia in High Tuberculosis Burden Countries (TB-Speed Pneumonia);Institut National de la Santé Et de la Recherche Médicale, France;UNITAID;COMPLETED;INTERVENTIONAL;False;2019-02-06;2019-03-20;2021-06-30;36395782;DERIVED;Effect of systematic tuberculosis detection on mortality in young children with severe pneumonia in countries with high incidence of tuberculosis: a stepped-wedge cluster-randomised trial.;"Marcy O; Wobudeya E; Font H; Vessière A; Chabala C; Khosa C; Taguebue JV; Moh R; Mwanga-Amumpaire J; Lounnas M; Mulenga V; Mavale S; Chilundo J; Rego D; Nduna B; Shankalala P; Chirwa U; De Lauzanne A; Dim B; Tiogouo Ngouana E; Folquet Amorrissani M; Cisse L; Amon Tanoh Dick F; Komena EA; Kwedi Nolna S; Businge G; Natukunda N; Cumbe S; Mbekeka P; Kim A; Kheang C; Pol S; Maleche-Obimbo E; Seddon JA; Mao TE; Graham SM; Delacourt C; Borand L; Bonnet M; TB-Speed Pneumonia Study Group";10.1016/S1473-3099(22)00668-5;2023;['Randomized Controlled Trial', 'Journal Article']
NCT03831906;Impact of Systematic Early Tuberculosis Detection Using Xpert MTB/RIF Ultra in Children With Severe Pneumonia in High Tuberculosis Burden Countries (TB-Speed Pneumonia);Institut National de la Santé Et de la Recherche Médicale, France;UNITAID;COMPLETED;INTERVENTIONAL;False;2019-02-06;2019-03-20;2021-06-30;32853411;DERIVED;Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children.;"Kay AW; González Fernández L; Takwoingi Y; Eisenhut M; Detjen AK; Steingart KR; Mandalakas AM";10.1002/14651858.CD013359.pub2;2020;"['Journal Article', 'Meta-Analysis', ""Research Support, Non-U.S. Gov't"", 'Systematic Review']"
NCT03831906;Impact of Systematic Early Tuberculosis Detection Using Xpert MTB/RIF Ultra in Children With Severe Pneumonia in High Tuberculosis Burden Countries (TB-Speed Pneumonia);Institut National de la Santé Et de la Recherche Médicale, France;UNITAID;COMPLETED;INTERVENTIONAL;False;2019-02-06;2019-03-20;2021-06-30;33743621;BACKGROUND;Impact of systematic early tuberculosis detection using Xpert MTB/RIF Ultra in children with severe pneumonia in high tuberculosis burden countries (TB-Speed pneumonia): a stepped wedge cluster randomized trial.;"Vessière A; Font H; Gabillard D; Adonis-Koffi L; Borand L; Chabala C; Khosa C; Mavale S; Moh R; Mulenga V; Mwanga-Amumpere J; Taguebue JV; Eang MT; Delacourt C; Seddon JA; Lounnas M; Godreuil S; Wobudeya E; Bonnet M; Marcy O";10.1186/s12887-021-02576-5;2021;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00148824;Antibody Responses to Pneumococcal Vaccines Among HIV-Infected Adults.;French National Agency for Research on AIDS and Viral Hepatitis;Wyeth is now a wholly owned subsidiary of Pfizer;COMPLETED;INTERVENTIONAL;False;2005-09-08;2003-02;2006-01;20210645;DERIVED;Cellular CD4 T cell responses to the diphtheria-derived carrier protein of conjugated pneumococcal vaccine and antibody response to pneumococcal vaccination in HIV-infected adults.;"Rabian C; Tschöpe I; Lesprit P; Katlama C; Molina JM; Meynard JL; Delfraissy JF; Chêne G; Lévy Y; ANRS 114 Pneumovac Study Group";10.1086/651418;2010;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT00901524;ANRS HC20 Effectiveness of an Optimized Anti HCV PegIFN-alpha2a + Ribavirin on Sustained Virological Response in Patients With HCV Genotype 1 and 4 Non Responders and Co-infected With HIV;ANRS, Emerging Infectious Diseases;Roche Pharma AG;COMPLETED;INTERVENTIONAL;False;2009-05-13;2009-06;2012-06;24905490;DERIVED;Apolipoprotein H expression is associated with IL28B genotype and viral clearance in hepatitis C virus infection.;"Laird ME; Mohsen A; Duffy D; Mamdouh R; LeFouler L; Casrouge A; El-Daly M; Rafik M; Abdel-Hamid M; Soulier A; Pawlotsky JM; Hézode C; Rosa I; Renard P; Mohamed MK; Bonnard P; Izopet J; Mallet V; Pol S; Albert ML; Fontanet A";10.1016/j.jhep.2014.05.040;2014;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT00870649;Efficacy of Bilhvax in Association With Praziquantel for Prevention of Clinical Recurrences of Schistosoma Haematobium;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2009-03-27;2009-02;2012-12;30532268;DERIVED;Safety and efficacy of the rSh28GST urinary schistosomiasis vaccine: A phase 3 randomized, controlled trial in Senegalese children.;"Riveau G; Schacht AM; Dompnier JP; Deplanque D; Seck M; Waucquier N; Senghor S; Delcroix-Genete D; Hermann E; Idris-Khodja N; Levy-Marchal C; Capron M; Capron A";10.1371/journal.pntd.0006968;2018;"['Clinical Trial, Phase III', 'Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT01207349;Type 2 Diabetes Secondary Prevention;Institut National de la Santé Et de la Recherche Médicale, France;Groupe Hospitalier Sud Réunion;COMPLETED;OBSERVATIONAL;False;2010-09-22;2002-08;2004-12;22030240;DERIVED;Quarterly individual outpatients lifestyle counseling after initial inpatients education on type 2 diabetes: the REDIA Prev-2 randomized controlled trial in Reunion Island.;"Debussche X; Rollot O; Le Pommelet C; Fianu A; Le Moullec N; Régnier C; Boyer MC; Cogne M; Bakiri F; Schwager JC; Favier F";10.1016/j.diabet.2011.07.002;2012;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT01531036;3D Breast Ultrasound Elastography in Patients Under Neoadjuvant Chemotherapy;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-02-10;2010-12;2012-11;20505064;BACKGROUND;Breast lesions: quantitative elastography with supersonic shear imaging--preliminary results.;"Athanasiou A; Tardivon A; Tanter M; Sigal-Zafrani B; Bercoff J; Deffieux T; Gennisson JL; Fink M; Neuenschwander S";10.1148/radiol.10090385;2010;['Journal Article']
NCT00651066;Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-infection in Vietnam;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2008-04-02;2010-06;2012-09;24465443;DERIVED;Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam.;"Lan NT; Thu NT; Barrail-Tran A; Duc NH; Lan NN; Laureillard D; Lien TT; Borand L; Quillet C; Connolly C; Lagarde D; Pym A; Lienhardt C; Dung NH; Taburet AM; Harries AD";10.1371/journal.pone.0084866;2014;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT02081066;Identification of CETP as a Marker of Atherosclerosis;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-03-07;2014-09-25;2020-09;;;;;;;
NCT01164436;Cohort of HIV Associated Lymphomas;ANRS, Emerging Infectious Diseases;Dr Yassine Taoufik Dr Houria Chavez Hôpital Bicêtre CIB Paris Sud France | Dr Guislaine Garcelain Hôpital Pitié Slapétrière Paris France | University Hospital, Grenoble | Dr Irène Joab Hôpital Paul Brousse Villejuif France | Dr Alex Duval Fondation Jean Dausset CEPH | Hopital Antoine Beclere;COMPLETED;OBSERVATIONAL;False;2010-07-16;2008-06;2017-06;;;;;;;
NCT01038999;Accelerated Aging, HIV Infection, Antiretroviral Therapies;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;OBSERVATIONAL;False;2009-12-24;2009-04;2012-03;23285253;DERIVED;"HIV protease inhibitors do not cause the accumulation of prelamin A in PBMCs from patients receiving first line therapy: the ANRS EP45 ""aging"" study.";"Perrin S; Cremer J; Faucher O; Reynes J; Dellamonica P; Micallef J; Solas C; Lacarelle B; Stretti C; Kaspi E; Robaglia-Schlupp A; Nicolino-Brunet C; Tamalet C; Lévy N; Poizot-Martin I; Cau P; Roll P";10.1371/journal.pone.0053035;2012;"['Controlled Clinical Trial', 'Journal Article', 'Multicenter Study', ""Research Support, Non-U.S. Gov't""]"
NCT01038999;Accelerated Aging, HIV Infection, Antiretroviral Therapies;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;OBSERVATIONAL;False;2009-12-24;2009-04;2012-03;22829920;DERIVED;"HIV-1 infection and first line ART induced differential responses in mitochondria from blood lymphocytes and monocytes: the ANRS EP45 ""Aging"" study.";"Perrin S; Cremer J; Roll P; Faucher O; Ménard A; Reynes J; Dellamonica P; Naqvi A; Micallef J; Jouve E; Tamalet C; Solas C; Pissier C; Arnoux I; Nicolino-Brunet C; Espinosa L; Lévy N; Kaspi E; Robaglia-Schlupp A; Poizot-Martin I; Cau P";10.1371/journal.pone.0041129;2012;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT00604149;Cardiac AResT And GENEtic;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2008-01-30;2008-01;2014-01;;;;;;;
NCT01569399;Efficacity of rTMS in Alcohol Dependance;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-04-03;2011-02-11;2016-08;;;;;;;
NCT01917175;Early Identification and Treatment of Early HIV Infection in Côte d'Ivoire;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2013-08-06;1997-06;2018-09;;;;;;;
NCT01592175;Magnetoencephalography (MEG), Attention and Conscience;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-05-07;2012-03-08;2013-07-02;;;;;;;
NCT01271842;Long-term Outcome and Lung Capacity in Survivors of ARDS Due to Influenza A (H1N1) v2009 The RESPIFLU Study;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2011-01-07;2010-10;;22948576;DERIVED;Long-term outcomes of pandemic 2009 influenza A(H1N1)-associated severe ARDS.;"Luyt CE; Combes A; Becquemin MH; Beigelman-Aubry C; Hatem S; Brun AL; Zraik N; Carrat F; Grenier PA; Richard JM; Mercat A; Brochard L; Brun-Buisson C; Chastre J; REVA Study Group";10.1378/chest.11-2196;2012;"['Journal Article', 'Multicenter Study', ""Research Support, Non-U.S. Gov't""]"
NCT00265642;Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C;ANRS, Emerging Infectious Diseases;Sanofi;COMPLETED;INTERVENTIONAL;False;2005-12-15;2006-10;2013-11;;;;;;;
NCT01008813;Clinical Trial to Evaluate the Immunogenicity and Safety of an Adjuvanted A(H1N1)v Influenza Vaccine and a Non-adjuvanted A(H1N1)v Influenza Vaccine in HIV-infected Patients (ANRS 151 Hifluvac);French National Agency for Research on AIDS and Viral Hepatitis;GlaxoSmithKline;COMPLETED;INTERVENTIONAL;False;2009-11-06;2009-10;2010-12;;;;;;;
NCT00158470;Feasibility Study of a Once Daily Antiretroviral Regimen in Vietnam (ANRS 1210 VIETAR);French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2005-09-12;2003-09;2007-05;;;;;;;
NCT04265742;Microbiota and Bone Fragility:Study of the Relation Between Gut Microbiota and Bone Microarchitecture;Institut National de la Santé Et de la Recherche Médicale, France;Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2020-02-12;2019-02-08;2022-02-04;;;;;;;
NCT04631224;Longitudinal Analysis of Oral Communication in Friedreich's Ataxia;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2020-11-17;2015-02;2017-02;;;;;;;
NCT01493934;Development of a Fast Measurement Technique of Insulin Resistance in Human;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-12-16;2010-04;2013-03;;;;;;;
NCT02978924;Trans-spinal Direct Current Stimulation in Primary Orthostatic Tremor;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-12-01;2017-01-17;2017-11-28;;;;;;;
NCT00226434;Early vs Late Introduction of Antiretroviral Therapy in HIV-infected Patients With Tuberculosis (ANRS 1295 CAMELIA);French National Agency for Research on AIDS and Viral Hepatitis;National Institutes of Health (NIH);COMPLETED;INTERVENTIONAL;False;2005-09-27;2006-01;2010-05;22010913;DERIVED;Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis.;"Blanc FX; Sok T; Laureillard D; Borand L; Rekacewicz C; Nerrienet E; Madec Y; Marcy O; Chan S; Prak N; Kim C; Lak KK; Hak C; Dim B; Sin CI; Sun S; Guillard B; Sar B; Vong S; Fernandez M; Fox L; Delfraissy JF; Goldfeld AE; CAMELIA (ANRS 1295–CIPRA KH001) Study Team";10.1056/NEJMoa1013911;2011;"['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', 'Research Support, N.I.H., Extramural', ""Research Support, Non-U.S. Gov't""]"
NCT00226434;Early vs Late Introduction of Antiretroviral Therapy in HIV-infected Patients With Tuberculosis (ANRS 1295 CAMELIA);French National Agency for Research on AIDS and Viral Hepatitis;National Institutes of Health (NIH);COMPLETED;INTERVENTIONAL;False;2005-09-27;2006-01;2010-05;24759827;DERIVED;Causes and determinants of mortality in HIV-infected adults with tuberculosis: an analysis from the CAMELIA ANRS 1295-CIPRA KH001 randomized trial.;"Marcy O; Laureillard D; Madec Y; Chan S; Mayaud C; Borand L; Prak N; Kim C; Lak KK; Hak C; Dim B; Sok T; Delfraissy JF; Goldfeld AE; Blanc FX; CAMELIA (ANRS 1295-CIPRA KH001) Study Team";10.1093/cid/ciu283;2014;"['Journal Article', 'Randomized Controlled Trial', 'Research Support, N.I.H., Extramural', ""Research Support, Non-U.S. Gov't""]"
NCT00226434;Early vs Late Introduction of Antiretroviral Therapy in HIV-infected Patients With Tuberculosis (ANRS 1295 CAMELIA);French National Agency for Research on AIDS and Viral Hepatitis;National Institutes of Health (NIH);COMPLETED;INTERVENTIONAL;False;2005-09-27;2006-01;2010-05;24096631;DERIVED;Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome after early initiation of antiretroviral therapy in a randomized clinical trial.;"Laureillard D; Marcy O; Madec Y; Chea S; Chan S; Borand L; Fernandez M; Prak N; Kim C; Dim B; Nerrienet E; Sok T; Delfraissy JF; Goldfeld AE; Blanc FX; CAMELIA (ANRS 1295 – CIPRA KH001) Study Team";10.1097/01.aids.0000432456.14099.c7;2013;"['Journal Article', 'Randomized Controlled Trial', 'Research Support, N.I.H., Extramural', ""Research Support, Non-U.S. Gov't""]"
NCT00226434;Early vs Late Introduction of Antiretroviral Therapy in HIV-infected Patients With Tuberculosis (ANRS 1295 CAMELIA);French National Agency for Research on AIDS and Viral Hepatitis;National Institutes of Health (NIH);COMPLETED;INTERVENTIONAL;False;2005-09-27;2006-01;2010-05;17624825;BACKGROUND;Treatment strategies for HIV-infected patients with tuberculosis: ongoing and planned clinical trials.;"Blanc FX; Havlir DV; Onyebujoh PC; Thim S; Goldfeld AE; Delfraissy JF";10.1086/518658;2007;"['Journal Article', 'Research Support, N.I.H., Extramural', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S."", 'Review']"
NCT00226434;Early vs Late Introduction of Antiretroviral Therapy in HIV-infected Patients With Tuberculosis (ANRS 1295 CAMELIA);French National Agency for Research on AIDS and Viral Hepatitis;National Institutes of Health (NIH);COMPLETED;INTERVENTIONAL;False;2005-09-27;2006-01;2010-05;23237982;DERIVED;Plasma concentrations of efavirenz with a 600 mg standard dose in Cambodian HIV-infected adults treated for tuberculosis with a body weight above 50 kg.;"Borand L; Laureillard D; Madec Y; Chou M; Pheng P; Marcy O; Sok T; Goldfeld AE; Taburet AM; Blanc FX; CAMELIA ANRS 1295-CIPRA KH001 Study Team";10.3851/IMP2483;2013;"['Journal Article', 'Research Support, N.I.H., Extramural', ""Research Support, Non-U.S. Gov't""]"
NCT00226434;Early vs Late Introduction of Antiretroviral Therapy in HIV-infected Patients With Tuberculosis (ANRS 1295 CAMELIA);French National Agency for Research on AIDS and Viral Hepatitis;National Institutes of Health (NIH);COMPLETED;INTERVENTIONAL;False;2005-09-27;2006-01;2010-05;24608960;DERIVED;Plasma concentrations, efficacy and safety of efavirenz in HIV-infected adults treated for tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA trial).;"Borand L; Madec Y; Laureillard D; Chou M; Marcy O; Pheng P; Prak N; Kim C; Lak KK; Hak C; Dim B; Nerrienet E; Fontanet A; Sok T; Goldfeld AE; Blanc FX; Taburet AM";10.1371/journal.pone.0090350;2014;"['Journal Article', 'Randomized Controlled Trial', 'Research Support, N.I.H., Extramural', ""Research Support, Non-U.S. Gov't""]"
NCT04392388;Health, Perception, Practices, Relations and Social Inequalities in the General Population During the Covid-19 Crisis;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2020-05-18;2020-05-01;2023-04-11;34293141;PUBMED;Antibody status and cumulative incidence of SARS-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: a multicohort study.;"Carrat F; de Lamballerie X; Rahib D; Blanché H; Lapidus N; Artaud F; Kab S; Renuy A; Szabo de Edelenyi F; Meyer L; Lydié N; Charles MA; Ancel PY; Jusot F; Rouquette A; Priet S; Saba Villarroel PM; Fourié T; Lusivika-Nzinga C; Nicol J; Legot S; Druesne-Pecollo N; Esseddik Y; Lai C; Gagliolo JM; Deleuze JF; Bajos N; Severi G; Touvier M; Zins M;  for the SAPRIS and SAPRIS-SERO study groups";10.1093/ije/dyab110;2021;['Journal Article']
NCT00928187;Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé);ANRS, Emerging Infectious Diseases;Gilead Sciences | Janssen Pharmaceutica;COMPLETED;INTERVENTIONAL;True;2009-06-25;2009-11;2015-12;31273686;DERIVED;Cost-Effectiveness of Three Alternative Boosted Protease Inhibitor-Based Second-Line Regimens in HIV-Infected Patients in West and Central Africa.;"Boyer S; Nishimwe ML; Sagaon-Teyssier L; March L; Koulla-Shiro S; Bousmah MQ; Toby R; Mpoudi-Etame MP; Ngom Gueye NF; Sawadogo A; Kouanfack C; Ciaffi L; Spire B; Delaporte E; 2-Lady Group";10.1007/s41669-019-0157-9;2020;['Journal Article']
NCT00640887;Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-infection in South Africa;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-02;2010-10;26482301;DERIVED;Effect of SLCO1B1 Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis.;"Hennig S; Naiker S; Reddy T; Egan D; Kellerman T; Wiesner L; Owen A; McIlleron H; Pym A";10.1128/AAC.01195-15;2016;"['Clinical Trial', 'Journal Article', 'Research Support, N.I.H., Extramural', ""Research Support, Non-U.S. Gov't""]"
NCT00640887;Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-infection in South Africa;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-02;2010-10;25406657;DERIVED;Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy.;"Naiker S; Connolly C; Wiesner L; Kellerman T; Reddy T; Harries A; McIlleron H; Lienhardt C; Pym A";10.1186/2050-6511-15-61;2014;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT01952587;X-linked Biological Response to HIV Sensing: the ANRS EP 53 Study;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2013-09-30;2013-11;2015-06;;;;;;;
NCT01089387;Intracavernous Bone Marrow Stem-cell Injection for Post Prostatectomy Erectile Dysfunction;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2010-03-18;2010-05;2015-03;25974235;DERIVED;Mesenchymal stem cell therapy for the treatment of erectile dysfunction.;"Khera M; Albersen M; Mulhall JP";10.1111/jsm.12871;2015;['Journal Article']
NCT01089387;Intracavernous Bone Marrow Stem-cell Injection for Post Prostatectomy Erectile Dysfunction;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2010-03-18;2010-05;2015-03;28753830;DERIVED;Intracavernous Injections of Bone Marrow Mononucleated Cells for Postradical Prostatectomy Erectile Dysfunction: Final Results of the INSTIN Clinical Trial.;"Yiou R; Hamidou L; Birebent B; Bitari D; Le Corvoisier P; Contremoulins I; Rodriguez AM; Augustin D; Roudot-Thoraval F; de la Taille A; Rouard H";10.1016/j.euf.2017.06.009;2017;"['Clinical Trial, Phase I', 'Clinical Trial, Phase II', 'Letter', ""Research Support, Non-U.S. Gov't""]"
NCT01089387;Intracavernous Bone Marrow Stem-cell Injection for Post Prostatectomy Erectile Dysfunction;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2010-03-18;2010-05;2015-03;26439886;PUBMED;Safety of Intracavernous Bone Marrow-Mononuclear Cells for Postradical Prostatectomy Erectile Dysfunction: An Open Dose-Escalation Pilot Study.;"Yiou R; Hamidou L; Birebent B; Bitari D; Lecorvoisier P; Contremoulins I; Khodari M; Rodriguez AM; Augustin D; Roudot-Thoraval F; de la Taille A; Rouard H";10.1016/j.eururo.2015.09.026;2016;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT02833961;Diffusion Spectroscopy in Stroke;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-07-14;2016-07-28;2019-10-25;36318030;PUBMED;Longitudinal Monitoring of Microstructural Alterations in Cerebral Ischemia with in Vivo Diffusion-weighted MR Spectroscopy.;"Genovese G; Diaz-Fernandez B; Lejeune FX; Ronen I; Marjańska M; Yahia-Cherif L; Lehéricy S; Branzoli F; Rosso C";10.1148/radiol.220430;2023;"['Journal Article', ""Research Support, Non-U.S. Gov't"", 'Research Support, N.I.H., Extramural']"
NCT02453061;A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease;Institut National de la Santé Et de la Recherche Médicale, France;Ultragenyx Pharmaceutical Inc;COMPLETED;INTERVENTIONAL;False;2015-05-25;2015-06-29;2019-12-03;31381524;DERIVED;Huntington's Disease Clinical Trials Corner: June 2019.;"Rodrigues FB; Ferreira JJ; Wild EJ";10.3233/JHD-199003;2019;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01494961;Couple-oriented Prenatal HIV Counseling in Low and Medium HIV Prevalence Countries;French National Agency for Research on AIDS and Viral Hepatitis;Elizabeth Glaser Pediatric AIDS Foundation;COMPLETED;INTERVENTIONAL;False;2011-12-19;2009-02;2011-10;23343912;DERIVED;Increasing HIV testing among male partners.;"Orne-Gliemann J; Balestre E; Tchendjou P; Miric M; Darak S; Butsashvili M; Perez-Then E; Eboko F; Plazy M; Kulkarni S; Desgrées du Loû A; Dabis F; Prenahtest ANRS 12127 Study Group";10.1097/QAD.0b013e32835f1d8c;2013;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT01494961;Couple-oriented Prenatal HIV Counseling in Low and Medium HIV Prevalence Countries;French National Agency for Research on AIDS and Viral Hepatitis;Elizabeth Glaser Pediatric AIDS Foundation;COMPLETED;INTERVENTIONAL;False;2011-12-19;2009-02;2011-10;29178852;DERIVED;Couples HIV counselling and couple relationships in India, Georgia and the Dominican Republic.;"Tiendrebeogo T; Plazy M; Darak S; Miric M; Perez-Then E; Butsashvili M; Tchendjou P; Dabis F; Orne-Gliemann J";10.1186/s12889-017-4901-8;2017;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT01494961;Couple-oriented Prenatal HIV Counseling in Low and Medium HIV Prevalence Countries;French National Agency for Research on AIDS and Viral Hepatitis;Elizabeth Glaser Pediatric AIDS Foundation;COMPLETED;INTERVENTIONAL;False;2011-12-19;2009-02;2011-10;21857289;RESULT;Factors associated with history of HIV testing among pregnant women and their partners in Cameroon: baseline data from a Behavioral Intervention Trial (ANRS 12127 Prenahtest).;"Tchendjou PT; Koki PN; Eboko F; Malateste K; Essounga AN; Amassana D; Mossus T; Tejiokem M; Boisier P; Orne-Gliemann J";10.1097/QAI.0b013e31821ec6e2;2011;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01494961;Couple-oriented Prenatal HIV Counseling in Low and Medium HIV Prevalence Countries;French National Agency for Research on AIDS and Viral Hepatitis;Elizabeth Glaser Pediatric AIDS Foundation;COMPLETED;INTERVENTIONAL;False;2011-12-19;2009-02;2011-10;20403152;RESULT;Couple-oriented prenatal HIV counseling for HIV primary prevention: an acceptability study.;"Orne-Gliemann J; Tchendjou PT; Miric M; Gadgil M; Butsashvili M; Eboko F; Perez-Then E; Darak S; Kulkarni S; Kamkamidze G; Balestre E; du Loû AD; Dabis F";10.1186/1471-2458-10-197;2010;"['Evaluation Study', 'Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01494961;Couple-oriented Prenatal HIV Counseling in Low and Medium HIV Prevalence Countries;French National Agency for Research on AIDS and Viral Hepatitis;Elizabeth Glaser Pediatric AIDS Foundation;COMPLETED;INTERVENTIONAL;False;2011-12-19;2009-02;2011-10;34329355;DERIVED;Couple oriented counselling improves male partner involvement in sexual and reproductive health of a couple: Evidence from the ANRS PRENAHTEST randomized trial.;"Kengne-Nde C; Tejiokem MC; Orne-Gliemann J; Melingui B; Koki Ndombo P; Essounga NA; Bissek AC; Cauchemez S; Tchendjou PT";10.1371/journal.pone.0255330;2021;"['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00301561;Antiretroviral Treatment Simplified Follow-up Management Assessment (ANRS 12110 STRATALL);French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2006-03-13;2006-05;2010-10;35248123;DERIVED;"Non-inferiority test for a continuous variable with a flexible margin in an active controlled trial: an application to the ""Stratall ANRS 12110 / ESTHER"" trial.";"Sandie AB; Molinari N; Wanjoya A; Kouanfack C; Laurent C; Tchatchueng-Mbougua JB";10.1186/s13063-022-06118-x;2022;['Journal Article', 'Randomized Controlled Trial']
NCT00301561;Antiretroviral Treatment Simplified Follow-up Management Assessment (ANRS 12110 STRATALL);French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2006-03-13;2006-05;2010-10;21831714;DERIVED;Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial.;"Laurent C; Kouanfack C; Laborde-Balen G; Aghokeng AF; Mbougua JB; Boyer S; Carrieri MP; Mben JM; Dontsop M; Kazé S; Molinari N; Bourgeois A; Mpoudi-Ngolé E; Spire B; Koulla-Shiro S; Delaporte E; Stratall ANRS 12110/ESTHER study group";10.1016/S1473-3099(11)70168-2;2011;"['Comparative Study', 'Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT01167283;Effect of Electrostimulation in Chronic Obstructive Pulmonary Disease (COPD);Institut National de la Santé Et de la Recherche Médicale, France;Centre Hospitalier Régional Universitaire Montpellier;COMPLETED;INTERVENTIONAL;False;2010-07-22;2006-07;2010-04;;;;;;;
NCT02150993;First-Line Treatment for HIV-2;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2014-05-30;2016-01-26;2019-05-15;;;;;;;
NCT01075061;"Study of a Large Family With Congenital Mirror Movements : From Underlying Pathophysiology to Culprit Gene Identification PROJET "" MOMIC """;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2010-02-24;2010-02;2011-07;;;;;;;
NCT02014883;Phase II Open Label Study Using Triheptanoin in Patients With Glucose Type 1 Transporter Deficiency GLUT1-DS;Institut National de la Santé Et de la Recherche Médicale, France;Ultragenyx Pharmaceutical Inc;COMPLETED;INTERVENTIONAL;False;2013-12-18;2013-12-04;2019-07-04;26536893;DERIVED;Triheptanoin dramatically reduces paroxysmal motor disorder in patients with GLUT1 deficiency.;"Mochel F; Hainque E; Gras D; Adanyeguh IM; Caillet S; Héron B; Roubertie A; Kaphan E; Valabregue R; Rinaldi D; Vuillaumier S; Schiffmann R; Ottolenghi C; Hogrel JY; Servais L; Roze E";10.1136/jnnp-2015-311475;2016;"['Clinical Trial', 'Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT00158483;Anti-Herpetic Treatment of Genital Ulcer : Effect on HIV & Herpes Shedding (ANRS 1212);French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2005-09-12;2003-05;2005-10;19530940;DERIVED;Impact of acyclovir on genital and plasma HIV-1 RNA, genital herpes simplex virus type 2 DNA, and ulcer healing among HIV-1-infected African women with herpes ulcers: a randomized placebo-controlled trial.;"Mayaud P; Legoff J; Weiss HA; Grésenguet G; Nzambi K; Bouhlal H; Frost E; Pépin J; Malkin JE; Hayes RJ; Mabey DC; Bélec L; ANRS 1212 Study Group";10.1086/599991;2009;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00158483;Anti-Herpetic Treatment of Genital Ulcer : Effect on HIV & Herpes Shedding (ANRS 1212);French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2005-09-12;2003-05;2005-10;16455895;BACKGROUND;Real-time PCR quantification of genital shedding of herpes simplex virus (HSV) and human immunodeficiency virus (HIV) in women coinfected with HSV and HIV.;"Legoff J; Bouhlal H; Grésenguet G; Weiss H; Khonde N; Hocini H; Désiré N; Si-Mohamed A; de Dieu Longo J; Chemin C; Frost E; Pépin J; Malkin JE; Mayaud P; Bélec L";10.1128/JCM.44.2.423-432.2006;2006;"['Evaluation Study', 'Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT00158483;Anti-Herpetic Treatment of Genital Ulcer : Effect on HIV & Herpes Shedding (ANRS 1212);French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2005-09-12;2003-05;2005-10;18385443;BACKGROUND;Performance of HerpeSelect and Kalon assays in detection of antibodies to herpes simplex virus type 2.;"LeGoff J; Mayaud P; Gresenguet G; Weiss HA; Nzambi K; Frost E; Pepin J; Belec L; ANRS 12-12 Study Group";10.1128/JCM.02332-07;2008;['Evaluation Study', 'Journal Article', 'Randomized Controlled Trial']
NCT02481453;Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-06-25;2015-07-15;2018-01-22;24975859;BACKGROUND;Evaluation and construction of diagnostic criteria for inclusion body myositis.;"Lloyd TE; Mammen AL; Amato AA; Weiss MD; Needham M; Greenberg SA";10.1212/WNL.0000000000000642;2014;['Journal Article', 'Review']
NCT02481453;Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-06-25;2015-07-15;2018-01-22;20413309;BACKGROUND;International Workshop on Inclusion Body Myositis held at the Institute of Myology, Paris, on 29 May 2009.;"Benveniste O; Hilton-Jones D";10.1016/j.nmd.2010.03.014;2010;['Congress']
NCT02481453;Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-06-25;2015-07-15;2018-01-22;38273639;PUBMED;Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial.;"Benveniste O; Hogrel JY; Belin L; Annoussamy M; Bachasson D; Rigolet A; Laforet P; Dzangué-Tchoupou G; Salem JE; Nguyen LS; Stojkovic T; Zahr N; Hervier B; Landon-Cardinal O; Behin A; Guilloux E; Reyngoudt H; Amelin D; Uruha A; Mariampillai K; Marty B; Eymard B; Hulot JS; Greenberg SA; Carlier PG; Allenbach Y";10.1016/S2665-9913(20)30280-0;2021;['Journal Article']
NCT02329054;Efficacy of Favipiravir Against Ebola (JIKI);Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-12-31;2014-12;2015-09;27046271;RESULT;Correction: Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea.;"Sissoko D; Laouenan C; Folkesson E; M'Lebing AB; Beavogui AH; Baize S; Camara AM; Maes P; Shepherd S; Danel C; Carazo S; Conde MN; Gala JL; Colin G; Savini H; Bore JA; Le Marcis F; Koundouno FR; Petitjean F; Lamah MC; Diederich S; Tounkara A; Poelart G; Berbain E; Dindart JM; Duraffour S; Lefevre A; Leno T; Peyrouset O; Irenge L; Bangoura N; Palich R; Hinzmann J; Kraus A; Barry TS; Berette S; Bongono A; Camara MS; Munoz VC; Doumbouya L; Harouna S; Kighoma PM; Koundouno FR; Lolamou R; Loua CM; Massala V; Moumouni K; Provost C; Samake N; Sekou C; Soumah A; Arnould I; Komano MS; Gustin L; Berutto C; Camara D; Camara FS; Colpaert J; Delamou L; Jansson L; Kourouma E; Loua M; Malme K; Manfrin E; Maomou A; Milinouno A; Ombelet S; Sidiboun AY; Verreckt I; Yombouno P; Bocquin A; Carbonnelle C; Carmoi T; Frange P; Mely S; Nguyen VK; Pannetier D; Taburet AM; Treluyer JM; Kolie J; Moh R; Gonzalez MC; Kuisma E; Liedigk B; Ngabo D; Rudolf M; Thom R; Kerber R; Gabriel M; Di Caro A; Wölfel R; Badir J; Bentahir M; Deccache Y; Dumont C; Durant JF; El Bakkouri K; Uwamahoro MG; Smits B; Toufik N; Van Cauwenberghe S; Ezzedine K; D'Ortenzio E; Pizarro L; Etienne A; Guedj J; Fizet A; de Sainte Fare EB; Murgue B; Tran-Minh T; Rapp C; Piguet P; Poncin M; Draguez B; Duverger TA; Barbe S; Baret G; Defourny I; Carroll M; Raoul H; Augier A; Eholie SP; Yazdanpanah Y; Levy-Marchal C; Antierrens A; Van Herp M; Günther S; de Lamballerie X; Keïta S; Mentre F; Anglaret X; Malvy D; JIKI Study Group";10.1371/journal.pmed.1002009;2016;['Published Erratum']
NCT02329054;Efficacy of Favipiravir Against Ebola (JIKI);Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-12-31;2014-12;2015-09;26930627;DERIVED;Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea.;"Sissoko D; Laouenan C; Folkesson E; M'Lebing AB; Beavogui AH; Baize S; Camara AM; Maes P; Shepherd S; Danel C; Carazo S; Conde MN; Gala JL; Colin G; Savini H; Bore JA; Le Marcis F; Koundouno FR; Petitjean F; Lamah MC; Diederich S; Tounkara A; Poelart G; Berbain E; Dindart JM; Duraffour S; Lefevre A; Leno T; Peyrouset O; Irenge L; Bangoura N; Palich R; Hinzmann J; Kraus A; Barry TS; Berette S; Bongono A; Camara MS; Chanfreau Munoz V; Doumbouya L; Souley Harouna; Kighoma PM; Koundouno FR; Réné Lolamou; Loua CM; Massala V; Moumouni K; Provost C; Samake N; Sekou C; Soumah A; Arnould I; Komano MS; Gustin L; Berutto C; Camara D; Camara FS; Colpaert J; Delamou L; Jansson L; Kourouma E; Loua M; Malme K; Manfrin E; Maomou A; Milinouno A; Ombelet S; Sidiboun AY; Verreckt I; Yombouno P; Bocquin A; Carbonnelle C; Carmoi T; Frange P; Mely S; Nguyen VK; Pannetier D; Taburet AM; Treluyer JM; Kolie J; Moh R; Gonzalez MC; Kuisma E; Liedigk B; Ngabo D; Rudolf M; Thom R; Kerber R; Gabriel M; Di Caro A; Wölfel R; Badir J; Bentahir M; Deccache Y; Dumont C; Durant JF; El Bakkouri K; Gasasira Uwamahoro M; Smits B; Toufik N; Van Cauwenberghe S; Ezzedine K; D'Ortenzio E; Pizarro L; Etienne A; Guedj J; Fizet A; Barte de Sainte Fare E; Murgue B; Tran-Minh T; Rapp C; Piguet P; Poncin M; Draguez B; Allaford Duverger T; Barbe S; Baret G; Defourny I; Carroll M; Raoul H; Augier A; Eholie SP; Yazdanpanah Y; Levy-Marchal C; Antierrens A; Van Herp M; Günther S; de Lamballerie X; Keïta S; Mentre F; Anglaret X; Malvy D; JIKI Study Group";10.1371/journal.pmed.1001967;2016;"['Clinical Trial', 'Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT02329054;Efficacy of Favipiravir Against Ebola (JIKI);Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-12-31;2014-12;2015-09;25435054;BACKGROUND;Dose regimen of favipiravir for Ebola virus disease.;"Mentré F; Taburet AM; Guedj J; Anglaret X; Keïta S; de Lamballerie X; Malvy D";10.1016/S1473-3099(14)71047-3;2015;['Letter']
NCT02329054;Efficacy of Favipiravir Against Ebola (JIKI);Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-12-31;2014-12;2015-09;28231247;DERIVED;Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted.;"Nguyen TH; Guedj J; Anglaret X; Laouénan C; Madelain V; Taburet AM; Baize S; Sissoko D; Pastorino B; Rodallec A; Piorkowski G; Carazo S; Conde MN; Gala JL; Bore JA; Carbonnelle C; Jacquot F; Raoul H; Malvy D; de Lamballerie X; Mentré F; JIKI study group";10.1371/journal.pntd.0005389;2017;"['Clinical Trial', 'Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT02027233;Clinical Trial to Assess the Influenza Vaccination of the Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-01-06;2014-01;2022-12-31;;;;;;;
NCT02093754;Assessing the Severity of Metabolic-related Liver Injuries in Aging HIV-monoinfected Patients;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2014-03-21;2014-05;2016-03;;;;;;;
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;23461846;RESULT;Factors associated with guideline-based hepatitis C virus (HCV) treatment initiation in HIV/HCV-coinfected patients: role of comorbidities and physicians' perceptions.;"Winnock M; Bani-Sadr F; Pambrun E; Loko MA; Carrieri P; Neau D; Morlat P; Marchou B; Dabis F; Salmon D; French National Agency for Research on AIDS and Viral Hepatitis (ANRS) CO13 HEPAVIH Study Group";10.1111/hiv.12023;2013;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;27073179;RESULT;No significant effect of cannabis use on the count and percentage of circulating CD4 T-cells in HIV-HCV co-infected patients (ANRS CO13-HEPAVIH French cohort).;"Marcellin F; Lions C; Rosenthal E; Roux P; Sogni P; Wittkop L; Protopopescu C; Spire B; Salmon-Ceron D; Dabis F; Carrieri MP; HEPAVIH ANRS CO13 Study Group*";10.1111/dar.12398;2017;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;22409788;RESULT;Engaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort, France).;"Salmon-Ceron D; Cohen J; Winnock M; Roux P; Sadr FB; Rosenthal E; Martin IP; Loko MA; Mora M; Sogni P; Spire B; Dabis F; Carrieri MP; HEPAVIH group";10.1186/1472-6963-12-59;2012;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;20493576;RESULT;Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection.;"Calès P; Halfon P; Batisse D; Carrat F; Perré P; Penaranda G; Guyader D; d'Alteroche L; Fouchard-Hubert I; Michelet C; Veillon P; Lambert J; Weiss L; Salmon D; Cacoub P";10.1016/j.jhep.2010.03.007;2010;"['Comparative Study', 'Journal Article', 'Multicenter Study', ""Research Support, Non-U.S. Gov't""]"
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;20969743;RESULT;The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010.;"Loko MA; Salmon D; Carrieri P; Winnock M; Mora M; Merchadou L; Gillet S; Pambrun E; Delaune J; Valantin MA; Poizot-Martin I; Neau D; Bonnard P; Rosenthal E; Barange K; Morlat P; Lacombe K; Gervais A; Rouges F; See AB; Lascoux-Combe C; Vittecoq D; Goujard C; Duvivier C; Spire B; Izopet J; Sogni P; Serfaty L; Benhamou Y; Bani-Sadr F; Dabis F; ANRS CO 13 HEPAVIH Study Group";10.1186/1471-2334-10-303;2010;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;24499953;RESULT;Correlates of HIV sustained viral suppression in HIV/hepatitis C virus coinfected patients: possible role of the hepatitis C virus sustained viral response.;"Bani-Sadr F; Loko MA; Pambrun E; Winnock M; Carrieri P; Gilbert C; Duvivier C; Bouchaud O; Gervais A; Dabis F; Salmon D; ANRS CO 13 HEPAVIH Study Group";10.1097/QAD.0000000000000218;2014;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;23421419;RESULT;Self-reported alcohol abuse in HIV-HCV co-infected patients: a better predictor of HIV virological rebound than physician's perceptions (HEPAVIH ARNS CO13 cohort).;"Marcellin F; Lions C; Winnock M; Salmon D; Durant J; Spire B; Mora M; Loko MA; Dabis F; Dominguez S; Roux P; Carrieri MP; ANRS CO13 HEPAVIH Study Group";10.1111/add.12149;2013;"['Journal Article', 'Multicenter Study', ""Research Support, Non-U.S. Gov't""]"
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;22781224;RESULT;Ribavirin and abacavir drug interaction in HIV-HCV coinfected patients: fact or fiction?;"Solas C; Pambrun E; Winnock M; Salmon D; Poizot-Martin I; Dominguez S; Bani-Sadr F; Izopet J; Garraffo R; Peytavin G; ANRS CO-13 HEPAVIH Study Group";10.1097/QAD.0b013e32835763a4;2012;"['Journal Article', 'Multicenter Study', ""Research Support, Non-U.S. Gov't""]"
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;25015913;RESULT;High levels of alcohol consumption increase the risk of advanced hepatic fibrosis in HIV/hepatitis C virus-coinfected patients: a sex-based analysis using transient elastography at enrollment in the HEPAVIH ANRS CO13 cohort.;"Marcellin F; Roux P; Loko MA; Lions C; Caumont-Prim A; Dabis F; Salmon-Ceron D; Spire B; Carrieri MP; HEPAVIH (ANRS CO13) Study Group";10.1093/cid/ciu525;2014;"['Letter', ""Research Support, Non-U.S. Gov't"", 'Comment']"
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;21920402;RESULT;Prevalence of immunity to hepatitis viruses A and B in a large cohort of HIV/HCV-coinfected patients, and factors associated with HAV and HBV vaccination.;"Winnock M; Bani-Sadr F; Pambrun E; Loko MA; Lascoux-Combe C; Garipuy D; Rosenthal E; Carrieri P; Dabis F; Salmon D";10.1016/j.vaccine.2011.08.125;2011;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;26528903;RESULT;HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients.;"Salmon D; Bani-Sadr F; Gilbert C; Rosenthal E; Valantin MA; Simon A; Neau D; Morlat P; Loko MA; Wittkop L; Dabis F; ANRS CO13HEPAVIH study group";10.1016/j.jcv.2015.10.010;2015;['Journal Article', 'Multicenter Study', 'Observational Study']
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;28942916;RESULT;Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients.;"Carrieri MP; Protopopescu C; Marcellin F; Rosellini S; Wittkop L; Esterle L; Zucman D; Raffi F; Rosenthal E; Poizot-Martin I; Salmon-Ceron D; Dabis F; Spire B; ANRS CO13 HEPAVIH Study Group";10.1016/j.jhep.2017.08.005;2017;"['Journal Article', 'Multicenter Study', ""Research Support, Non-U.S. Gov't""]"
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;26372388;RESULT;Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patients.;ANRS CO13 HEPAVIH Cohort;10.1097/QAD.0000000000000787;2015;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;23052829;RESULT;Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohort.;"Loko MA; Bani-Sadr F; Valantin MA; Lascoux-Combe C; Fontaine H; Bonnard P; Gervais A; Bouchaud O; Garipuy D; Quertainmont Y; Vittecoq D; Tehrani MS; Winnock M; Dabis F; Salmon D; ANRS CO 13 HEPAVIH Study Group";10.3851/IMP2419;2012;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;22173166;RESULT;Insulin resistance is associated with a higher risk of hepatocellular carcinoma in cirrhotic HIV/HCV-co-infected patients: results from ANRS CO13 HEPAVIH.;"Salmon D; Bani-Sadr F; Loko MA; Stitou H; Gervais A; Durant J; Rosenthal E; Quertainmont Y; Barange K; Vittecoq D; Shoai-Tehrani M; Alvarez M; Winnock M; Trinchet JC; Dabis F; Sogni P";10.1016/j.jhep.2011.11.009;2012;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;22535683;RESULT;Elevated coffee consumption and reduced risk of insulin resistance in HIV-HCV coinfected patients (HEPAVIH ANRS CO-13).;"Carrieri MP; Sogni P; Cohen J; Loko MA; Winnock M; Spire B; HEPAVIH Study Group";10.1002/hep.25813;2012;['Letter', 'Comment']
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;27317796;RESULT;All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort.;"Sogni P; Gilbert C; Lacombe K; Piroth L; Rosenthal E; Miailhes P; Gervais A; Esterle L; Chas J; Poizot-Martin I; Dominguez S; Simon A; Morlat P; Neau D; Zucman D; Bouchaud O; Lascoux-Combe C; Bani-Sadr F; Alric L; Goujard C; Vittecoq D; Billaud E; Aumaître H; Boué F; Valantin MA; Dabis F; Salmon D; Wittkop L";10.1093/cid/ciw379;2016;"['Journal Article', 'Observational Study', ""Research Support, Non-U.S. Gov't""]"
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;20876416;RESULT;Chocolate intake, depression, and clinical progression in HIV-HCV coinfected patients: still more questions than answers.;"Carrieri MP; Cohen J; Winnock M; Salmon D";10.1001/archinternmed.2010.330;2010;['Comment', 'Letter']
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;21888878;RESULT;Coffee consumption and reduced self-reported side effects in HIV-HCV co-infected patients during PEG-IFN and ribavirin treatment: results from ANRS CO13 HEPAVIH.;"Carrieri MP; Cohen J; Salmon-Ceron D; Winnock M";10.1016/j.jhep.2011.08.005;2012;"['Letter', ""Research Support, Non-U.S. Gov't""]"
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;27339598;RESULT;A new 3p25 locus is associated with liver fibrosis progression in human immunodeficiency virus/hepatitis C virus-coinfected patients.;"Ulveling D; Le Clerc S; Cobat A; Labib T; Noirel J; Laville V; Coulonges C; Carpentier W; Nalpas B; Heim MH; Poynard T; Cerny A; Pol S; Bochud PY; Dabis F; Theodorou I; Lévy Y; Salmon D; Abel L; Dominguez S; Zagury JF; HEPAVIH ANRS CO13 Cohort Study Group; Swiss Hepatitis C Cohort Study Group; French ANRS HC EP 26 Genoscan Study Group";10.1002/hep.28695;2016;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;23978720;RESULT;Association between elevated coffee consumption and daily chocolate intake with normal liver enzymes in HIV-HCV infected individuals: results from the ANRS CO13 HEPAVIH cohort study.;"Carrieri MP; Lions C; Sogni P; Winnock M; Roux P; Mora M; Bonnard P; Salmon D; Dabis F; Spire B; ANRS CO13 HEPAVIH Study Group";10.1016/j.jhep.2013.08.014;2014;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;27177169;RESULT;Short article: Fatigue in the long term after HCV treatment in HIV-HCV-coinfected patients: functional limitations persist despite viral clearance in patients exposed to peg-interferon/ribavirin-containing regimens (ANRS CO13-HEPAVIH cohort).;"Marcellin F; Protopopescu C; Poizot-Martin I; Miailhes P; Esterle L; Wittkop L; Spire B; Bocquier A; Salmon-Ceron D; Dabis F; Carrieri MP; HEPAVIH ANRS CO13 Study Group";10.1097/MEG.0000000000000664;2016;['Journal Article', 'Multicenter Study', 'Observational Study']
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;28418984;RESULT;Short article: Anger and quality of life in patients co-infected with HIV and hepatitis C virus: a cross-sectional study (ANRS CO13-HEPAVIH).;"Marcellin F; Protopopescu C; Esterle L; Wittkop L; Piroth L; Aumaitre H; Bouchaud O; Goujard C; Vittecoq D; Dabis F; Salmon-Ceron D; Spire B; Roux P; Carrieri MP; ANRS CO13-HEPAVIH Study Group";10.1097/MEG.0000000000000883;2017;['Journal Article']
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;25778750;RESULT;Cannabis Use and Reduced Risk of Insulin Resistance in HIV-HCV Infected Patients: A Longitudinal Analysis (ANRS CO13 HEPAVIH).;"Carrieri MP; Serfaty L; Vilotitch A; Winnock M; Poizot-Martin I; Loko MA; Lions C; Lascoux-Combe C; Roux P; Salmon-Ceron D; Spire B; Dabis F; ANRS CO13 HEPAVIH Study Group";10.1093/cid/civ217;2015;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;28430385;RESULT;Significant reductions in alcohol use after hepatitis C treatment: results from the ANRS CO13-HEPAVIH cohort.;"Knight R; Roux P; Vilotitch A; Marcellin F; Rosenthal E; Esterle L; Boué F; Rey D; Piroth L; Dominguez S; Sogni P; Salmon-Ceron D; Spire B; Carrieri MP; ANRS CO13-HEPAVIH Study Group";10.1111/add.13851;2017;['Journal Article']
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;22285372;RESULT;Hepatitis C virus RNA quantitation in a nationwide French cohort of patients co-infected with HIV and HCV: should the same test be applied to all samples?;"Trimoulet P; Merchadou L; Winnock M; Loko MA; Fleury H; Salmon D; Dabis F; Neau D; ANRS CO 13 HEPAVIH Study Group";10.1016/j.jviromet.2012.01.006;2012;['Comparative Study', 'Journal Article']
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;21239121;RESULT;Determinants of the underreporting of alcohol consumption by HIV/HCV co-infected patients during face-to-face medical interviews: the role of the physician.;"Roux P; Cohen J; Lascoux-Combe C; Sogni P; Winnock M; Salmon-Ceron D; Spire B; Dabis F; Carrieri MP; ANRS-CO13-HEPAVIH study group";10.1016/j.drugalcdep.2010.09.025;2011;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;28235612;RESULT;Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort.;"Piroth L; Wittkop L; Lacombe K; Rosenthal E; Gilbert C; Miailhes P; Carrieri P; Chas J; Poizot-Martin I; Gervais A; Dominguez S; Neau D; Zucman D; Billaud E; Morlat P; Aumaitre H; Lascoux-Combe C; Simon A; Bouchaud O; Teicher E; Bani-Sadr F; Alric L; Vittecoq D; Boué F; Duvivier C; Valantin MA; Esterle L; Dabis F; Sogni P; Salmon D; ANRS CO13 HEPAVIH study group";10.1016/j.jhep.2017.02.012;2017;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;32798585;DERIVED;Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death.;"Chalouni M; Pol S; Sogni P; Fontaine H; Lacombe K; Marc-Lacombe J; Esterle L; Dorival C; Bourlière M; Bani-Sadr F; de Ledinghen V; Zucman D; Larrey D; Salmon D; Carrat F; Wittkop L; ANRS CO13 HEPAVIH and ANRS CO22 HEPATHER cohort study groups";10.1016/j.jhep.2020.08.008;2021;"['Journal Article', 'Multicenter Study', 'Observational Study', ""Research Support, Non-U.S. Gov't""]"
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;23226258;RESULT;HIV-1 tropism and liver fibrosis in HIV-HCV co-infected patients.;"Abravanel F; Raymond S; Pambrun E; Winnock M; Bonnard P; Sogni P; Trimoulet P; Dabis F; Salmon-Ceron D; Izopet J; ANRS CO13 HEPAVIH Study Group";10.1371/journal.pone.0050289;2012;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;34212476;DERIVED;Risk of severe clinical events after sustained virological response following direct-acting antiviral therapy in HIV and hepatitis C virus coinfected participants.;"Chalouni M; Wittkop L; Bani-Sadr F; Lacombe K; Esterle L; Gilbert C; Miailhes P; Zucman D; Valantin MA; Brégigeon-Ronot S; Morlat P; Billaud E; Piroth L; Naqvi A; Sogni P; Salmon D; ANRS CO13 HEPAVIH Cohort Study Group";10.1111/hiv.13127;2021;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;21692942;RESULT;Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV/HCV-coinfected patients.;"Loko MA; Bani-Sadr F; Winnock M; Lacombe K; Carrieri P; Neau D; Morlat P; Serfaty L; Dabis F; Salmon D; ANRS CO 13 HEPAVIH Study Group";10.1111/j.1365-2893.2010.01417.x;2011;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;28780609;RESULT;Unstable Housing Still a Barrier to Receiving HCV Treatment in France (ANRS CO13 HEPAVIH Cohort).;"Yaya I; Roux P; Marcellin F; Salmon-Ceron D; Carrieri MP";10.1007/s10620-017-4703-y;2017;['Letter', 'Comment']
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;30570526;DERIVED;Nadir CD4 Is Negatively Associated With Antinuclear Antibody Detection in HCV/HIV-Coinfected Patients.;"Poizot-Martin I; Rosenthal E; Gilbert C; Cano CE; Simon A; Lascoux-Combe C; Alric L; Gervais A; Neau D; Esterle L; Salmon D; Sogni P; Wittkop L; ANRS CO13 HEPAVIH Study Group";10.1097/QAI.0000000000001940;2019;"['Journal Article', 'Observational Study', ""Research Support, Non-U.S. Gov't""]"
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;24580042;RESULT;Using patient-reported outcomes to improve the management of co-infection with HIV and HCV: the ANRS CO13 HEPAVIH cohort.;"Marcellin F; Roux P; Winnock M; Lions C; Dabis F; Salmon-Ceron D; Loko MA; Spire B; Carrieri MP";10.1586/17474124.2014.888949;2014;"['Journal Article', ""Research Support, Non-U.S. Gov't"", 'Review']"
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;21819472;RESULT;Positive impact of hepatitis C virus (HCV) treatment on antiretroviral treatment adherence in human immunodeficiency virus-HCV coinfected patients: one more argument for expanded access to HCV treatment for injecting drug users.;"Roux P; Fugon L; Winnock M; Salmon-Céron D; Lacombe K; Sogni P; Spire B; Dabis F; Carrieri MP; ANRS-CO-13-HEPAVIH Study Group";10.1111/j.1360-0443.2011.03608.x;2012;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;24166726;RESULT;Impact of HCV treatment and depressive symptoms on adherence to HAART among HIV-HCV-coinfected patients: results from the ANRS-CO13-HEPAVIH cohort.;"Roux P; Lions C; Cohen J; Winnock M; Salmon-Céron D; Bani-Sadr F; Sogni P; Spire B; Dabis F; Carrieri MP; ANRS-CO13-HEPAVIH Study Group";10.3851/IMP2699;2014;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT04842851;Cardiac Resynchronization Therapy in Congenital Heart Diseases With Systemic Right Ventricle;Paris Cardiovascular Research Center (Inserm U970);Marie Lannelongue Hospital, Le Plessis Robinson, France | Clinique Pasteur Toulouse | Groupe Hospitalier Pitie-Salpetriere | Hopital Louis Pradel | University Hospital, Montpellier | European Georges Pompidou Hospital;COMPLETED;OBSERVATIONAL;False;2021-04-13;2004-01-01;2020-12-31;;;;;;;
NCT04409405;Evaluation and Support to EVD Cured Patients and Their Contacts (Les Vainqueurs d'Ebola);Institut National de la Santé Et de la Recherche Médicale, France;Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo | Institut de Recherche pour le Developpement;COMPLETED;OBSERVATIONAL;False;2020-06-01;2020-04-16;2021-10-18;38043556;PUBMED;Effect of anti-Ebola virus monoclonal antibodies on endogenous antibody production in survivors of Ebola virus disease in the Democratic Republic of the Congo: an observational cohort study.;"Nkuba-Ndaye A; Dilu-Keti A; Tovar-Sanchez T; Diallo MSK; Mukadi-Bamuleka D; Kitenge R; Formenty P; Legand A; Edidi-Atani F; Thaurignac G; Pelloquin R; Mbala-Kingebeni P; Toure A; Ayouba A; Muyembe-Tamfum JJ; Delaporte E; Peeters M; Ahuka-Mundeke S; Les Vainqueurs d’Ebola Study Group";10.1016/S1473-3099(23)00552-2;2024;['Observational Study', 'Journal Article']
NCT00158405;Randomised Trial of Structured Treatment Interruption of HAART in HIV-Infected Adults in Abidjan (ANRS 1269 TRIVACAN);French National Agency for Research on AIDS and Viral Hepatitis;Bristol-Myers Squibb;COMPLETED;INTERVENTIONAL;False;2005-09-12;2002-12;2006-12;16152755;BACKGROUND;Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Côte d'Ivoire.;"Moh R; Danel C; Sorho S; Sauvageot D; Anzian A; Minga A; Gomis OB; Konga C; Inwoley A; Gabillard D; Bissagnene E; Salamon R; Anglaret X";10.1177/135965350501000510;2005;"['Clinical Trial', 'Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00158405;Randomised Trial of Structured Treatment Interruption of HAART in HIV-Infected Adults in Abidjan (ANRS 1269 TRIVACAN);French National Agency for Research on AIDS and Viral Hepatitis;Bristol-Myers Squibb;COMPLETED;INTERVENTIONAL;False;2005-09-12;2002-12;2006-12;16782488;RESULT;CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial.;"Danel C; Moh R; Minga A; Anzian A; Ba-Gomis O; Kanga C; Nzunetu G; Gabillard D; Rouet F; Sorho S; Chaix ML; Eholié S; Menan H; Sauvageot D; Bissagnene E; Salamon R; Anglaret X; Trivacan ANRS 1269 trial group";10.1016/S0140-6736(06)68887-9;2006;"['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00158405;Randomised Trial of Structured Treatment Interruption of HAART in HIV-Infected Adults in Abidjan (ANRS 1269 TRIVACAN);French National Agency for Research on AIDS and Viral Hepatitis;Bristol-Myers Squibb;COMPLETED;INTERVENTIONAL;False;2005-09-12;2002-12;2006-12;18986246;RESULT;Two-months-off, four-months-on antiretroviral regimen increases the risk of resistance, compared with continuous therapy: a randomized trial involving West African adults.;"Danel C; Moh R; Chaix ML; Gabillard D; Gnokoro J; Diby CJ; Toni T; Dohoun L; Rouzioux C; Bissagnene E; Salamon R; Anglaret X; Trivacan ANRS 1269 Trial Group";10.1086/595298;2009;"['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT02960698;Impulsivity in Tourette Syndrome : Behavioral and Neuroimaging Study;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-11-10;2016-10-14;2018-04-24;;;;;;;
NCT02931097;DBS of the MLR for Gait and Balance Disorders in PD Patients;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-10-12;2016-10;2020-10;;;;;;;
NCT00657397;Initialization of Methadone in Primary Care, Randomized Intervention Research for Preventing HCV Transmission Practices;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2008-04-14;2009-01;2011-12;27048152;DERIVED;Correlates of cocaine use during methadone treatment: implications for screening and clinical management (ANRS Methaville study).;"Roux P; Lions C; Vilotitch A; Michel L; Mora M; Maradan G; Marcellin F; Spire B; Morel A; Carrieri PM; ANRS Methaville study group";10.1186/s12954-016-0100-7;2016;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00657397;Initialization of Methadone in Primary Care, Randomized Intervention Research for Preventing HCV Transmission Practices;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2008-04-14;2009-01;2011-12;27770695;DERIVED;Decrease in self-reported offences and incarceration rates during methadone treatment: A comparison between patients switching from buprenorphine to methadone and maintenance treatment incident users (ANRS-Methaville trial).;"Carrieri P; Vilotitch A; Nordmann S; Lions C; Michel L; Mora M; Morel A; Maradan G; Spire B; Roux P; Methaville Study Group";10.1016/j.drugpo.2016.08.005;2017;"['Comparative Study', 'Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT00657397;Initialization of Methadone in Primary Care, Randomized Intervention Research for Preventing HCV Transmission Practices;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2008-04-14;2009-01;2011-12;22741944;DERIVED;Methadone induction in primary care (ANRS-Methaville): a phase III randomized intervention trial.;"Roux P; Michel L; Cohen J; Mora M; Morel A; Aubertin JF; Desenclos JC; Spire B; Carrieri PM; ANRS Methaville Study Group";10.1186/1471-2458-12-488;2012;"['Clinical Trial, Phase III', 'Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00657397;Initialization of Methadone in Primary Care, Randomized Intervention Research for Preventing HCV Transmission Practices;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2008-04-14;2009-01;2011-12;24268548;DERIVED;Predictors of non-prescribed opioid use after one year of methadone treatment: an attributable-risk approach (ANRS-Methaville trial).;"Lions C; Carrieri MP; Michel L; Mora M; Marcellin F; Morel A; Spire B; Roux P; Methaville Study Group";10.1016/j.drugalcdep.2013.10.018;2014;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT00657397;Initialization of Methadone in Primary Care, Randomized Intervention Research for Preventing HCV Transmission Practices;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2008-04-14;2009-01;2011-12;25209306;DERIVED;Factors associated with HCV risk practices in methadone-maintained patients: the importance of considering the couple in prevention interventions.;"Roux P; Lions C; Michel L; Mora M; Daulouède JP; Marcellin F; Spire B; Morel A; Carrieri PM; ANRS Methaville study group";10.1186/1747-597X-9-37;2014;"['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00657397;Initialization of Methadone in Primary Care, Randomized Intervention Research for Preventing HCV Transmission Practices;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2008-04-14;2009-01;2011-12;25393311;DERIVED;Methadone induction in primary care for opioid dependence: a pragmatic randomized trial (ANRS Methaville).;"Carrieri PM; Michel L; Lions C; Cohen J; Vray M; Mora M; Marcellin F; Spire B; Morel A; Roux P; Methaville Study Group";10.1371/journal.pone.0112328;2014;"['Journal Article', 'Multicenter Study', 'Pragmatic Clinical Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00421551;Study Comparing Efficacy and Safety of Darunavir Boosted With Ritonavir to HART With 2 NRTI and Darunavir Boosted With Ritonavir in HIV-1 Infected Patients ANRS136;French National Agency for Research on AIDS and Viral Hepatitis;Tibotec Pharmaceutical Limited;COMPLETED;INTERVENTIONAL;False;2007-01-12;2007-03;2011-02;22848481;DERIVED;Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks.;"Lambert-Niclot S; Flandre P; Valantin MA; Soulie C; Fourati S; Wirden M; Sayon S; Pakianather S; Bocket L; Masquelier B; Dos Santos G; Katlama C; Calvez V; Marcelin AG";10.1371/journal.pone.0041390;2012;"['Comparative Study', 'Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00421551;Study Comparing Efficacy and Safety of Darunavir Boosted With Ritonavir to HART With 2 NRTI and Darunavir Boosted With Ritonavir in HIV-1 Infected Patients ANRS136;French National Agency for Research on AIDS and Viral Hepatitis;Tibotec Pharmaceutical Limited;COMPLETED;INTERVENTIONAL;False;2007-01-12;2007-03;2011-02;20802297;DERIVED;Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136.;"Katlama C; Valantin MA; Algarte-Genin M; Duvivier C; Lambert-Niclot S; Girard PM; Molina JM; Hoen B; Pakianather S; Peytavin G; Marcelin AG; Flandre P";10.1097/QAD.0b013e32833dec20;2010;"['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00421551;Study Comparing Efficacy and Safety of Darunavir Boosted With Ritonavir to HART With 2 NRTI and Darunavir Boosted With Ritonavir in HIV-1 Infected Patients ANRS136;French National Agency for Research on AIDS and Viral Hepatitis;Tibotec Pharmaceutical Limited;COMPLETED;INTERVENTIONAL;False;2007-01-12;2007-03;2011-02;29767684;DERIVED;Ultrasensitive Human Immunodeficiency Virus Type 1 Viral Load as a Marker of Treatment Choice for Simplification Strategies.;"Lambert-Niclot S; Grude M; Meynard JL; Marcelin AG; Valantin MA; Flandre P; Izopet J; Moinot L; Bouteloup V; Calvez V; Katlama C; Girard PM; Morand-Joubert L";10.1093/cid/ciy382;2018;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00623051;Evaluation of the Extension at Community Level of Safe Male Circumcision (ANRS 12126 ORANGE FARM 2);French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2008-02-25;2008-01;2012-12;;;;;;;
NCT00116454;Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2005-06-30;2005-07;2013-08;;;;;;;
NCT03954054;Therapeutic Education for Harm Reduction in People With Alcohol Use Disorder;Institut National de la Santé Et de la Recherche Médicale, France;Regional Agency for Health PACA | SESSTIM UMR1252 (Aix-Marseille Univ, INSERM, IRD);COMPLETED;OBSERVATIONAL;False;2019-05-17;2019-10-28;2021-07-31;35012570;DERIVED;Evaluation of a novel therapeutic education programme for people with alcohol use disorder in France: a mixed-methods intervention study protocol (ETHER).;"Antwerpes S; Costa M; Coste M; Bureau M; Maradan G; Cutarella C; Leloutre J; Riccobono-Soulier O; Hedoire S; Frot E; Vernier F; Vassas-Goyard S; Barré T; Casanova D; Carrieri P";10.1186/s12954-021-00587-0;2022;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT02976298;Effects of Cerebellum or Supplementary Motor Area Functional Inactivation on Gait and Balance Control;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-11-29;2013-02;2015-01;;;;;;;
NCT02101398;Study of the Effect of Transcranial Stimulations in Aphasic Subject Within a Year of Their Stroke;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-04-02;2014-10-02;2016-07;;;;;;;
NCT05472051;Health and Migration Trajectories of Housekeepers in Bamako;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2022-07-25;2022-02-28;2023-06-22;;;;;;;
NCT00495651;Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO);French National Agency for Research on AIDS and Viral Hepatitis;Gilead Sciences | Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-07-03;2008-03;2015-01;26193126;DERIVED;A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.;"TEMPRANO ANRS 12136 Study Group; Danel C; Moh R; Gabillard D; Badje A; Le Carrou J; Ouassa T; Ouattara E; Anzian A; Ntakpé JB; Minga A; Kouame GM; Bouhoussou F; Emieme A; Kouamé A; Inwoley A; Toni TD; Ahiboh H; Kabran M; Rabe C; Sidibé B; Nzunetu G; Konan R; Gnokoro J; Gouesse P; Messou E; Dohoun L; Kamagate S; Yao A; Amon S; Kouame AB; Koua A; Kouamé E; Ndri Y; Ba-Gomis O; Daligou M; Ackoundzé S; Hawerlander D; Ani A; Dembélé F; Koné F; Guéhi C; Kanga C; Koule S; Séri J; Oyebi M; Mbakop N; Makaila O; Babatunde C; Babatounde N; Bleoué G; Tchoutedjem M; Kouadio AC; Sena G; Yededji SY; Assi R; Bakayoko A; Mahassadi A; Attia A; Oussou A; Mobio M; Bamba D; Koman M; Horo A; Deschamps N; Chenal H; Sassan-Morokro M; Konate S; Aka K; Aoussi E; Journot V; Nchot C; Karcher S; Chaix ML; Rouzioux C; Sow PS; Perronne C; Girard PM; Menan H; Bissagnene E; Kadio A; Ettiegne-Traore V; Moh-Semdé C; Kouame A; Massumbuko JM; Chêne G; Dosso M; Domoua SK; N'Dri-Yoman T; Salamon R; Eholié SP; Anglaret X";10.1056/NEJMoa1507198;2015;"['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00495651;Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO);French National Agency for Research on AIDS and Viral Hepatitis;Gilead Sciences | Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-07-03;2008-03;2015-01;29297443;DERIVED;Screening for active tuberculosis before isoniazid preventive therapy among HIV-infected West African adults.;"Moh R; Badjé A; N'takpé JB; Kouamé GM; Gabillard D; Ouassa T; Ouattara E; Le Carrou J; Bohoussou F; Messou E; Eholié S; Anglaret X; Danel C";10.5588/ijtld.17.0016;2017;"['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00495651;Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO);French National Agency for Research on AIDS and Viral Hepatitis;Gilead Sciences | Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-07-03;2008-03;2015-01;29020361;DERIVED;Higher Mortality Despite Early Antiretroviral Therapy in Human Immunodeficiency Virus and Hepatitis B Virus (HBV)-Coinfected Patients With High HBV Replication.;"Kouamé GM; Boyd A; Moh R; Badje A; Gabillard D; Ouattara E; Ntakpe JB; Emième A; Maylin S; Chekaraou MA; Eholié SP; Zoulim F; Lacombe K; Anglaret X; Danel C; French National Agency for Research on AIDS and Viral Hepatitis (ANRS) 12136 Temprano and ANRS 12240 VarBVA Study Groups";10.1093/cid/cix747;2018;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT00495651;Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO);French National Agency for Research on AIDS and Viral Hepatitis;Gilead Sciences | Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-07-03;2008-03;2015-01;23639243;DERIVED;Early upper digestive tract side effects of zidovudine with tenofovir plus emtricitabine in West African adults with high CD4 counts.;"Ouattara E; Danel C; Moh R; Gabillard D; Peytavin G; Konan R; Carrou JL; Bohoussou F; Eholie SP; Anglaret X";10.7448/IAS.16.1.18059;2013;"['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00495651;Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO);French National Agency for Research on AIDS and Viral Hepatitis;Gilead Sciences | Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-07-03;2008-03;2015-01;25330161;DERIVED;Quantiferon-TB Gold: performance for ruling out active tuberculosis in HIV-infected adults with high CD4 count in Côte d'Ivoire, West Africa.;"Danel C; Kabran M; Inwoley A; Badje A; Herrmann JL; Moh R; Lecarrou J; Gabillard D; Ntakpe JB; Deschamps N; Ouattara E; Perronne C; Eholie S; Anglaret X";10.1371/journal.pone.0107245;2014;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00495651;Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO);French National Agency for Research on AIDS and Viral Hepatitis;Gilead Sciences | Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-07-03;2008-03;2015-01;24985779;DERIVED;Decrease in sexual risk behaviours after early initiation of antiretroviral therapy: a 24-month prospective study in Côte d'Ivoire.;"Jean K; Gabillard D; Moh R; Danel C; Desgrées-du-Loû A; N'takpe JB; Le Carrou J; Badjé A; Eholié S; Lert F; Anglaret X; Dray-Spira R";10.7448/IAS.17.1.18977;2014;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00495651;Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO);French National Agency for Research on AIDS and Viral Hepatitis;Gilead Sciences | Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-07-03;2008-03;2015-01;35093007;DERIVED;Association of cellular HIV-1 DNA and virological success of antiretroviral treatment in HIV-infected sub-Saharan African adults.;"Moh DR; Ntakpé JB; Gabillard D; Yayo-Emieme AA; Badjé A; Kouame GM; d'Aquin TT; Danel C; Anglaret X; Eholié SP";10.1186/s12879-022-07082-2;2022;['Journal Article', 'Randomized Controlled Trial']
NCT01693861;"""Cancersensor"" Chemotherapy";Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-09-26;2012-10;2015-02;;;;;;;
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;28033414;DERIVED;Effect of Multimorbidity on Health-Related Quality of Life in Adults Aged 55 Years or Older: Results from the SU.VI.MAX 2 Cohort.;"Walker V; Perret-Guillaume C; Kesse-Guyot E; Agrinier N; Hercberg S; Galan P; Assmann KE; Briançon S; Rotonda C";10.1371/journal.pone.0169282;2016;['Journal Article']
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;31164347;DERIVED;Plasma Metabolomic Signatures Associated with Long-term Breast Cancer Risk in the SU.VI.MAX Prospective Cohort.;"Lécuyer L; Dalle C; Lyan B; Demidem A; Rossary A; Vasson MP; Petera M; Lagree M; Ferreira T; Centeno D; Galan P; Hercberg S; Deschasaux M; Partula V; Srour B; Latino-Martel P; Kesse-Guyot E; Druesne-Pecollo N; Durand S; Pujos-Guillot E; Touvier M";10.1158/1055-9965.EPI-19-0154;2019;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;26409628;DERIVED;Are different vascular risk scores calculated at midlife uniformly associated with subsequent poor cognitive performance?;"Kesse-Guyot E; Lassale C; Assmann KE; Andreeva VA; Julia C; Blacher J; Fezeu L; Hercberg S; Galan P";10.1016/j.atherosclerosis.2015.09.023;2015;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;28356432;DERIVED;The Inflammatory Potential of the Diet Is Associated with Depressive Symptoms in Different Subgroups of the General Population.;"Adjibade M; Andreeva VA; Lemogne C; Touvier M; Shivappa N; Hébert JR; Wirth MD; Hercberg S; Galan P; Julia C; Assmann KE; Kesse-Guyot E";10.3945/jn.116.245167;2017;['Journal Article']
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;22633793;DERIVED;Adherence to Mediterranean diet reduces the risk of metabolic syndrome: a 6-year prospective study.;"Kesse-Guyot E; Ahluwalia N; Lassale C; Hercberg S; Fezeu L; Lairon D";10.1016/j.numecd.2012.02.005;2013;['Journal Article', 'Randomized Controlled Trial']
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;30517725;DERIVED;Unsaturated Fatty Acid Intakes During Midlife Are Positively Associated with Later Cognitive Function in Older Adults with Modulating Effects of Antioxidant Supplementation.;"Assmann KE; Adjibade M; Hercberg S; Galan P; Kesse-Guyot E";10.1093/jn/nxy206;2018;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;28494135;DERIVED;Prospective association between body mass index at midlife and healthy aging among French adults.;"Ruhunuhewa I; Adjibade M; Andreeva VA; Galan P; Hercberg S; Assmann KE; Kesse-Guyot E";10.1002/oby.21853;2017;['Journal Article']
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;22378736;DERIVED;Modulation of the association between plasma intercellular adhesion molecule-1 and cancer risk by n-3 PUFA intake: a nested case-control study.;"Touvier M; Kesse-Guyot E; Andreeva VA; Fezeu L; Charnaux N; Sutton A; Druesne-Pecollo N; Hercberg S; Galan P; Zelek L; Latino-Martel P; Czernichow S";10.3945/ajcn.111.027805;2012;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;29546305;DERIVED;The Inflammatory Potential of the Diet at Midlife Is Associated with Later Healthy Aging in French Adults.;"Assmann KE; Adjibade M; Shivappa N; Hébert JR; Wirth MD; Touvier M; Akbaraly T; Hercberg S; Galan P; Julia C; Kesse-Guyot E";10.1093/jn/nxx061;2018;"['Journal Article', 'Randomized Controlled Trial', 'Research Support, N.I.H., Extramural', ""Research Support, Non-U.S. Gov't""]"
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;20176858;DERIVED;Gene-nutrient interactions with dietary fat modulate the association between genetic variation of the ACSL1 gene and metabolic syndrome.;"Phillips CM; Goumidi L; Bertrais S; Field MR; Cupples LA; Ordovas JM; Defoort C; Lovegrove JA; Drevon CA; Gibney MJ; Blaak EE; Kiec-Wilk B; Karlstrom B; Lopez-Miranda J; McManus R; Hercberg S; Lairon D; Planells R; Roche HM";10.1194/jlr.M003046;2010;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;25994566;DERIVED;Prospective association between alcohol intake and hormone-dependent cancer risk: modulation by dietary fiber intake.;"Chhim AS; Fassier P; Latino-Martel P; Druesne-Pecollo N; Zelek L; Duverger L; Hercberg S; Galan P; Deschasaux M; Touvier M";10.3945/ajcn.114.098418;2015;"['Journal Article', 'Observational Study', ""Research Support, Non-U.S. Gov't""]"
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;27000099;DERIVED;Prospective association between a dietary quality index based on a nutrient profiling system and cardiovascular disease risk.;"Adriouch S; Julia C; Kesse-Guyot E; Méjean C; Ducrot P; Péneau S; Donnenfeld M; Deschasaux M; Menai M; Hercberg S; Touvier M; Fezeu LK";10.1177/2047487316640659;2016;"['Journal Article', 'Multicenter Study', ""Research Support, Non-U.S. Gov't""]"
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;26962176;DERIVED;The Dietary Inflammatory Index Is Associated with Prostate Cancer Risk in French Middle-Aged Adults in a Prospective Study.;"Graffouillère L; Deschasaux M; Mariotti F; Neufcourt L; Shivappa N; Hébert JR; Wirth MD; Latino-Martel P; Hercberg S; Galan P; Julia C; Kesse-Guyot E; Touvier M";10.3945/jn.115.225623;2016;['Journal Article']
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;21490142;DERIVED;Dietary intake of 337 polyphenols in French adults.;"Pérez-Jiménez J; Fezeu L; Touvier M; Arnault N; Manach C; Hercberg S; Galan P; Scalbert A";10.3945/ajcn.110.007096;2011;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;21106918;DERIVED;Adherence to nutritional recommendations and subsequent cognitive performance: findings from the prospective Supplementation with Antioxidant Vitamins and Minerals 2 (SU.VI.MAX 2) study.;"Kesse-Guyot E; Amieva H; Castetbon K; Henegar A; Ferry M; Jeandel C; Hercberg S; Galan P; SU.VI.MAX 2 Research Group";10.3945/ajcn.2010.29761;2011;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;25651444;DERIVED;Overall and abdominal adiposity in midlife and subsequent cognitive function.;"Kesse-Guyot E; Andreeva VA; Touvier M; Jeandel C; Ferry M; Hercberg S; Galan P; SU.VI.MAX 2 Research Group";10.1007/s12603-014-0508-2;2015;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;26817718;DERIVED;Weight Status and Alcohol Intake Modify the Association between Vitamin D and Breast Cancer Risk.;"Deschasaux M; Souberbielle JC; Latino-Martel P; Sutton A; Charnaux N; Druesne-Pecollo N; Galan P; Hercberg S; Le Clerc S; Kesse-Guyot E; Ezzedine K; Touvier M";10.3945/jn.115.221481;2016;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;24089418;DERIVED;Midlife iron status is inversely associated with subsequent cognitive performance, particularly in perimenopausal women.;"Andreeva VA; Galan P; Arnaud J; Julia C; Hercberg S; Kesse-Guyot E";10.3945/jn.113.177089;2013;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;20431391;DERIVED;Associations between dietary patterns and arterial stiffness, carotid artery intima-media thickness and atherosclerosis.;"Kesse-Guyot E; Vergnaud AC; Fezeu L; Zureik M; Blacher J; Péneau S; Hercberg S; Galan P; Czernichow S";10.1097/HJR.0b013e32833a197f;2010;['Journal Article', 'Randomized Controlled Trial']
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;23284983;DERIVED;Alcohol consumption in midlife and cognitive performance assessed 13 years later in the SU.VI.MAX 2 cohort.;"Kesse-Guyot E; Andreeva VA; Jeandel C; Ferry M; Touvier M; Hercberg S; Galan P";10.1371/journal.pone.0052311;2012;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;26156743;DERIVED;Prospective association between dietary folate intake and skin cancer risk: results from the Supplémentation en Vitamines et Minéraux Antioxydants cohort.;"Donnenfeld M; Deschasaux M; Latino-Martel P; Diallo A; Galan P; Hercberg S; Ezzedine K; Touvier M";10.3945/ajcn.115.109041;2015;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;21775560;DERIVED;French adults' cognitive performance after daily supplementation with antioxidant vitamins and minerals at nutritional doses: a post hoc analysis of the Supplementation in Vitamins and Mineral Antioxidants (SU.VI.MAX) trial.;"Kesse-Guyot E; Fezeu L; Jeandel C; Ferry M; Andreeva V; Amieva H; Hercberg S; Galan P";10.3945/ajcn.110.007815;2011;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;26447153;DERIVED;Prospective associations between vitamin D status, vitamin D-related gene polymorphisms, and risk of tobacco-related cancers.;"Deschasaux M; Souberbielle JC; Latino-Martel P; Sutton A; Charnaux N; Druesne-Pecollo N; Galan P; Hercberg S; Le Clerc S; Kesse-Guyot E; Ezzedine K; Touvier M";10.3945/ajcn.115.110510;2015;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;24027184;DERIVED;Intakes of PUFAs were inversely associated with plasma C-reactive protein 12 years later in a middle-aged population with vitamin E intake as an effect modifier.;"Julia C; Touvier M; Meunier N; Papet I; Galan P; Hercberg S; Kesse-Guyot E";10.3945/jn.113.180943;2013;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;20605091;DERIVED;Incidence of skin cancers during 5-year follow-up after stopping antioxidant vitamins and mineral supplementation.;"Ezzedine K; Latreille J; Kesse-Guyot E; Galan P; Hercberg S; Guinot C; Malvy D";10.1016/j.ejca.2010.06.008;2010;['Journal Article', 'Randomized Controlled Trial']
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;29649036;DERIVED;Association Between Alexithymia and Risk of Incident Cardiovascular Diseases in the SUpplémentation en VItamines et Minéraux AntioXydants (SU.VI.MAX) Cohort.;"Wiernik E; Lemogne C; Fezeu L; Arnault N; Hercberg S; Kesse-Guyot E; Galan P";10.1097/PSY.0000000000000592;2018;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;19491388;DERIVED;Effects of long-term antioxidant supplementation and association of serum antioxidant concentrations with risk of metabolic syndrome in adults.;"Czernichow S; Vergnaud AC; Galan P; Arnaud J; Favier A; Faure H; Huxley R; Hercberg S; Ahluwalia N";10.3945/ajcn.2009.27635;2009;['Journal Article', 'Randomized Controlled Trial']
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;26812508;DERIVED;Consumption of Dairy Products and Cognitive Functioning: Findings from the SU.VI.MAX 2 Study.;"Kesse-Guyot E; Assmann KE; Andreeva VA; Ferry M; Hercberg S; Galan P; SU.VI.MAX 2 Research Group";10.1007/s12603-015-0593-x;2016;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;23283500;DERIVED;Mediterranean diet and cognitive function: a French study.;"Kesse-Guyot E; Andreeva VA; Lassale C; Ferry M; Jeandel C; Hercberg S; Galan P; SU.VI.MAX 2 Research Group";10.3945/ajcn.112.047993;2013;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;19828715;DERIVED;Complement component 3 polymorphisms interact with polyunsaturated fatty acids to modulate risk of metabolic syndrome.;"Phillips CM; Goumidi L; Bertrais S; Ferguson JF; Field MR; Kelly ED; Peloso GM; Cupples LA; Shen J; Ordovas JM; McManus R; Hercberg S; Portugal H; Lairon D; Planells R; Roche HM";10.3945/ajcn.2009.28101;2009;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;23082222;DERIVED;Cross-sectional and longitudinal associations of different sedentary behaviors with cognitive performance in older adults.;"Kesse-Guyot E; Charreire H; Andreeva VA; Touvier M; Hercberg S; Galan P; Oppert JM";10.1371/journal.pone.0047831;2012;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;31927670;DERIVED;Untargeted plasma metabolomic profiles associated with overall diet in women from the SU.VI.MAX cohort.;"Lécuyer L; Dalle C; Micheau P; Pétéra M; Centeno D; Lyan B; Lagree M; Galan P; Hercberg S; Rossary A; Demidem A; Vasson MP; Partula V; Deschasaux M; Srour B; Latino-Martel P; Druesne-Pecollo N; Kesse-Guyot E; Durand S; Pujos-Guillot E; Manach C; Touvier M";10.1007/s00394-020-02177-5;2020;['Journal Article']
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;26864363;DERIVED;Prospective association between the Dietary Inflammatory Index and mortality: modulation by antioxidant supplementation in the SU.VI.MAX randomized controlled trial.;"Graffouillère L; Deschasaux M; Mariotti F; Neufcourt L; Shivappa N; Hébert JR; Wirth MD; Latino-Martel P; Hercberg S; Galan P; Julia C; Kesse-Guyot E; Touvier M";10.3945/ajcn.115.126243;2016;"['Journal Article', 'Randomized Controlled Trial', 'Research Support, N.I.H., Extramural', ""Research Support, Non-U.S. Gov't""]"
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;24527713;DERIVED;Interpretation of plasma PTH concentrations according to 25OHD status, gender, age, weight status, and calcium intake: importance of the reference values.;"Touvier M; Deschasaux M; Montourcy M; Sutton A; Charnaux N; Kesse-Guyot E; Fezeu LK; Latino-Martel P; Druesne-Pecollo N; Malvy D; Galan P; Hercberg S; Ezzedine K; Souberbielle JC";10.1210/jc.2013-3349;2014;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;24553693;DERIVED;Dietary total and insoluble fiber intakes are inversely associated with prostate cancer risk.;"Deschasaux M; Pouchieu C; His M; Hercberg S; Latino-Martel P; Touvier M";10.3945/jn.113.189670;2014;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;22158670;DERIVED;Long-term antioxidant supplementation has no effect on health-related quality of life: the randomized, double-blind, placebo-controlled, primary prevention SU.VI.MAX trial.;"Briançon S; Boini S; Bertrais S; Guillemin F; Galan P; Hercberg S";10.1093/ije/dyr161;2011;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;21955649;DERIVED;Fruit and vegetable intake and cognitive function in the SU.VI.MAX 2 prospective study.;"Péneau S; Galan P; Jeandel C; Ferry M; Andreeva V; Hercberg S; Kesse-Guyot E; SU.VI.MAX 2 Research Group";10.3945/ajcn.111.014712;2011;"['Clinical Trial', 'Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;33738534;DERIVED;The inflammatory potential of the diet is prospectively associated with subjective hearing loss.;"Andreeva VA; Péneau S; Julia C; Shivappa N; Hébert JR; Wirth MD; Touvier M; Hercberg S; Galan P; Kesse-Guyot E";10.1007/s00394-021-02531-1;2021;['Journal Article']
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;27055851;DERIVED;Long-term association between the dietary inflammatory index and cognitive functioning: findings from the SU.VI.MAX study.;"Kesse-Guyot E; Assmann KE; Andreeva VA; Touvier M; Neufcourt L; Shivappa N; Hébert JR; Wirth MD; Hercberg S; Galan P; Julia C";10.1007/s00394-016-1211-3;2017;['Journal Article', 'Observational Study']
NCT00272428;Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.;Institut National de la Santé Et de la Recherche Médicale, France;French private agencies;COMPLETED;INTERVENTIONAL;False;2006-01-06;1994-10;2005-09;15557412;RESULT;The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals.;"Hercberg S; Galan P; Preziosi P; Bertrais S; Mennen L; Malvy D; Roussel AM; Favier A; Briançon S";10.1001/archinte.164.21.2335;2004;"['Clinical Trial', 'Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT02052271;Experimental Therapeutics in Essential Tremor Using Cerebellar Transcranial Direct Current Stimulation;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-02-03;2014-06-03;2018-03-27;;;;;;;
NCT01534728;Identification of Hepatitis C Virus (HCV) Specific T Cells;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-02-17;2012-02;2014-03;;;;;;;
NCT01492985;Lipopeptide Immunisation With GTU-multiHIV Trial;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2011-12-15;2013-07;2017-04-08;33568510;DERIVED;A Randomized Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-Infected Individuals: VRI02 ANRS 149 LIGHT Phase II Trial.;"Lévy Y; Lacabaratz C; Lhomme E; Wiedemann A; Bauduin C; Fenwick C; Foucat E; Surenaud M; Guillaumat L; Boilet V; Rieux V; Bouchaud O; Girard PM; Molina JM; Morlat P; Hocqueloux L; Richert L; Pantaleo G; Lelièvre JD; Thiébaut R";10.1128/JVI.02165-20;2021;"['Clinical Trial, Phase II', 'Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00120185;Efficacy of Using Interleukin-2 in Antiretroviral Naïve HIV Patients (ANRS119);French National Agency for Research on AIDS and Viral Hepatitis;Chiron Corporation;COMPLETED;INTERVENTIONAL;False;2005-07-15;2003-12;2006-11;19508157;DERIVED;Interleukin-2 before antiretroviral therapy in patients with HIV infection: a randomized trial (ANRS 119).;"Molina JM; Levy Y; Fournier I; Hamonic S; Bentata M; Beck-Wirth G; Gougeon ML; Venet A; Madelaine I; Sereni D; Jeanblanc F; Boulet T; Simon F; Aboulker JP; Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS) 119 Interstart Study Team";10.1086/599989;2009;"['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT01463956;Efficacy of PegInterferon-Ribavirin-Boceprevir Therapy in Patients Infected With G1 HCV With Cirrhosis, Awaiting Liver Transplantation;French National Agency for Research on AIDS and Viral Hepatitis;Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2011-11-02;2012-01-06;2015-01-22;;;;;;;
NCT00334256;Tenofovir/Emtricitabine for PMTCT in Africa and Asia (ANRS 12109 TEmAA);French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | Gilead Sciences;COMPLETED;INTERVENTIONAL;False;2006-06-07;2006-10;2009-12;19104016;RESULT;Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates.;"Hirt D; Urien S; Rey E; Arrivé E; Ekouévi DK; Coffié P; Leang SK; Lalsab S; Avit D; Nerrienet E; McIntyre J; Blanche S; Dabis F; Tréluyer JM";10.1128/AAC.00860-08;2009;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT00334256;Tenofovir/Emtricitabine for PMTCT in Africa and Asia (ANRS 12109 TEmAA);French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | Gilead Sciences;COMPLETED;INTERVENTIONAL;False;2006-06-07;2006-10;2009-12;19307941;RESULT;Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1.;"TEmAA ANRS 12109 Study group; Arrivé E; Chaix ML; Nerrienet E; Blanche S; Rouzioux C; Coffie PA; Kruy Leang S; McIntyre J; Avit D; Srey VH; Gray G; N'Dri-Yoman T; Diallo A; Ekouévi DK; Dabis F";10.1097/QAD.0b013e32832949d5;2009;"['Clinical Trial, Phase I', 'Clinical Trial, Phase II', 'Journal Article', 'Multicenter Study', ""Research Support, Non-U.S. Gov't""]"
NCT00334256;Tenofovir/Emtricitabine for PMTCT in Africa and Asia (ANRS 12109 TEmAA);French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | Gilead Sciences;COMPLETED;INTERVENTIONAL;False;2006-06-07;2006-10;2009-12;18987623;RESULT;Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109).;"Hirt D; Urien S; Ekouévi DK; Rey E; Arrivé E; Blanche S; Amani-Bosse C; Nerrienet E; Gray G; Kone M; Leang SK; McIntyre J; Dabis F; Tréluyer JM; ANRS 12109";10.1038/clpt.2008.201;2009;"['Clinical Trial, Phase II', 'Comparative Study', 'Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT00822315;Efficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis;ANRS, Emerging Infectious Diseases;Gilead Sciences | Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2009-01-14;2009-07;2012-05;24726095;DERIVED;Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial.;"Grinsztejn B; De Castro N; Arnold V; Veloso VG; Morgado M; Pilotto JH; Brites C; Madruga JV; Barcellos NT; Santos BR; Vorsatz C; Fagard C; Santini-Oliveira M; Patey O; Delaugerre C; Chêne G; Molina JM; ANRS 12 180 Reflate TB study group";10.1016/S1473-3099(14)70711-X;2014;"['Clinical Trial, Phase II', 'Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT04120415;A HIV Vaccine Trial in Individuals Who Started Antiretrovirals During Primary or Chronic Infection (EHVA T02);ANRS, Emerging Infectious Diseases;EuroVacc Foundation | European AIDS Treatment Group (EATG) | Medical Research Council | University College London Hospitals | University of Liverpool | Erasmus Medical Center | Henri Mondor University Hospital | European Georges Pompidou Hospital | Saint-Louis Hospital, Paris, France | Centre Hospitalier Universitaire Vaudois | Chelsea and Westminster Hospital, UK | Universitätsklinikum Hamburg-Eppendorf | Hospital Clinic of Barcelona | Istituto Nazionale Malattie Infettive Lazaro Spallanzani | Imperial College London | Institut d'Investigacions Biomèdiques August Pi i Sunyer | European Commission | Swiss Government;COMPLETED;INTERVENTIONAL;False;2019-10-09;2022-06-21;2023-07-12;;;;;;;
NCT02567071;Natural Microbiota Restoration After C-section Birth;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-10-02;2016-04-06;2019-04;;;;;;;
NCT01331811;Improving Diagnosis of Tuberculosis in HIV Infected Children in Asia (Cambodia, Vietnam)and Africa (Burkina Faso, Cameroon);ANRS, Emerging Infectious Diseases;Institut Pasteur, Cambodia | National Pediatric Hospital, Cambodia | Angkor Hospital for Children | Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam | Pediatric Hospital Nhi Dong 1, Ho Chi Minh City, Vietnam | Number 2 Children's Hospital, Ho Chi Minh City | Hôpital Necker-Enfants Malades, Paris, France | Groupe Hospitalier Pitie-Salpetriere | CHRU Arnaud de Villeveuve, Montpellier, France | IRD, Yaounde, Cameroon | Fondation Chantal Biya,Yaounde, Cameroon | CHU Sourô Sanou, Bobo Dioulasso, Burkina Faso | Centre Muraz | Centre Pasteur du Cameroun | Centre Hospitalier D'essos;COMPLETED;INTERVENTIONAL;False;2011-04-08;2011-04;2014-05;26908804;DERIVED;Performance of Xpert MTB/RIF and Alternative Specimen Collection Methods for the Diagnosis of Tuberculosis in HIV-Infected Children.;"Marcy O; Ung V; Goyet S; Borand L; Msellati P; Tejiokem M; Nguyen Thi NL; Nacro B; Cheng S; Eyangoh S; Pham TH; Ouedraogo AS; Tarantola A; Godreuil S; Blanche S; Delacourt C";10.1093/cid/ciw036;2016;"['Clinical Trial', 'Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01331811;Improving Diagnosis of Tuberculosis in HIV Infected Children in Asia (Cambodia, Vietnam)and Africa (Burkina Faso, Cameroon);ANRS, Emerging Infectious Diseases;Institut Pasteur, Cambodia | National Pediatric Hospital, Cambodia | Angkor Hospital for Children | Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam | Pediatric Hospital Nhi Dong 1, Ho Chi Minh City, Vietnam | Number 2 Children's Hospital, Ho Chi Minh City | Hôpital Necker-Enfants Malades, Paris, France | Groupe Hospitalier Pitie-Salpetriere | CHRU Arnaud de Villeveuve, Montpellier, France | IRD, Yaounde, Cameroon | Fondation Chantal Biya,Yaounde, Cameroon | CHU Sourô Sanou, Bobo Dioulasso, Burkina Faso | Centre Muraz | Centre Pasteur du Cameroun | Centre Hospitalier D'essos;COMPLETED;INTERVENTIONAL;False;2011-04-08;2011-04;2014-05;29174612;DERIVED;Mortality and its determinants in antiretroviral treatment-naive HIV-infected children with suspected tuberculosis: an observational cohort study.;"Marcy O; Tejiokem M; Msellati P; Truong Huu K; Do Chau V; Tran Ngoc D; Nacro B; Ateba-Ndongo F; Tetang-Ndiang S; Ung V; Dim B; Neou L; Berteloot L; Borand L; Delacourt C; Blanche S; ANRS 12229 PAANTHER 01 Study Group";10.1016/S2352-3018(17)30206-0;2018;"['Clinical Trial', 'Journal Article', 'Multicenter Study', 'Observational Study', ""Research Support, Non-U.S. Gov't""]"
NCT01331811;Improving Diagnosis of Tuberculosis in HIV Infected Children in Asia (Cambodia, Vietnam)and Africa (Burkina Faso, Cameroon);ANRS, Emerging Infectious Diseases;Institut Pasteur, Cambodia | National Pediatric Hospital, Cambodia | Angkor Hospital for Children | Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam | Pediatric Hospital Nhi Dong 1, Ho Chi Minh City, Vietnam | Number 2 Children's Hospital, Ho Chi Minh City | Hôpital Necker-Enfants Malades, Paris, France | Groupe Hospitalier Pitie-Salpetriere | CHRU Arnaud de Villeveuve, Montpellier, France | IRD, Yaounde, Cameroon | Fondation Chantal Biya,Yaounde, Cameroon | CHU Sourô Sanou, Bobo Dioulasso, Burkina Faso | Centre Muraz | Centre Pasteur du Cameroun | Centre Hospitalier D'essos;COMPLETED;INTERVENTIONAL;False;2011-04-08;2011-04;2014-05;30689814;DERIVED;Isolation of Nontuberculous Mycobacteria in Southeast Asian and African Human Immunodeficiency Virus-infected Children With Suspected Tuberculosis.;"Borand L; de Lauzanne A; Nguyen NL; Cheng S; Pham TH; Eyangoh S; Ouedraogo AS; Ung V; Msellati P; Tejiokem M; Nacro B; Inghammar M; Dim B; Delacourt C; Godreuil S; Blanche S; Marcy O; Pediatric Asian African Network for Tuberculosis and HIV Research (PAANTHER) Study Group";10.1093/cid/ciy897;2019;"['Clinical Trial', 'Journal Article', 'Multicenter Study', ""Research Support, Non-U.S. Gov't""]"
NCT01331811;Improving Diagnosis of Tuberculosis in HIV Infected Children in Asia (Cambodia, Vietnam)and Africa (Burkina Faso, Cameroon);ANRS, Emerging Infectious Diseases;Institut Pasteur, Cambodia | National Pediatric Hospital, Cambodia | Angkor Hospital for Children | Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam | Pediatric Hospital Nhi Dong 1, Ho Chi Minh City, Vietnam | Number 2 Children's Hospital, Ho Chi Minh City | Hôpital Necker-Enfants Malades, Paris, France | Groupe Hospitalier Pitie-Salpetriere | CHRU Arnaud de Villeveuve, Montpellier, France | IRD, Yaounde, Cameroon | Fondation Chantal Biya,Yaounde, Cameroon | CHU Sourô Sanou, Bobo Dioulasso, Burkina Faso | Centre Muraz | Centre Pasteur du Cameroun | Centre Hospitalier D'essos;COMPLETED;INTERVENTIONAL;False;2011-04-08;2011-04;2014-05;31455612;DERIVED;A Treatment-Decision Score for HIV-Infected Children With Suspected Tuberculosis.;"Marcy O; Borand L; Ung V; Msellati P; Tejiokem M; Huu KT; Do Chau V; Ngoc Tran D; Ateba-Ndongo F; Tetang-Ndiang S; Nacro B; Sanogo B; Neou L; Goyet S; Dim B; Pean P; Quillet C; Fournier I; Berteloot L; Carcelain G; Godreuil S; Blanche S; Delacourt C; ANRS 12229 PAANTHER 01 STUDY GROUP";10.1542/peds.2018-2065;2019;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT02214511;Biomarkers of Social Sensitivity in Major Depression;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2014-08-12;2014-10-23;2017-03-01;;;;;;;
NCT01698411;Study of the Influence of Sleep on Hemodynamic Parameters in Patients With Sleep Disorders;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-10-03;2012-10;2015-02;;;;;;;
NCT04288128;Integrated Functional Evaluation of the Cerebellum;Institut National de la Santé Et de la Recherche Médicale, France;Biogen | Ionis Pharmaceuticals, Inc.;COMPLETED;OBSERVATIONAL;False;2020-02-28;2020-05-28;2022-06-01;38419144;PUBMED;Digital Gait Measures Capture 1-Year Progression in Early-Stage Spinocerebellar Ataxia Type 2.;"Seemann J; Daghsen L; Cazier M; Lamy JC; Welter ML; Giese MA; Synofzik M; Durr A; Ilg W; Coarelli G";10.1002/mds.29757;2024;['Journal Article']
NCT04288128;Integrated Functional Evaluation of the Cerebellum;Institut National de la Santé Et de la Recherche Médicale, France;Biogen | Ionis Pharmaceuticals, Inc.;COMPLETED;OBSERVATIONAL;False;2020-02-28;2020-05-28;2022-06-01;38421662;PUBMED;ATXN7-Related Cone-Rod Dystrophy: The Integrated Functional Evaluation of the Cerebellum (CERMOI) Study.;"Nassisi M; Coarelli G; Blanchard B; Dubec-Fleury C; Drine K; Kitic N; Sancho S; Hilab R; Tezenas du Montcel S; Junge C; Lane R; Arnold HM; Durr A; Audo I";10.1001/jamaophthalmol.2024.0001;2024;['Journal Article']
NCT02157311;4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV Patients;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2014-06-06;2014-07;2016-01;29186458;DERIVED;Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial.;"de Truchis P; Assoumou L; Landman R; Mathez D; Le Dû D; Bellet J; Amat K; Katlama C; Gras G; Bouchaud O; Duracinsky M; Abe E; Alvarez JC; Izopet J; Saillard J; Melchior JC; Leibowitch J; Costagliola D; Girard PM; Perronne C; ANRS 162-4D Study Group";10.1093/jac/dkx434;2018;"['Clinical Trial', 'Journal Article', 'Multicenter Study', ""Research Support, Non-U.S. Gov't""]"
NCT02082171;Multidomain Intervention to Prevent Disability in Elders;Institut National de la Santé Et de la Recherche Médicale, France;National Research Agency, France;COMPLETED;INTERVENTIONAL;False;2014-03-10;2013-10-16;2016-01-27;;;;;;;
NCT00918307;Efficacy and Safety of Varenicline Among HIV-infected Patients;ANRS, Emerging Infectious Diseases;Pfizer;COMPLETED;INTERVENTIONAL;False;2009-06-11;2009-10;2014-07;29329763;DERIVED;Efficacy and safety of varenicline for smoking cessation in people living with HIV in France (ANRS 144 Inter-ACTIV): a randomised controlled phase 3 clinical trial.;"Mercié P; Arsandaux J; Katlama C; Ferret S; Beuscart A; Spadone C; Duvivier C; Reynes J; Wirth N; Moinot L; Bénard A; Zucman D; Duval X; Molina JM; Spire B; Fagard C; Chêne G; ANRS 144 Inter-ACTIV study group";10.1016/S2352-3018(18)30002-X;2018;"['Clinical Trial, Phase III', 'Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00918307;Efficacy and Safety of Varenicline Among HIV-infected Patients;ANRS, Emerging Infectious Diseases;Pfizer;COMPLETED;INTERVENTIONAL;False;2009-06-11;2009-10;2014-07;34611902;DERIVED;Interventions for preventing weight gain after smoking cessation.;"Hartmann-Boyce J; Theodoulou A; Farley A; Hajek P; Lycett D; Jones LL; Kudlek L; Heath L; Hajizadeh A; Schenkels M; Aveyard P";10.1002/14651858.CD006219.pub4;2021;"['Journal Article', 'Meta-Analysis', ""Research Support, Non-U.S. Gov't"", 'Review', 'Systematic Review']"
NCT05090956;Developpement of 3T MRI Protocol;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2021-10-25;2012-06-08;2020-01-29;;;;;;;
NCT02346409;Cerebello-thalamo-cortical Coupling in Essential Tremor;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-01-27;2015-02-04;2018-02-16;;;;;;;
NCT00196599;Pilot Study on Once Daily FTC, ddI, Efavirenz Combination in Antiretroviral Naive HIV Infected Adults;French National Agency for Research on AIDS and Viral Hepatitis;Triangle Pharmaceuticals | Gilead Sciences | Bristol-Myers Squibb | Dupont Applied Biosciences;COMPLETED;INTERVENTIONAL;False;2005-09-20;1999-02;2004-09;15012649;RESULT;Pharmacokinetics of emtricitabine, didanosine and efavirenz administered once-daily for the treatment of HIV-infected adults (pharmacokinetic substudy of the ANRS 091 trial).;"Molina JM; Peytavin G; Perusat S; Lascoux-Combes C; Sereni D; Rozenbaum W; Chene G";10.1111/j.1468-1293.2004.00194.x;2004;"['Clinical Trial', 'Journal Article', 'Multicenter Study', ""Research Support, Non-U.S. Gov't""]"
NCT00196599;Pilot Study on Once Daily FTC, ddI, Efavirenz Combination in Antiretroviral Naive HIV Infected Adults;French National Agency for Research on AIDS and Viral Hepatitis;Triangle Pharmaceuticals | Gilead Sciences | Bristol-Myers Squibb | Dupont Applied Biosciences;COMPLETED;INTERVENTIONAL;False;2005-09-20;1999-02;2004-09;10915095;RESULT;Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients.;"Molina JM; Ferchal F; Rancinan C; Raffi F; Rozenbaum W; Sereni D; Morlat P; Journot V; Decazes JM; Chêne G";10.1086/315711;2000;"['Clinical Trial', 'Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT02102737;Comparison of A New Technique of Measure of the Insulin Resistance By Scintigraphy With the Reference Technique;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-04-03;2014-05-13;2018-03;;;;;;;
NCT00454337;Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load;French National Agency for Research on AIDS and Viral Hepatitis;Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-03-30;2007-05;2008-09;19995925;RESULT;High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial.;"Barau C; Delaugerre C; Braun J; de Castro N; Furlan V; Charreau I; Gérard L; Lascoux-Combe C; Molina JM; Taburet AM";10.1128/AAC.01261-09;2010;['Journal Article', 'Randomized Controlled Trial']
NCT00454337;Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load;French National Agency for Research on AIDS and Viral Hepatitis;Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-03-30;2007-05;2008-09;21326075;RESULT;Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia.;"Gallien S; Delaugerre C; Charreau I; Braun J; Boulet T; Barrail-Tran A; de Castro N; Molina JM; Kuritzkes DR";10.1097/QAD.0b013e3283445834;2011;"['Journal Article', 'Research Support, N.I.H., Extramural', ""Research Support, Non-U.S. Gov't""]"
NCT00454337;Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load;French National Agency for Research on AIDS and Viral Hepatitis;Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-03-30;2007-05;2008-09;22416781;RESULT;Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replication.;"Delaugerre C; Braun J; Charreau I; Delarue S; Nere ML; de Castro N; May T; Marchou B; Simon F; Molina JM; Aboulker JP; ANRS 138-EASIER study group";10.1111/j.1468-1293.2012.01002.x;2012;['Comparative Study', 'Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT00454337;Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load;French National Agency for Research on AIDS and Viral Hepatitis;Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-03-30;2007-05;2008-09;21576452;RESULT;Switch from enfuvirtide to raltegravir lowers plasma concentrations of darunavir and tipranavir: a pharmacokinetic substudy of the EASIER-ANRS 138 trial.;"Goldwirt L; Braun J; de Castro N; Charreau I; Barrail-Tran A; Delaugerre C; Raffi F; Lascoux-Combe C; Aboulker JP; Taburet AM; Molina JM";10.1128/AAC.01827-10;2011;['Journal Article']
NCT00454337;Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load;French National Agency for Research on AIDS and Viral Hepatitis;Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-03-30;2007-05;2008-09;27042193;DERIVED;Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial.;"de Castro N; Braun J; Charreau I; Lafeuillade A; Viard JP; Allavena C; Aboulker JP; Molina JM; EASIER ANRS 138 study group";10.1186/s12981-016-0101-3;2016;"['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00454337;Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load;French National Agency for Research on AIDS and Viral Hepatitis;Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-03-30;2007-05;2008-09;21126958;RESULT;Impact on health-related quality of life of a switch from enfuvirtide to raltegravir among multidrug-resistant HIV-1-infected patients: a randomized open-label trial (EASIER-ANRS 138).;"Boulet T; Pavie J; Charreau I; Braun J; Reynes J; Morlat P; Piroth L; Spire B; Molina JM; Aboulker JP; Easier-Anrs 138 Study Group";10.1310/hct1105-283;2010;"['Comparative Study', 'Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00454337;Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load;French National Agency for Research on AIDS and Viral Hepatitis;Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-03-30;2007-05;2008-09;21712241;RESULT;Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial.;"Gallien S; Braun J; Delaugerre C; Charreau I; Reynes J; Jeanblanc F; Verdon R; de Truchis P; May T; Madelaine-Chambrin I; Aboulker JP; Molina JM; EASIER ANRS 138 Study Group";10.1093/jac/dkr269;2011;"['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00454337;Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load;French National Agency for Research on AIDS and Viral Hepatitis;Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-03-30;2007-05;2008-09;19757993;DERIVED;Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial.;"De Castro N; Braun J; Charreau I; Pialoux G; Cotte L; Katlama C; Raffi F; Weiss L; Meynard JL; Yazdanpanah Y; Delaugerre C; Madelaine-Chambrin I; Aboulker JP; Molina JM; EASIER ANRS 138 study group";10.1086/605674;2009;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00454337;Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load;French National Agency for Research on AIDS and Viral Hepatitis;Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-03-30;2007-05;2008-09;20683319;RESULT;Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen.;"Delaugerre C; Charreau I; Braun J; Néré ML; de Castro N; Yeni P; Ghosn J; Aboulker JP; Molina JM; Simon F; ANRS 138 study group";10.1097/QAD.0b013e32833d214c;2010;['Journal Article', 'Randomized Controlled Trial']
NCT02656407;Intraoperative Functional Ultrasound;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-01-15;2016-02-11;2018-02;25955583;BACKGROUND;Spatiotemporal Clutter Filtering of Ultrafast Ultrasound Data Highly Increases Doppler and fUltrasound Sensitivity.;"Demené C; Deffieux T; Pernot M; Osmanski BF; Biran V; Gennisson JL; Sieu LA; Bergel A; Franqui S; Correas JM; Cohen I; Baud O; Tanter M";10.1109/TMI.2015.2428634;2015;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT00158509;Randomised Controlled Trial Assessing the Impact of Genital Herpes Suppressive Therapy on HIV Shedding;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2005-09-12;2004-08;2005-07;18593294;DERIVED;Roles of clinical and subclinical reactivated herpes simplex virus type 2 infection and human immunodeficiency virus type 1 (HIV-1)-induced immunosuppression on genital and plasma HIV-1 levels.;"Nagot N; Ouedraogo A; Konate I; Weiss HA; Foulongne V; Defer MC; Sanon A; Becquart P; Segondy M; Sawadogo A; Van de Perre P; Mayaud P; ANRS 1285 Study Group";10.1086/589621;2008;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00158509;Randomised Controlled Trial Assessing the Impact of Genital Herpes Suppressive Therapy on HIV Shedding;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2005-09-12;2004-08;2005-07;17314338;DERIVED;Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus.;"Nagot N; Ouédraogo A; Foulongne V; Konaté I; Weiss HA; Vergne L; Defer MC; Djagbaré D; Sanon A; Andonaba JB; Becquart P; Segondy M; Vallo R; Sawadogo A; Van de Perre P; Mayaud P; ANRS 1285 Study Group";10.1056/NEJMoa062607;2007;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT00158509;Randomised Controlled Trial Assessing the Impact of Genital Herpes Suppressive Therapy on HIV Shedding;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2005-09-12;2004-08;2005-07;16044019;RESULT;Longitudinal assessment of HIV-1 and HSV-2 shedding in the genital tract of West African women.;"Nagot N; Foulongne V; Becquart P; Mayaud P; Konate I; Ouedraogo A; Defer MC; Weiss H; Van de Perre P; Segondy M";;2005;"['Evaluation Study', 'Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT00158509;Randomised Controlled Trial Assessing the Impact of Genital Herpes Suppressive Therapy on HIV Shedding;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2005-09-12;2004-08;2005-07;18596069;DERIVED;Effect of HIV-1 and antiretroviral therapy on herpes simplex virus type 2: a prospective study in African women.;"Mayaud P; Nagot N; Konaté I; Ouedraogo A; Weiss HA; Foulongne V; Defer MC; Sawadogo A; Segondy M; Van de Perre P; ANRS 1285 Study Group";10.1136/sti.2008.030692;2008;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT02038842;Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates in Healthy Volunteers;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2014-01-17;2014-03;2016-03;;;;;;;
NCT01725542;Pilot Study to Assess the Efficacy of and Tolerance to a QUadruple Therapy to Treat HIV-HCV Coinfected Patients Previously Null Responders;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb;COMPLETED;INTERVENTIONAL;False;2012-11-14;2012-12;2014-06;25977266;DERIVED;High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Genotype 1/4 Coinfection: The ANRS HC30 QUADRIH Study.;"Piroth L; Paniez H; Taburet AM; Vincent C; Rosenthal E; Lacombe K; Billaud E; Rey D; Zucman D; Bailly F; Bronowicki JP; Simony M; Diallo A; Izopet J; Aboulker JP; Meyer L; Molina JM; ANRS HC30 QUADRIH Study Group";10.1093/cid/civ381;2015;"['Clinical Trial, Phase II', 'Journal Article', 'Multicenter Study', ""Research Support, Non-U.S. Gov't""]"
NCT06260319;Decoding Developmental Disorders in Humams;Institut National de la Santé Et de la Recherche Médicale, France;Imagine Institute | Commissariat A L'energie Atomique;COMPLETED;OBSERVATIONAL;False;2024-02-15;2019-01-01;2024-01-01;;;;;;;
NCT01842919;Dance and Huntington Disease;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2013-04-30;2013-04;2016-07-08;;;;;;;
NCT02906137;Gut-Associated Lymphocyte Trafficking;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2016-09-19;2017-02-06;2020-02-25;;;;;;;
NCT01192737;"""COhort Study on A/H1N1 FLU During PREGnancy""";Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2010-09-01;2009-10;2010-11;;;;;;;
NCT02647632;Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2016-01-06;2016-01;2017-04;29077864;DERIVED;Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study.;"de Lédinghen V; Laforest C; Hézode C; Pol S; Renault A; Alric L; Larrey D; Métivier S; Tran A; Jézéquel C; Samuel D; Zoulim F; Tual C; Pailhé A; Gibowski S; Bourlière M; Bellissant E; Pawlotsky JM";10.1093/cid/cix916;2018;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial']
NCT01065207;Patients Infected With HIV Since More Than 10 Years With a Plasma Viral RNA <400 Copies / mL in the Absence of Any Treatment: Study Mechanisms Involved in Controlling the Infection;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2010-02-09;2009-03;2012-03;;;;;;;
NCT02542800;The Influence of Collective Schemas on Individual Memory;Institut National de la Santé Et de la Recherche Médicale, France;La Région Basse-Normandie | Université de Caen Normandie | University Hospital, Caen | Ecole Pratique des Hautes Etudes | Equipement d'Excellence Matrice;COMPLETED;INTERVENTIONAL;False;2015-09-07;2015-09;2017-06-02;;;;;;;
NCT01089400;Immuno-virological Characterization of Severe H1N1v Influenza Infection in Bronchoalveolar Lavage;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris | Institut Pasteur;COMPLETED;OBSERVATIONAL;False;2010-03-18;2009-10;2011-04;24646009;DERIVED;Low titers of serum antibodies inhibiting hemagglutination predict fatal fulminant influenza A(H1N1) 2009 infection.;"Guihot A; Luyt CE; Parrot A; Rousset D; Cavaillon JM; Boutolleau D; Fitting C; Pajanirassa P; Mallet A; Fartoukh M; Agut H; Musset L; Zoorob R; Kirilovksy A; Combadière B; van der Werf S; Autran B; Carcelain G; FluBAL Study Group";10.1164/rccm.201311-2071OC;2014;"['Clinical Trial', 'Journal Article', 'Multicenter Study', ""Research Support, Non-U.S. Gov't""]"
NCT00574652;Evaluation of Clinical Efficacy and Immunologic Response After IL-2 Therapy in HCV-related Vasculitis Patients;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2007-12-17;2008-03;2010-09;22129253;DERIVED;Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis.;"Saadoun D; Rosenzwajg M; Joly F; Six A; Carrat F; Thibault V; Sene D; Cacoub P; Klatzmann D";10.1056/NEJMoa1105143;2011;"['Clinical Trial, Phase I', 'Clinical Trial, Phase II', 'Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;16249701;BACKGROUND;Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study).;"Arribas JR; Pulido F; Delgado R; Lorenzo A; Miralles P; Arranz A; González-García JJ; Cepeda C; Hervás R; Paño JR; Gaya F; Carcas A; Montes ML; Costa JR; Peña JM";10.1097/01.qai.0000180077.59159.f4;2005;"['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;20010070;BACKGROUND;The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml.;"Arribas JR; Horban A; Gerstoft J; Fätkenheuer G; Nelson M; Clumeck N; Pulido F; Hill A; van Delft Y; Stark T; Moecklinghoff C";10.1097/QAD.0b013e3283348944;2010;"['Clinical Trial, Phase III', 'Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;28566227;DERIVED;Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.;"Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E; MOBIDIP study group";10.1016/S2352-3018(17)30069-3;2017;"['Clinical Trial', 'Equivalence Trial', 'Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;23075703;BACKGROUND;A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study.;"Bunupuradah T; Chetchotisakd P; Ananworanich J; Munsakul W; Jirajariyavej S; Kantipong P; Prasithsirikul W; Sungkanuparph S; Bowonwatanuwong C; Klinbuayaem V; Kerr SJ; Sophonphan J; Bhakeecheep S; Hirschel B; Ruxrungtham K; HIV STAR Study Group";10.3851/IMP2443;2012;"['Comparative Study', 'Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;21886816;BACKGROUND;Pilot, randomized study assessing safety, tolerability and efficacy of simplified LPV/r maintenance therapy in HIV patients on the 1 PI-based regimen.;"Cahn P; Montaner J; Junod P; Patterson P; Krolewiecki A; Andrade-Villanueva J; Cassetti I; Sierra-Madero J; Casiró AD; Bortolozzi R; Lupo SH; Longo N; Rampakakis E; Ackad N; Sampalis JS";10.1371/journal.pone.0023726;2011;"['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;20802298;BACKGROUND;Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir.;"Gutmann C; Cusini A; Günthard HF; Fux C; Hirschel B; Decosterd LA; Cavassini M; Yerly S; Vernazza PL; Swiss HIV Cohort Study (SHCS)";10.1097/QAD.0b013e32833db9a1;2010;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;20802297;BACKGROUND;Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136.;"Katlama C; Valantin MA; Algarte-Genin M; Duvivier C; Lambert-Niclot S; Girard PM; Molina JM; Hoen B; Pakianather S; Peytavin G; Marcelin AG; Flandre P";10.1097/QAD.0b013e32833dec20;2010;"['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;22814125;BACKGROUND;Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA).;"Gilks CF; Walker AS; Dunn DT; Gibb DM; Kikaire B; Reid A; Musana H; Mambule I; Kasirye R; Robertson V; Ssali F; Spyer M; Pillay D; Yirrell D; Kaleebu P; DART Virology Group and Trial Team";10.3851/IMP2253;2012;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;16549962;BACKGROUND;Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study).;"Castagna A; Danise A; Menzo S; Galli L; Gianotti N; Carini E; Boeri E; Galli A; Cernuschi M; Hasson H; Clementi M; Lazzarin A";10.1097/01.aids.0000218542.08845.b2;2006;"['Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;21811554;BACKGROUND;Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis.;"Mathis S; Khanlari B; Pulido F; Schechter M; Negredo E; Nelson M; Vernazza P; Cahn P; Meynard JL; Arribas J; Bucher HC";10.1371/journal.pone.0022003;2011;"['Comparative Study', 'Journal Article', 'Meta-Analysis', ""Research Support, Non-U.S. Gov't"", 'Review']"
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;18097218;BACKGROUND;Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV.;"Pulido F; Arribas JR; Delgado R; Cabrero E; González-García J; Pérez-Elias MJ; Arranz A; Portilla J; Pasquau J; Iribarren JA; Rubio R; Norton M; OK04 Study Group";10.1097/QAD.0b013e3282f4243b;2008;"['Classical Article', 'Comparative Study', 'Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;22441252;BACKGROUND;Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings.;"Bartlett JA; Ribaudo HJ; Wallis CL; Aga E; Katzenstein DA; Stevens WS; Norton MR; Klingman KL; Hosseinipour MC; Crump JA; Supparatpinyo K; Badal-Faesen S; Kallungal BA; Kumarasamy N";10.1097/QAD.0b013e328353b066;2012;"['Journal Article', 'Multicenter Study', 'Research Support, N.I.H., Extramural', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]"
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;17545707;BACKGROUND;The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial.;"Vernazza P; Daneel S; Schiffer V; Decosterd L; Fierz W; Klimkait T; Hoffmann M; Hirschel B";10.1097/QAD.0b013e32814e6b1c;2007;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;18540803;BACKGROUND;A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy.;"Cameron DW; da Silva BA; Arribas JR; Myers RA; Bellos NC; Gilmore N; King MS; Bernstein BM; Brun SC; Hanna GJ";10.1086/589622;2008;"['Controlled Clinical Trial', 'Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT02125500;Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-dose Combination in Treatment Experienced Subjects With Hepatitis C Virus (HCV) Genotype 1 - HIV Co-infection;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2014-04-29;2014-08;2015-12;;;;;;;
NCT01413152;Residual Risk Assessment Of HIV Transmission;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2011-08-10;2011-07;2012-03;;;;;;;
NCT02236832;Study of the Neural Basis of Analogical Reasoning;Institut National de la Santé Et de la Recherche Médicale, France;Fondation pour la Recherche Médicale;COMPLETED;INTERVENTIONAL;False;2014-09-11;2015-02;2021-02;;;;;;;
NCT00115609;Efficacy of Tenofovir-Emtricitabine and Efavirenz in HIV Infected Patients With Tuberculosis (ANRS129);French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2005-06-24;2006-01;2009-11;;;;;;;
NCT04396288;Ultrasound Imaging-based Measurement of Intra-osseous Vascular Response;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-05-20;2021-09-14;2024-01-30;;;;;;;
NCT00445575;Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone;Institut National de la Santé Et de la Recherche Médicale, France;ZonMw: The Netherlands Organisation for Health Research and Development | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Charite University, Berlin, Germany;COMPLETED;INTERVENTIONAL;False;2007-03-09;2007-07-22;2017-12-07;;;;;;;
NCT01024400;Immunogenicity and Safety of an Inactivated Non-adjuvanted A(H1N1)v Influenza Vaccine in Pregnant Women;Institut National de la Santé Et de la Recherche Médicale, France;MCM Vaccines B.V.;COMPLETED;INTERVENTIONAL;False;2009-12-02;2009-11;2010-07;22147712;DERIVED;Maternal immune response and neonatal seroprotection from a single dose of a monovalent nonadjuvanted 2009 influenza A(H1N1) vaccine: a single-group trial.;"Tsatsaris V; Capitant C; Schmitz T; Chazallon C; Bulifon S; Riethmuller D; Picone O; Poulain P; Lewin F; Lainé F; Jacqz-Aigrain E; Aboulker JP; Launay O; Inserm C09-33 PREFLUVAC (Immunogenicity and Safety of an Inactivated Nonadjuvanted A[H1N1v] Influenza Vaccine in Pregnant Women) Study Group";10.7326/0003-4819-155-11-201112060-00005;2011;"['Clinical Trial, Phase II', 'Journal Article', 'Multicenter Study', ""Research Support, Non-U.S. Gov't""]"
NCT01779752;Vestibular Cortex and TMS;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2013-01-30;2013-01-20;2016-01;;;;;;;
NCT03215732;Cross Sectional Survey on the Burden and Impacts of Chronic Hepatitis B in the Rural Area of Niakhar, Senegal;ANRS, Emerging Infectious Diseases;Institute of Research for Development, France;COMPLETED;OBSERVATIONAL;False;2017-07-12;2017-10-19;2019-07-31;37143029;PUBMED;Hepatitis B prevention and treatment needs in women in Senegal (ANRS 12356 AmBASS survey).;"Djaogol T; Périères L; Marcellin F; Diouf A; Carrieri MP; Diallo A; Boyer S; ANRS 12356 AmBASS Study Group";10.1186/s12889-023-15710-y;2023;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT03215732;Cross Sectional Survey on the Burden and Impacts of Chronic Hepatitis B in the Rural Area of Niakhar, Senegal;ANRS, Emerging Infectious Diseases;Institute of Research for Development, France;COMPLETED;OBSERVATIONAL;False;2017-07-12;2017-10-19;2019-07-31;31320358;DERIVED;Burden and impacts of chronic hepatitis B infection in rural Senegal: study protocol of a cross-sectional survey in the area of Niakhar (AmBASS ANRS 12356).;"Coste M; De Sèze M; Diallo A; Carrieri MP; Marcellin F; Boyer S; ANRS 12356 AmBASS Study Group";10.1136/bmjopen-2019-030211;2019;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT03005652;Effects Of An 8-Weeks Mindfulness-based Intervention In Individuals With Subjective Cognitive Decline;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-12-29;2017-04-21;2018-09-18;33873195;DERIVED;Effects of a Mindfulness-Based Intervention versus Health Self-Management on Subclinical Anxiety in Older Adults with Subjective Cognitive Decline: The SCD-Well Randomized Superiority Trial.;"Marchant NL; Barnhofer T; Coueron R; Wirth M; Lutz A; Arenaza-Urquijo EM; Collette F; Poisnel G; Demnitz-King H; Schild AK; Coll-Padros N; Delphin-Combe F; Whitfield T; Schlosser M; Gonneaud J; Asselineau J; Walker Z; Krolak-Salmon P; Molinuevo JL; Frison E; Chételat G; Jessen F; Klimecki OM; The Medit-Ageing Research Group";10.1159/000515669;2021;['Journal Article', 'Randomized Controlled Trial']
NCT03005652;Effects Of An 8-Weeks Mindfulness-based Intervention In Individuals With Subjective Cognitive Decline;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-12-29;2017-04-21;2018-09-18;38100477;PUBMED;Effects of a mindfulness-based intervention and a health self-management programme on psychological well-being in older adults with subjective cognitive decline: Secondary analyses from the SCD-Well randomised clinical trial.;"Schlosser M; Demnitz-King H; Barnhofer T; Collette F; Gonneaud J; Chételat G; Jessen F; Kliegel M; Klimecki OM; Lutz A; Marchant NL; Medit-Ageing Research Group";10.1371/journal.pone.0295175;2023;['Randomized Controlled Trial', 'Journal Article']
NCT03005652;Effects Of An 8-Weeks Mindfulness-based Intervention In Individuals With Subjective Cognitive Decline;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-12-29;2017-04-21;2018-09-18;35853750;DERIVED;Association of Self-reflection With Cognition and Brain Health in Cognitively Unimpaired Older Adults.;"Demnitz-King H; Gonneaud J; Klimecki OM; Chocat A; Collette F; Dautricourt S; Jessen F; Krolak-Salmon P; Lutz A; Morse RM; Molinuevo JL; Poisnel G; Touron E; Wirth M; Walker Z; Chételat G; Marchant NL; Medit-Ageing Research Group";10.1212/WNL.0000000000200951;2022;"['Clinical Trial', 'Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT03005652;Effects Of An 8-Weeks Mindfulness-based Intervention In Individuals With Subjective Cognitive Decline;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-12-29;2017-04-21;2018-09-18;36068621;DERIVED;Effects of a mindfulness-based versus a health self-management intervention on objective cognitive performance in older adults with subjective cognitive decline (SCD): a secondary analysis of the SCD-Well randomized controlled trial.;"Whitfield T; Demnitz-King H; Schlosser M; Barnhofer T; Frison E; Coll-Padros N; Dautricourt S; Requier F; Delarue M; Gonneaud J; Klimecki OM; Lutz A; Paly L; Salmon E; Schild AK; Walker Z; Jessen F; Chételat G; Collette F; Wirth M; Marchant NL; Medit-Ageing Research Group";10.1186/s13195-022-01057-w;2022;['Journal Article', 'Randomized Controlled Trial']
NCT02916732;Zika Virus Infection's Pregnancy Consequences in French Department of America;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2016-09-27;2016-04;2019-02;33657112;RESULT;Reassessment of the risk of birth defects due to Zika virus in Guadeloupe, 2016.;"Funk AL; Hoen B; Vingdassalom I; Ryan C; Kadhel P; Schepers K; Gaete S; Tressières B; Fontanet A";10.1371/journal.pntd.0009048;2021;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT02916732;Zika Virus Infection's Pregnancy Consequences in French Department of America;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2016-09-27;2016-04;2019-02;29539287;RESULT;Pregnancy Outcomes after ZIKV Infection in French Territories in the Americas.;"Hoen B; Schaub B; Funk AL; Ardillon V; Boullard M; Cabié A; Callier C; Carles G; Cassadou S; Césaire R; Douine M; Herrmann-Storck C; Kadhel P; Laouénan C; Madec Y; Monthieux A; Nacher M; Najioullah F; Rousset D; Ryan C; Schepers K; Stegmann-Planchard S; Tressières B; Voluménie JL; Yassinguezo S; Janky E; Fontanet A";10.1056/NEJMoa1709481;2018;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01311752;Study of Human Papillomavirus Related Genital Pathology Among HIV Positive Women;French National Agency for Research on AIDS and Viral Hepatitis;Virology study Heather A Cubie Catherine Moore Edinburg United Kingdom | Anatomopathology study Christine Bergeron Laboratoire Pasteur Cerba Cergy Pontoise France | Paris, Isabelle Cartier, M.D. | Immunology study Guislaine Carcelain Groupe Hospitalier Pitié Salpétrière Paris | Surgery study Hervé Foulot Cochin Paris;COMPLETED;OBSERVATIONAL;False;2011-03-09;2007-11;2012-12;;;;;;;
NCT01269632;Cohort of Young Adults Infected With HIV Since Birth or During Childhood;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2011-01-04;2010-06;2018-12-27;;;;;;;
NCT01495897;Abnormal Movements, Cerebellum and Sensorimotor : Oculomotor Study;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-12-20;2011-03;2014-03;;;;;;;
NCT00463983;Treatment of Idiopathic Pulmonary Fibrosis With Long Acting Octreotide;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2007-04-20;2006-10;2012-01;22379151;DERIVED;Octreotide treatment of idiopathic pulmonary fibrosis: a proof-of-concept study.;"Crestani B; Chapron J; Wallaert B; Bergot E; Delaval P; Israel-Biet D; Lacronique J; Monnet I; Reynaud-Gaubert M; Tazi A; Lebtahi R; Debray MP; Brauner M; Dehoux M; Dornic Q; Aubier M; Mentré F; Duval X";10.1183/09031936.00113011;2012;['Clinical Trial, Phase II', 'Letter', 'Multicenter Study']
NCT00463983;Treatment of Idiopathic Pulmonary Fibrosis With Long Acting Octreotide;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2007-04-20;2006-10;2012-01;16883006;BACKGROUND;Increased uptake of 111In-octreotide in idiopathic pulmonary fibrosis.;"Lebtahi R; Moreau S; Marchand-Adam S; Debray MP; Brauner M; Soler P; Marchal J; Raguin O; Gruaz-Guyon A; Reubi JC; Le Guludec D; Crestani B";;2006;['Clinical Trial', 'Journal Article']
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-05-03;2004-02;2016-06;24465584;BACKGROUND;Blunted response to combination antiretroviral therapy in HIV elite controllers: an international HIV controller collaboration.;"Boufassa F; Lechenadec J; Meyer L; Costagliola D; Hunt PW; Pereyra F; Deeks S; Pancino G; Taulera O; Lichterfeld M; Delobel P; Saez-Cirion A; Lambotte O; ANRS CO18 HIV Controllers Cohort; Cascade Collaboration in Eurocoord; SCOPE Cohort; International HIV Controllers Study";10.1371/journal.pone.0085516;2014;"['Journal Article', 'Research Support, N.I.H., Extramural', ""Research Support, Non-U.S. Gov't""]"
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-05-03;2004-02;2016-06;26636578;BACKGROUND;Late Antiretroviral Therapy (ART) Initiation Is Associated with Long-Term Persistence of Systemic Inflammation and Metabolic Abnormalities.;"Ghislain M; Bastard JP; Meyer L; Capeau J; Fellahi S; Gérard L; May T; Simon A; Vigouroux C; Goujard C; ANRS-COPANA Cohort Study Group";10.1371/journal.pone.0144317;2015;"['Clinical Trial', 'Journal Article', 'Multicenter Study', ""Research Support, Non-U.S. Gov't""]"
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-05-03;2004-02;2016-06;22267473;BACKGROUND;Immune deficiency could be an early risk factor for altered insulin sensitivity in antiretroviral-naive HIV-1-infected patients: the ANRS COPANA cohort.;"Boufassa F; Goujard C; Viard JP; Carlier R; Lefebvre B; Yeni P; Bouchaud O; Capeau J; Meyer L; Vigouroux C; ANRS COPANA Cohort Study Group";10.3851/IMP1916;2012;"['Journal Article', 'Multicenter Study', ""Research Support, Non-U.S. Gov't""]"
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-05-03;2004-02;2016-06;23079802;BACKGROUND;Does pregnancy affect the early response to cART?;"Rachas A; Warszawski J; Le Chenadec J; Legeai C; Teglas JP; Goujard C; Rouzioux C; Mandelbrot L; Tubiana R; Meyer L";10.1097/QAD.0b013e32835ac8bc;2013;"['Journal Article', 'Multicenter Study', ""Research Support, Non-U.S. Gov't""]"
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-05-03;2004-02;2016-06;23936509;BACKGROUND;Is clinical practice concordant with the changes in guidelines for antiretroviral therapy initiation during primary and chronic HIV-1 infection? The ANRS PRIMO and COPANA cohorts.;"Krastinova E; Seng R; Yeni P; Viard JP; Vittecoq D; Lascoux-Combe C; Fourn E; Pahlavan G; Delfraissy JF; Goujard C; Meyer L; ANRS PRIMO and COPANA Cohorts";10.1371/journal.pone.0071473;2013;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-05-03;2004-02;2016-06;24058636;BACKGROUND;Associations between 25-hydroxyvitamin D and immunologic, metabolic, inflammatory markers in treatment-naive HIV-infected persons: the ANRS CO9 «COPANA» cohort study.;"Legeai C; Vigouroux C; Souberbielle JC; Bouchaud O; Boufassa F; Bastard JP; Carlier R; Capeau J; Goujard C; Meyer L; Viard JP; ANRS-COPANA Cohort Study Group";10.1371/journal.pone.0074868;2013;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-05-03;2004-02;2016-06;27509048;BACKGROUND;Elevated Basal Pre-infection CXCL10 in Plasma and in the Small Intestine after Infection Are Associated with More Rapid HIV/SIV Disease Onset.;"Ploquin MJ; Madec Y; Casrouge A; Huot N; Passaes C; Lécuroux C; Essat A; Boufassa F; Jacquelin B; Jochems SP; Petitjean G; Angin M; Gärtner K; Garcia-Tellez T; Noël N; Booiman T; Boeser-Nunnink BD; Roques P; Saez-Cirion A; Vaslin B; Dereudre-Bosquet N; Barré-Sinoussi F; Ghislain M; Rouzioux C; Lambotte O; Albert ML; Goujard C; Kootstra N; Meyer L; Müller-Trutwin MC";10.1371/journal.ppat.1005774;2016;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-05-03;2004-02;2016-06;25573889;BACKGROUND;Plasma cholesterol efflux capacity from human THP-1 macrophages is reduced in HIV-infected patients: impact of HAART.;"El Khoury P; Ghislain M; Villard EF; Le Goff W; Lascoux-Combe C; Yeni P; Meyer L; Vigouroux C; Goujard C; Guerin M";10.1194/jlr.M054510;2015;"['Clinical Trial', 'Journal Article', 'Multicenter Study', ""Research Support, Non-U.S. Gov't""]"
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-05-03;2004-02;2016-06;22008658;BACKGROUND;Burden of HIV disease and comorbidities on the chances of maintaining employment in the era of sustained combined antiretoviral therapies use.;"Dray-Spira R; Legeai C; Le Den M; Boué F; Lascoux-Combe C; Simon A; May T; Goujard C; Meyer L; ANRS-COPANA Cohort Study Group";10.1097/QAD.0b013e32834dcf61;2012;"['Journal Article', 'Multicenter Study', ""Research Support, Non-U.S. Gov't""]"
NCT01037777;RISCA : Prospective Study of Individuals at Risk for SCA1, SCA2, SCA3, SCA6, SCA7;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2009-12-23;2009-05-07;2017-12-14;23707147;DERIVED;Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study: analysis of baseline data.;"Jacobi H; Reetz K; du Montcel ST; Bauer P; Mariotti C; Nanetti L; Rakowicz M; Sulek A; Durr A; Charles P; Filla A; Antenora A; Schöls L; Schicks J; Infante J; Kang JS; Timmann D; Di Fabio R; Masciullo M; Baliko L; Melegh B; Boesch S; Bürk K; Peltz A; Schulz JB; Dufaure-Garé I; Klockgether T";10.1016/S1474-4422(13)70104-2;2013;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01037777;RISCA : Prospective Study of Individuals at Risk for SCA1, SCA2, SCA3, SCA6, SCA7;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2009-12-23;2009-05-07;2017-12-14;24780882;DERIVED;Prediction of the age at onset in spinocerebellar ataxia type 1, 2, 3 and 6.;"Tezenas du Montcel S; Durr A; Rakowicz M; Nanetti L; Charles P; Sulek A; Mariotti C; Rola R; Schols L; Bauer P; Dufaure-Garé I; Jacobi H; Forlani S; Schmitz-Hübsch T; Filla A; Timmann D; van de Warrenburg BP; Marelli C; Kang JS; Giunti P; Cook A; Baliko L; Melegh B; Boesch S; Szymanski S; Berciano J; Infante J; Buerk K; Masciullo M; Di Fabio R; Depondt C; Ratka S; Stevanin G; Klockgether T; Brice A; Golmard JL";10.1136/jmedgenet-2013-102200;2014;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01037777;RISCA : Prospective Study of Individuals at Risk for SCA1, SCA2, SCA3, SCA6, SCA7;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2009-12-23;2009-05-07;2017-12-14;32822634;DERIVED;Conversion of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 to manifest ataxia (RISCA): a longitudinal cohort study.;"Jacobi H; du Montcel ST; Romanzetti S; Harmuth F; Mariotti C; Nanetti L; Rakowicz M; Makowicz G; Durr A; Monin ML; Filla A; Roca A; Schöls L; Hengel H; Infante J; Kang JS; Timmann D; Casali C; Masciullo M; Baliko L; Melegh B; Nachbauer W; Bürk-Gergs K; Schulz JB; Riess O; Reetz K; Klockgether T";10.1016/S1474-4422(20)30235-0;2020;"['Clinical Trial', 'Journal Article', 'Multicenter Study', 'Observational Study', ""Research Support, Non-U.S. Gov't""]"
NCT01037777;RISCA : Prospective Study of Individuals at Risk for SCA1, SCA2, SCA3, SCA6, SCA7;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2009-12-23;2009-05-07;2017-12-14;35264424;DERIVED;Levels of Neurofilament Light at the Preataxic and Ataxic Stages of Spinocerebellar Ataxia Type 1.;"Wilke C; Mengel D; Schöls L; Hengel H; Rakowicz M; Klockgether T; Durr A; Filla A; Melegh B; Schüle R; Reetz K; Jacobi H; Synofzik M";10.1212/WNL.0000000000200257;2022;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01842477;Evaluation of Efficacy and Safety of Autologous MSCs Combined to Biomaterials to Enhance Bone Healing;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2013-04-29;2013-05;2016-02-05;;;;;;;
NCT02721745;Cause and Consequence of Neural Fatigue;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-03-29;2016-05-23;2020-12;;;;;;;
NCT02408354;Pilot Study, Comparative, Single-center, Randomized, Crossover, Double-blind, Against Placebo, Testing the Effectiveness of Triheptanoin Oil in Alternating Hemiplegia of Childhood;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-04-03;2015-04-15;2017-04-05;28969699;DERIVED;A randomized, controlled, double-blind, crossover trial of triheptanoin in alternating hemiplegia of childhood.;"Hainque E; Caillet S; Leroy S; Flamand-Roze C; Adanyeguh I; Charbonnier-Beaupel F; Retail M; Le Toullec B; Atencio M; Rivaud-Péchoux S; Brochard V; Habarou F; Ottolenghi C; Cormier F; Méneret A; Ruiz M; Doulazmi M; Roubergue A; Corvol JC; Vidailhet M; Mochel F; Roze E";10.1186/s13023-017-0713-2;2017;['Journal Article', 'Randomized Controlled Trial']
NCT01688453;Overweight Management and Social Inequalities;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-09-19;2012-04;2015-11;29696179;DERIVED;Reducing social inequalities in access to overweight and obesity care management for adolescents: The PRALIMAP-INÈS trial protocol and inclusion data analysis.;"Legrand K; Lecomte E; Langlois J; Muller L; Saez L; Quinet MH; Böhme P; Spitz E; Omorou AY; Briançon S; PRALIMAP-INÈS trial group";10.1016/j.conctc.2017.05.010;2017;['Journal Article']
NCT01688453;Overweight Management and Social Inequalities;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-09-19;2012-04;2015-11;32097754;DERIVED;Physical activity rather than sedentary behaviour is socially determined in French adolescents with overweight and obesity.;"Omorou AY; Manneville F; Langlois J; Legrand K; Böhme P; Muller L; Guillemin F; Briançon S; Lecomte E; PRALIMAP-INÈS Trial Group";10.1016/j.ypmed.2020.106043;2020;"['Journal Article', 'Multicenter Study', ""Research Support, Non-U.S. Gov't""]"
NCT01688453;Overweight Management and Social Inequalities;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-09-19;2012-04;2015-11;34087324;DERIVED;Sociodemographic and psychological characteristics associated with discrepancy between body satisfaction and weight change among adolescents.;"Manneville F; Omorou AY; Legrand K; Lecomte E; Rydberg JA; Briançon S; Guillemin F; PRALIMAP Trial Group";10.1016/j.ypmed.2021.106668;2021;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01688453;Overweight Management and Social Inequalities;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-09-19;2012-04;2015-11;29776897;DERIVED;Reach and Acceptability of a Mobile Reminder Strategy and Facebook Group Intervention for Weight Management in Less Advantaged Adolescents: Insights From the PRALIMAP-INÈS Trial.;"Saez L; Langlois J; Legrand K; Quinet MH; Lecomte E; Omorou AY; Briançon S; PRALIMAP-INÈS Trial Group";10.2196/mhealth.7657;2018;['Journal Article']
NCT01688453;Overweight Management and Social Inequalities;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-09-19;2012-04;2015-11;35272723;PUBMED;Behavioural risk patterns in adolescents with excess weight participating in the PRALIMAP-INÈS trial.;"Julia C; Omorou A; Lecomte E; Langlois J; Touvier M; Hercberg S; Briançon S; Kesse-Guyot E; Guillemin F; PRALIMAP-INÈS Trial Group";10.1017/S136898002200057X;2023;"['Journal Article', ""Research Support, Non-U.S. Gov't""]"
NCT01688453;Overweight Management and Social Inequalities;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-09-19;2012-04;2015-11;29934380;DERIVED;Using facilitator-receiver peer dyads matched according to socioeconomic status to promote behaviour change in overweight adolescents: a feasibility study.;"Saez L; Legrand K; Alleyrat C; Ramisasoa S; Langlois J; Muller L; Omorou AY; De Lavenne R; Kivits J; Lecomte E; Briançon S; PRALIMAP-INÈS Trial Group";10.1136/bmjopen-2017-019731;2018;"['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT02172677;The Influence of Collective Schemas on Individual Memory;Institut National de la Santé Et de la Recherche Médicale, France;La Région Basse-Normandie | Université de Caen Normandie | University Hospital, Caen | Ecole Pratique des Hautes Etudes | Equipement d'Excellence Matrice;COMPLETED;INTERVENTIONAL;False;2014-06-24;2014-10;2016-10-14;;;;;;;
NCT01880151;Neuroelectrical Biomarkers for Alzheimer's Disease Stages;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2013-06-18;2013-07-12;2019-01;;;;;;;
NCT02658253;Trial to Evaluate the Safety and Immunogenicity of a Placental Malaria Vaccine Candidate (PRIMVAC ) in Healthy Adults;Institut National de la Santé Et de la Recherche Médicale, France;EVI Industries, Inc. | Recherche Clinique Paris Descartes Necker Cochin Sainte Anne | Centre national de recherche et de formation sur le paludisme | EUCLID Clinical Trial Platform;COMPLETED;INTERVENTIONAL;False;2016-01-18;2016-01;2019-02-21;33717176;DERIVED;Progress and Insights Toward an Effective Placental Malaria Vaccine.;"Gamain B; Chêne A; Viebig NK; Tuikue Ndam N; Nielsen MA";10.3389/fimmu.2021.634508;2021;"['Journal Article', ""Research Support, Non-U.S. Gov't"", 'Review']"
NCT02658253;Trial to Evaluate the Safety and Immunogenicity of a Placental Malaria Vaccine Candidate (PRIMVAC ) in Healthy Adults;Institut National de la Santé Et de la Recherche Médicale, France;EVI Industries, Inc. | Recherche Clinique Paris Descartes Necker Cochin Sainte Anne | Centre national de recherche et de formation sur le paludisme | EUCLID Clinical Trial Platform;COMPLETED;INTERVENTIONAL;False;2016-01-18;2016-01;2019-02-21;32032566;DERIVED;PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study.;"Sirima SB; Richert L; Chêne A; Konate AT; Campion C; Dechavanne S; Semblat JP; Benhamouda N; Bahuaud M; Loulergue P; Ouédraogo A; Nébié I; Kabore M; Kargougou D; Barry A; Ouattara SM; Boilet V; Allais F; Roguet G; Havelange N; Lopez-Perez E; Kuppers A; Konaté E; Roussillon C; Kanté M; Belarbi L; Diarra A; Henry N; Soulama I; Ouédraogo A; Esperou H; Leroy O; Batteux F; Tartour E; Viebig NK; Thiebaut R; Launay O; Gamain B";10.1016/S1473-3099(19)30739-X;2020;"['Clinical Trial, Phase I', 'Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]"
NCT02027051;Etude génétique Des Arméniens;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2014-01-03;2014-01;2017-01;;;;;;;
NCT00118677;Long-Term Supervised Treatment Interruption in HIV-Infected Patients;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2005-07-12;2003-02;2007-05;20657770;DERIVED;Relationship between regulatory T cells and immune activation in human immunodeficiency virus-infected patients interrupting antiretroviral therapy.;"Weiss L; Piketty C; Assoumou L; Didier C; Caccavelli L; Donkova-Petrini V; Levy Y; Girard PM; Burgard M; Viard JP; Rouzioux C; Costagliola D; ANRS 116 SALTO study group";10.1371/journal.pone.0011659;2010;"['Clinical Trial', 'Journal Article', 'Multicenter Study', ""Research Support, Non-U.S. Gov't""]"
NCT00647205;Evaluation of 2 Interferon γ Assays in the Diagnosis of Latent Tuberculosis in HIV-infected Patients.ANRS EP 40 QUANTI SPOT;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2008-03-31;2008-01;2010-11;;;;;;;
